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2.   RESUMEN/SUMMARY 
RESUMEN 
El daño hepático inducido por drogas (DILI) es un grave problema en las sociedades 
desarrolladas, siendo el responsable de más del 50% de los casos de fallo hepático agudo. Un 
área de gran interés, tanto en el diagnóstico clínico como en la industria farmacéutica, es la 
búsqueda de marcadores no invasivos, tanto para el diagnóstico de esta patología, como para 
dilucidar el mecanismo molecular que se encuentra tras ella. En este sentido, el 
descubrimiento de vesículas extracelulares (EVs) secretadas por células, ha proporcionado un 
nuevo componente celular con la posibilidad de ser un agente activo en diferentes procesos 
tanto fisiológicos como patológicos. Estas vesículas han sido detectadas tanto en muestras de 
sangre como de orina, proporcionando una nueva plataforma para la identificación de 
marcadores no invasivos de enfermedades de diversa índole. Estas vesículas son secretadas 
por la mayoría de tipos celulares, incluyendo el hepatocito. Sin embargo, a pesar de la intensa 
investigación llevada a cabo en estas vesículas, actualmente poco se conoce acerca de su 
papel fisiológico y de su implicación en el desarrollo de enfermedades. 
Los hepatocitos secretan EVs que contienen enzimas implicadas en el metabolismo de drogas, 
sugiriendo una posible implicación de estas vesículas en el desarrollo de DILI. En este 
sentido, en esta tesis doctoral se ha caracterizado la secreción de EVs hepáticas en diferentes 
modelos de DILI in vitro mediante el uso de técnicas tanto bioquímicas como moleculares. 
Los resultados obtenidos muestran que el contenido de las EVs hepáticas es sensible a los 
diferentes modelos de DILI empleados, lo que podría ser de utilidad para fines diagnósticos. 
Además, las EVs hepáticas contienen diversas enzimas activas relacionadas con DILI 
incluyendo: la carboxylesterasa (CES), methionine adenosyl transferasa (MAT) y catechol O-
methyltransferasa (COMT). En base a la caracterización mediante UPLC-MS del metaboloma 
asociado a EVs hepáticas, se han detectado diversas rutas celulares así como funciones 
susceptibles de ser modificadas mediante estas vesículas. Un ejemplo de ello son el ciclo de la 
metionina, el metabolismo enérgético, la síntesis de purinas y ADN o el control de la presión 
sanguínea local. 
En conclusión, los resultados obtenidos apoyan que las EVs hepáticas podrían estar 
implicadas tanto en DILI como en la respuesta a otro tipo de daño hepático. Asimismo, 
también se presentan varias enzimas y moléculas como candidatos a marcadores de baja 
invasividad para la detección de DILI. 
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SUMMARY 
Drug induced liver injury (DILI) is a serious worldwide health problem that accounts for 
more than 50% of acute liver failure. A great interest in clinical diagnosis and pharmaceutical 
industry is to find non-invasive markers for this pathology and also to elucidate the molecular 
mechanisms behind it. The discovery of cell-secreted extracellular vesicles (EVs) has 
provided a new cellular component with the ability to influence different biological and 
pathological processes. These EVs have been detected in blood and urine samples providing a 
new platform to identify non-invasive markers for different diseases. These vesicles are 
secreted by most cell types of the body including hepatocytes but despite the intense research 
on EVs, there is currently not too much knowledge neither on their physiological role or their 
implication in the development of diseases.  
Hepatic EVs contain enzymes involved in drug metabolism, suggesting a possible role of 
these EVs in DILI. In this regard, in this doctoral thesis it has been characterized the secretion 
of hepatic EVs in different DILI in vitro models using molecular and biochemical approaches. 
The results showed that the molecular cargo of hepatic EVs is sensitive to DILI condition 
what could be useful for diagnosis purposes. In addition, hepatic EVs displayed several 
enzymatic activities that have been related with DILI including carboxylesterase (CES), 
methionine adenosyl transferase (MAT) and catechol O-methyltransferase (COMT). 
Furthermore, by using UPLC-MS based metabolomics to characterize the metabolome 
associated to hepatic EVs, a number of cellular pathways and functions susceptible to be 
modified by these vesicles were unravelled including methionine cycle metabolism, purine 
and DNA (Deoxyribonucleic acid) synthesis, energetic metabolism and local blood pressure. 
In conclusion, our data support that hepatic EVs could play a role in DILI as well as in the 
response to other liver stresses, and also provide a number of molecules and activities as low-
invasive candidate biomarkers for drug-induced liver injury. 
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3.   INTRODUCTION 
3.1.   LIVER AND DRUG INDUCED LIVER INJURY  
The liver is a multifunctional organ essential for the life. It is involved in an elevated number 
of metabolic pathways [1] such as glucose, proteins and fat metabolism. Particularly, the liver 
plays a prominent role in regulating blood glucose levels, storing the glucose as a glycogen 
reservoir or releasing it in the bloodstream as necessary under hormonal control [2]. As for 
protein metabolism, this organ not only synthesizes non-essential amino acid by means of 
transaminases, but also the most plasma proteins including albumin and coagulation factors. 
Conversely, it also breaks down proteins and removes the resulting toxic ammonium ion by 
converting it into urea [3]. In addition to this, the liver metabolizes fats or synthesizes 
triglycerides from excess carbohydrates and proteins and synthesizes cholesterol from fatty 
acids [4]. This organ also produces bile, which takes part in fat digestion along with the 
lipases to breakdown the ingested fat. Finally, the liver also acts as vitamin and mineral 
storage and is the main organ involved in xenobiotics metabolism [5].  
To accomplish all these tasks, the liver employs not just hepatocytes, but also other non-
parenchymal immune and non-immune cells. Liver tissue macrophages (Kupffer cells), 
natural killer cells, T cells and B cells are members of the hepatic immune system [6]. These 
cell populations regulate the immune system  in liver and are important mediators in 
inflammation [7]. Among non-immune cells, the hepatic stellate cells, also known as Ito cells, 
are involved in angiogenesis and fibrosis processes [8]. However, the parenchyma of liver 
consists mostly of hepatocytes, which are the main cell type in the liver (~80%). Hepatocytes 
are polarized cells with multiple and complex functions. Among them, hepatocytes play an 
important role in detoxification, production and clearance of blood components. 
The liver is prone to xenobiotic-induced injury because of its central role in xenobiotic 
metabolism, its portal location within the circulation, and its anatomic and physiologic 
structure [5][9]. In this regard, drug-induced liver injury (DILI) remains a major cause of 
worldwide mortality, according to the United States Acute Liver Failure Study Group [10]. 
DILI is a clinically important etiology of hepatic disease that, if not recognized, can lead to 
hepatic severe failure. Indeed, it accounts for more than 50% of acute liver failure. DILI can 
affect both parenchymal and nonparenchymal cells of the liver, leading to a wide variety of 
pathological conditions, including acute and chronic hepatocellular hepatitis, 
fibrosis/cirrhosis, cholestasis, steatosis, as well as sinusoidal and hepatic artery/vein damage 
[11]. Between these pathologies, the predominant forms of DILI include acute hepatitis (liver 
inflammation of abrupt onset), cholestasis (interruption in the excretion of bile), and a mixed 
pattern [12].  
Although the exact mechanism of DILI remains unknown, it appears to involve 2 pathways; 
direct hepatotoxicity and adverse immune reactions (innate and adaptative immunity), being 
direct hepatotoxicity the most common pathway [13]. Direct hepatotoxicity is often caused by 
the direct action of a drug, or more often a reactive metabolite of the drug against different 
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components of the hepatocytes causing a malfunctioning of them. In most instances, DILI is 
initiated by the bioactivation of drugs to chemically reactive metabolites, which have the 
ability to interact with cellular macromolecules such as proteins, lipids, and nucleic acids, 
leading to protein dysfunction, lipid peroxidation, DNA damage, and oxidative stress. These 
reactive metabolites may induce disruption of ionic gradients and intracellular calcium stores, 
resulting in mitochondrial dysfunction and loss of energy production. This impairment of 
cellular function can culminate in cell death and possible liver failure [13]. In adverse immune 
reactions, hepatocyte damage triggers the activation of other cells, which can initiate an innate 
and/or an adaptive immune response. The innate immune system provides an inflammatory 
reaction that is first line of defense against microbial infection, but it is not sufficient in 
eliminating all the components of infectious organisms. In this regard, cells of the innate 
immune system play an integral role in the initiation of adaptive immunity by presenting 
antigens and are crucial in determining the subsequent T cell or antibody-mediated immune 
response. Collectively, the innate and adaptive immune cells contribute to the unique immune 
responses of the liver, such as removal of pathogenic microorganisms or  clearance of 
particles and soluble molecules from circulation [14].  
The idiosyncratic nature and poor prognosis of DILI, makes it a major safety issue during 
drug development, as well as the most common cause for the withdrawal of drugs from the 
pharmaceutical market. Indeed, because of the significant patient morbidity and mortality 
associated with DILI [15], the U.S. Food and Drug Administration (FDA) has removed 
several drugs from the market, representing a serious clinical and financial problem [16]. The 
cost of introducing a new drug to the market (estimated at hundreds of millions of dollars) 
generates a high socio-economical pressure to understand the underlined mechanisms and to 
generate new tools and approaches for the identification of sensitive biomarkers for 
hepatotoxicity. In this regard, the clinical diagnosis and prediction of DILI remain a major 
challenge due to various confounding factors which include preexisting liver disease, multiple 
drug usage by patients, and most important, lack of reliable screening methods and diagnostic 
standards [13]. Currently, besides liver biopsy, the activity of a series of hepatic enzymes and 
proteins released into the blood by damaged liver cells are the most useful tools available in 
detecting liver damage in a non-invasive manner. Hepatic screening test measuring bilirubin 
(total and unconjugated), alkaline phosphatase, aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), albumin, gamma-glutamyl transferase (GGT), prothrombin time and 
glutathione-S-transferase are routinely used in both preclinical and human clinical drug 
studies [17]. As a general rule, ALT levels greater than 3 times the upper limits of normal 
have been identified as a marker for liver injury. This observation is currently employed by 
the FDA in the evaluation of hepatotoxicity for newly developed drugs [15]. Nevertheless, 
none of them is sensitive or specific enough to be consider as specific marker for detecting 
DILI [17][18]. Therefore, the development of novel diagnostic biomarkers with greater 
sensitivity and specificity is needed for the development of improved preclinical screens and 
the design of more effective clinical trials to evaluate potential hepatotoxic effects of new 
drugs before its release into the pharmaceutical market.  
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Over 1000 drugs and herbal products have been implicated in the development of DILI and 
the list continue to grow [19]. In the present doctoral thesis, different liver injury models are 
studied in order to find new and specific biomarkers for DILI. Such models are based on 
galactosamine (GalN), acetaminophen (APAP) and diclofenac (DCF), three compounds that 
cause liver damage by different mechanisms. GalN is a well characterized hepatotoxin that 
causes acute liver injury similar to human viral hepatitis via depletion of uridine nucleotides, 
which subsequently diminishes synthesis of RNA (Ribonucleic acid)  and proteins [20][21]. 
Although this compound also inhibits the energy metabolism of hepatocytes [22]. Model of 
GalN hepatotoxicity is frequently used in animal experiments in vivo [20]. Similarly, APAP is 
a classically used drug to study the mechanisms of hepatotoxicity [13]. This drug is an over-
the-counter analgesic that is safe at therapeutic doses but at overdose can produce 
centrilobular hepatic necrosis, which may lead to acute liver failure. According to the United 
States Acute Liver Failure Study Group, hepatotoxicity caused by overdose of APAP 
accounts for 39% of acute liver failure. APAP is metabolized to its toxic metabolite, N-
acetylp-benzoquinoneimine (NAPQI) [23], which during APAP overdose leads to the 
disruption of calcium homeostasis, mitochondrial dysfunction, oxidative stress and may 
eventually culminate in cellular damage and death [24][25]. Finally, the nonsteroidal 
antiinflammatory drug (NSAID) DCF is a model of idiosyncratic hepatotoxicity. It causes 
rare but significant cases of serious hepatotoxicity, typically with a delayed onset (1–3 
months) [26]. Like other NSAIDs, DCF acts by inhibiting cellular cyclooxygenases (Cox-1 
and Cox-2), which results in a decreased production of pro-inflammatory prostaglandin, 
prostacyclin and thromboxane products, important mediators of inflammation and pain. This 
drug is one of the most frequently used over-the-counter antiinflamatory worldwide. More 
than a hundred instances of clinically apparent liver injury due to DCF have been reported in 
the literature. Indeed, DCF ranks in the top 10 causes of drug induced liver injury. In 
overdose, it causes oxidative stress and mitochondrial injury with a pattern predominantly 
hepatocellular [27].   
 
3.2.   EXTRACELLULAR VESICLES (EVs) 
A molecular biomarker is any biological molecule or pattern (proteins, metabolites, RNAs, 
gene expression profiles, etc.) that functions as a measurable indicator of the presence of a 
disease including its stage, progression and localization. As a consequence, a variety of 
strategies have been adopted for their discovery such as metabolomics, proteomics or 
transcriptional profiling. A key interest in clinical diagnosis and pharmaceutical industry is to 
have a repertoire of low-invasive biomarkers to be able to predict the degree of injury caused 
by a pathological condition or a drug. In this regard, the study of cell-secreted EVs as a 
platform to identify new disease biomarkers [28] has evolved rapidly in the recent years.  
The discovery of EVs dates back to 1940, when preliminary studies were performed, 
addressing the “biological significance of the thromboplastic protein of blood” [29].  More 
than 20 years later, in 1967, this subcellular fraction was identified by electron microscopy 
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and was shown to consist of small vesicles originating from platelets and termed “platelet 
dust” [30]. One decade later, fetal bovine serum was also shown to contain “numerous 
microvesicles” and they were presented as the breakdown products of normal cell components 
[31]. Meanwhile, within a completely different line of research, EVs were identified as being 
released from reticulocytes during their maturation into erythrocytes, whereby the transferrin 
receptor as a constituent component of those EVs becomes downregulated in the mature 
erythrocytes [32]. 
Since then, EVs are known to be released from most cell types including mast cells, dendritic 
cells, B lymphocyte cell lines, astrocytes, platelets, hepatocytes, neurons, endothelial cells, 
and epithelial cells [33]. Furthermore, EVs have been isolated from diverse body fluids, 
including semen [34][35], blood [36], urine [37], saliva [38], breast milk [39], amniotic fluid 
[40], ascites fluid [41], cerebrospinal fluid [42] and bile [43]. 
There is accumulating evidence that vesicles released from cells are heterogeneous in terms of 
biogenesis, secretion process and size [44]. In this regard, three main groups have been 
identified (Figure 1): endosome-derived vesicles named exosomes, plasma membrane-
shedding vesicles called ectosomes or microvesicles (MVs), and apoptotic bodies [1]. 
 
 
 
 
 
Figure 1. Schematic representation of the different type of extracellular vesicles (EVs). Major populations 
include exosomes, microvesicles and apoptotic bodies. Adapted from György et al. 2011[45]. 
 
 
 
Regarding cell-derived vesicles formation, at present, the detailed underlying mechanisms 
remain unclear [33]. However, there is enough evidence supporting the endocytic origin of 
some of these vesicles [46][47][48]. The release of this type of EVs is a process that appears 
INTRODUCTION 
 
40 
 
to be conserved throughout evolution [49][50] suggesting essential functions of a dynamic 
EVs compartment. The endocytic pathway consists of highly dynamic membrane 
compartments involved in the internalization of extracellular ligands or cellular components, 
their recycling to the plasma membrane, and/or their degradation  [51]. One of the 
compartments of the endocityc pathway are early endosomes, that matures into late 
endosomes [52] by changes in form, size, content and pH. During this process, late 
endosomes accumulate intraluminal vesicles (ILVs) that are formed by inward budding of the 
late endosome membrane, at the same time that some cytoplasmic molecules are engulfed. 
Because of the morphological features of late endosomes, they are generally referred to as 
multivesicular bodies (MVBs). The MVBs, have then two possible fates; fusion with 
lysosome (acidic compartment that contains lysosomal hydrolases), ensuring the degradation 
of their content, or fusion with the plasma membrane and consequent release of ILVs to the 
extracellular milieu, which are then called exosomes [53] (Figure 2). Regarding MVs and 
apoptotic bodies, they are formed by regulated release of outward budding of the plasmatic 
membrane and as blebs containing cellular portions undergoing apoptosis respectively. 
 
 
Figure 2. Biogenesis of EVs. Microvesicles bud directly from the plasma membrane. Exosomes are first termed 
ILVs when formed by inward budding into late endosomes (MVBs). Then, when ILVs are released by fusion of 
MVBs with the plasma membrane, are called exosomes. MVBs content can also go to degradation and therefore 
fuse with lysosomes. Plasma membrane proteins and lipids are represented in yellow, purple and blue. Cytosolic 
components in red and Trans Golgi network derived proteins in green. Arrows indicate proposed directions of 
protein and lipid transport between organelles and between MVBs and the plasma membrane for exosomes and 
MVs secretion. 
 
All EVs present important differences but share some characteristics. As mentioned, 
exosomes have endocityc origin while MVs and apoptotic bodies are originated from plasma 
membrane. Moreover, the size is another of the main differences among the different types of 
EVs. Apoptotic bodies are the biggest vesicles, ranging from 1 to 5µm; then MVs, with a 
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diameter size that ranges from 100 to 1000 nm and finally the exosomes, ranging between 50 
and 150 nm. However, all EVs contain proteins, lipids and nucleic acids and also share some 
markers such as Annexin V, Cd81 or CD9 in the case of exosomes and MVs [45]. Table 1 
summarized the major key features of the different EVs. 
 
 
   Table 1.  Main features of cell-derived EVs 
 
 
 
 
 
There are several isolation methods described for EVs. The conventional procedure to isolate 
exosomes and MVs involves mainly differential ultracentrifugation [60]. Briefly, the culture 
media is collected and filtered through 0.22 microns-pore filters, followed by subsequent 
ultracentrifugations at 10,000 x g (30 min) and 100,000 x g (60 min). The resulting pellet is 
enriched in EVs. An extra purification step involving a continuous density gradient has also 
been indicated to ensure obtaining exosomes-enriched preparations. The density at which 
exosomes float has been determined to range from 1.13 to 1.21 g/ml. In addition, in the last 
years, different commercial precipitating agents (e.g. Exoquick) have been developed in order 
to isolate EVs using methods more suitable for clinical practise. However, it is important to 
bear in mind that the EVs isolated using these precipitating methods are contaminated with 
non-vesicular material [54]. 
Most studies reported so far regarding biochemical composition of EVs, involve analysis of 
mixed populations of vesicles obtained by differential ultracentrifugation. Thus, the actual 
constitution of each subtype of EVs remains unknown. As a whole, EVs harbor a wide variety 
of proteins, phospholipids, lipids, mRNAs and microRNAs. Figure 3 shows the overall 
composition of EVs. Nevertheless, their specific composition depends on the cell type of 
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origin and the state of them, which is revealed by proteomic analysis in large scale of EVs 
from various cell types [33].  
 
 
 
Figure 3. Overall composition of EVs (Adapted from Colombo and Raposo. 2014) Schematic representation of 
the composition (families of proteins, lipids, and nucleic acids) and membrane orientation of EVs. Examples of 
tetraspanins commonly found in EVs include CD63, CD81, and CD9. Note that each listed component may in 
fact be present in some subtypes of EVs and not in others. For instance, histones and proteasome and ribosome 
components are probably secreted in large plasma membrane–derived EVs rather than exosomes. Abbreviations: 
ARF, ADP ribosylation factor; ESCRT, endosomal sorting complex required for transport; LAMP, lysosome-
associated membrane protein; MHC, major histocompatibility complex; MFGE8, milk fat globule–epidermal 
growth factor-factor VIII; RAB, Ras-related proteins in brain; TfR, transferrin receptor. 
 
Proteomic analysis shows a large overlap of protein expression between exosomes and MVs. 
As a consequence of their origin, EVs from different cell types contain endosome-associated 
proteins (e.g., Rab GTPase, SNAREs, Annexins and Flotillin), some of which are involved in 
MVB biogenesis (e.g., Alix and Tsg101 [55]). Membrane proteins that are known to cluster 
into microdomains at the plasma membrane or at endosomes often are also enriched on EVs. 
These include tetraspanins, a family of more than 30 proteins that are composed of four 
transmembrane domains [56]. Some of the tetraspanins contained in EVs are Cd63, Cd81, 
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Cd82, Cd53, and Cd37. EVs are also enriched in proteins that associate with lipid rafts, 
including glycosylphosphatidylinositol- anchored proteins and Flotillin [49]. 
After the demonstration that EVs cargo included both mRNA and miRNA of various sizes 
and that EVs associated mRNAs could be translated into proteins by target cells [57][58],  
numerous groups have analyzed the presence of genetic material in EVs. Recently, it has been 
demonstrated that, in addition to mRNA and miRNA, EVs also contain a large variety of 
other small noncoding RNA species, including RNA transcripts overlapping with protein 
coding regions, repeat sequences, structural RNAs, tRNA fragments, vault RNA, Y RNA, and 
small interfering RNAs [59][60]. 
Fewer studies have analyzed the lipid and metabolites composition of EVs [61]. When 
comparing secreted vesicles with the total cell membranes, most of these studies observed 
enrichment of sphingomyelin, cholesterol, phosphatidylserine (PS), phosphatidylcholine, 
phosphatidylethanolamine and generally of saturated fatty acids [49]. These fatty acids 
together with the high concentration of cholesterol, may account for lateral segregation of 
these lipids into ILVs during their formation at MVBs. In this line, EVs are also enriched in 
proteins associated with lipid rafts, including glycosylphosphatidylinositol- anchored proteins 
and flotillin [62] [63]. 
The overall composition of EVs described above is representative of vesicles mixed 
populations. The databases ExoCarta [64], Vesiclepedia [65] and  EVSpedia [66] catalog 
proteins, lipids, and RNA that have been identified in EVs from different sources.  
Regarding EVs functions, they were first described to work as a cellular mechanism to 
remove unwanted plasma membrane proteins during the maturation process of reticulocytes. 
Ten years later, EVs were shown to bear MHC molecules and participate of immune 
reactions. Since then, several functions in cell-to-cell communication processes have been 
attributed to EVs such as a vehicle to exchange genetic material (mRNA and miRNA) 
between cells or as a shuttle for infectious agents (HIV, prions) to escape immune 
surveillance [57][67].  
Many other functions have been assigned to EVs such as immune suppression, antigen-
presenting, signaling molecules carriers, inflammation control, tumor growth (i.e. metastasis 
and angiogenesis), cell adhesion, coagulation, vascular repair, waste management and 
protection against stress among others [68].  
 
3.3.     HEPATIC EVs 
Despite the increasing interest in EVs, at present there are few studies focusing on hepatic 
EVs. They were first described and characterized in 2008 by Conde-Vancell et al [69] in non-
tumoral hepatocytes. In the study, it was reported a proteomic analysis of hepatic EVs where 
the vesicles content reflected the cell type of origin [69]. The proteomics analysis identified 
multiple proteins known to be involved in the endosomal pathway, such as annexins, small 
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GTP-binding proteins and several cytoskeletal (actin, tubulin), cytoskeletal binding-proteins 
(moesin, cofilin-1) and motor proteins (myosins). Another significant group consisted of 
secreted proteins, such as coagulation-related proteins, serum albumin and apolipoproteins 
that are released to the blood stream mainly by the liver. Conversely, numerous cytosolic 
proteins, presumably trapped during EVs biogenesis, were also identified. Besides these, 
many other proteins were also detected, such as cytochromes and UDP-
glucuronosyltransferases that are involved in detoxification processes of both exogenous and 
endogenous compounds.  
Regarding nucleic acid content, 1300 transcripts were detected associated to EVs released by 
rat hepatocytes [70]. From them, 223 transcripts were found associated mainly with 
hepatocyte functions. Remarkably, some of those RNAs are enriched in the EVs in 
comparison with the intracellular transcriptome suggesting that RNA cargo is selectively 
incorporated [26].  
Several physiological roles for hepatic EVs have been suggested: 
 Intercellular communication: Recently, the role of secreted EVs  in the exchange of 
proteins, nucleic acids and lipids has awakened considerable interest in the field of 
intercellular signaling [6]. Indeed, several reports [71][72] have identified and 
characterized the role of EVs in intercellular communications. As mentioned before, 
EVs can transfer different types of molecules (e.g. proteins, lipids,  mRNAs or even if 
viruses) to target cells, inducing a change in composition or behavior of target cells 
[70]. Remarkably, circulating liver-specific mRNA associated with EVs has been 
described in the bloodstream [73]. In general, the role of bloodstream mRNAs is still 
unclear. Since the first descriptions of mRNA associated to EVs, functional transfer of 
EV-associated RNA to the acceptor cells has been shown [57]. 
 EV pathway for virus propagation: Hepatitis C virus (HCV) is a major cause of 
chronic liver disease. HCV can entry into the cell and be delivered into early 
endosomes [74]. Indeed, in HCV-infected patients, viral RNA is associated with EVs 
in plasma [75]. 
 EVs in regeneration and differentiation: Liver is involved in detoxification of 
xenobiotics and noxious endobiotics, and therefore, continuously exposed to injuries. 
According to this, tissue regeneration is an important defensive mechanism 
maintaining the viability of this organ. Several studies support the possible role of 
hepatic EVs in liver regeneration [76][77][78]. 
 EVs in bile duct proliferation: Biliary EVs secreted by cholangiocytes take part in a 
pathway associated with the inhibition of cholangiocyte proliferation [79]. 
 EVs in liver inflammation: Non-alcoholic fatty liver disease is emerging as a major 
global liver disorder. It encompasses a spectrum of diseases from simple steatosis to 
hepatocellular carcinoma. But, the role of EVs in inflammation is ambiguous because 
EVs can elicit either inflammation [80] or immunosuppressive effects [81][82]. 
 EVs´ miRNA and cancer: Tumoral cells undergo deregulation of miRNA expression 
and are known to release miRNAs associated with EVs [83]. An exhaustive catalogue 
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of miRNAs present in EVs released by hepatic cancer cells has pointed towards TAK1 
protein as one of the central targets of tumour-derived EV miRNA [84], which is an 
essential inhibitor of hepatocarcinogenesis. 
 
To elucidate whether one or several of these possibilities are achieved by hepatic EVs, further 
investigation and better knowledge of the cargo and activities that are present in EVs is 
needed. 
 
 
3.4.   HEPATIC EVs IN DRUG INDUCED LIVER INJURY 
Liver is the major body reservoir for enzymes involved in the metabolism of endogenous and 
xenobiotic compounds. In this regard, there are several works that have revealed the presence 
of different xenobiotic metabolizing enzymes in hepatic EVs [85][86]. Thus, several members 
of Cytochromes P450 (P450s), UDP-glucuronosyltransferases (UGTs), and Glutathione S-
transferases (GSTs) proteins families [87], all of them important enzymes involved in 
xenobiotic metabolism, were detected in EVs secreted by hepatocytes.  
Cytochromes P450s are monooxygenases that catalyze phase I reactions. They constitute the 
largest family of xenobiotic compound metabolizing enzymes. It metabolizes a wide variety 
of xenobiotics to pharmacologically inactive metabolites (approximately 75% of all clinically 
relevant drugs), and occasionally, to toxicologically active metabolites [35]. Impairment of 
cytochrome P450 activity, which may be either genetic or environmental, may lead to toxicity 
caused by the parent compound itself, affecting the susceptibility to hepatic injury. P450 
enzymes may also convert the drug to a chemically reactive metabolite, which, if not 
detoxified, may lead to various forms of hepatic and extrahepatic toxicity, including cellular 
necrosis, hypersensitivity, teratogenicity, and carcinogenicity. 
UGTs catalyze phase II glucuronidation reactions and metabolize a wide range of drugs as 
well as other xenobiotics, including environmental and dietary xenobiotics [88]. In addition, 
the other major contributor to drug metabolism, the GSTs family, also catalyzes Phase II 
reactions. The general action of  GST enzymes is the addition of glutathione (GSH) to a wide 
variety of endogenous and exogenous substrates [89]. GSTs are commonly responsible for the 
metabolism of oxidation products such as epoxides derived from the metabolism of P450s on 
polycyclic aromatic hydrocarbons. The addition of GSH moieties to these metabolically 
reactive epoxides turns them up into inactive forms that are readily excretable from the body 
[90]. Interestingly, the mediated conjugation of GSH to xenobiotic compounds by GSTs has 
also been observed to yield metabolites that are cytotoxic and if not detoxified, may lead to 
various forms of hepatic and extrahepatic toxicity, including cellular necrosis, 
hypersensitivity, teratogenicity, and carcinogenicity [91]. 
These drug-metabolizing enzymes, apart from metabolizing drugs to their corresponding 
inactive forms, may also cause a toxicological effect provoking direct hepatotoxicity by 
reacting with different molecules and altering their normal functions. For instance, it is 
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reported that P450 and UGT families are target proteins of autoantibodies in several hepatic 
and extrahepatic autoimmune diseases, causing immune-mediated liver injury [92]. All these 
data support a role of hepatic EVs in establishment and propagation of DILI. 
EVs act as vectors since they transport and protect not only proteins but also phospholipids, 
microRNAs and messenger RNAs (mRNAs) as biological messages [33]. In particular, 
hepatocyte-derived EVs contain liver specific mRNAs that are found in the bloodstream [93]. 
Importantly, amplification and quantification of these nucleic acids in blood samples have 
proved to be more sensitive than traditional transaminase activity quantification for detecting 
liver damage [73]. In this regard, it has been reported the possible role of hepatic RNA-
containing EVs as a suitable non-invasive biomarker for liver toxicity [94]. Using in vitro and 
in vivo liver disease models based on GalN, APAP and DFC it was found that the expression 
of various RNAs enriched in the corresponding EVs was altered.  
By examining the levels of albumin and beta polypeptide 2-like 1 (Gnb21) transcripts it was 
possible to distinguish between the three treatments. Therefore, liver damaging drugs are able 
to modify RNA content of these vesicles. Overall, these results suggest that the RNAs 
contained in hepatic EVs are a suitable biological source for non-invasive biomarker 
discovery of liver toxicity and for discrimination between different liver injuries. 
In addition, the comprehensive proteomic analysis performed in hepatocyte-derived EVs, 
revealed the presence of other relevant metabolic enzymes [69][95], such as Carboxylesterase 
1d (Ces1d), Methyl-adenosyltransferase (MAT) and Cathecol-O-methyl transferase (COMT) 
that could also play a role in the development of DILI. 
 
3.4.1.   CARBOXYLESTERASE (CES) 
There are different types of chemical reactions used to metabolize drugs, being the hydrolysis 
reactions the most common. In this sense, there is an immense variety of hydrolases, being 
CES one of the most significant related with xenobiotic metabolisms playing an important 
role in detoxification processes [87]. 
CES proteins belong to Phase I group of drug metabolizing enzymes. These enzymes 
efficiently catalyze the hydrolysis of a variety of ester- and amide-bonds containing chemicals 
and drugs to their respective free acids. They are involved in detoxification and metabolic 
activation of various drugs, environmental toxicants and carcinogens. CES also catalyze the 
hydrolysis of endogenous compounds such as short and long chain acyl-glycerols, long-chain 
acyl-carnitine and long-chain acyl-CoA esters [96]. 
CES comprise a multi-gene family whose gene products are localized in the endoplasmatic 
reticulum of many mammal tissues including liver, small intestine, lung, testis and 
macrophages [97]. Experimentally, microsomes purification from CES expressing cells is the 
best source of this type of enzymes [96]. 
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Mammalian CES are members of an α,β-hydrolase-fold family and they can be classified into 
five major groups denominated CES1-CES5 according to the homology of the amino acid 
sequence. There are some differences between these groups in terms of substrate specificity, 
tissue distribution, immunological properties and gene regulation [96], [98].  
CES1, CES2 and CES3 are the three major carboxylesterases detected in human liver [99]. 
Ces1d isoform, which is homologous to human CES1 [69], is the most abundant in EVs 
secreted by rat hepatocytes. In this regard, one of the objectives in this doctoral thesis is to 
demonstrate that this enzyme is active in hepatocytes-secreted EVs. 
 
3.4.2.   METHIONINE ADENOSYL-TRANSFERASE (MAT) 
MAT is the only enzyme responsible for the biosynthesis of S-adenosylmethionine (SAMe), 
the principal biological methyl donor, precursor of polyamines and in the liver, precursor of 
glutathione [100], that has a relevant role in controlling oxidative stress. 
The unique chemical structure of SAMe confers it the ability to participate in multiple 
biological reactions, being methylation, transsulfuration and aminopropylation the three major 
ones [101] (Figure 4). In methylation reactions, the methyl group is transferred to a large 
variety of substrates, such as DNA, RNA, proteins, phosphatidylethanolamine (PE), glycine 
and guanidinoacetate. These transmethylation reactions are catalyzed by specific 
methyltransferases (MTs) and over 200 proteins in the human genome have been identified as 
known or putative SAMe-dependent MTs [102]. During transmethylation, the methyl group 
of SAMe is transferred to the acceptor substrates and S-adenosylhomocysteine (SAH) is 
generated. SAH is then hydrolyzed to homocysteine (Hcy) and adenosine in a reversible 
reaction. In transsulfuration reactions, the sulfur atom of SAMe undergoes a series of 
reactions and is converted to cysteine and GSH, one of the main anti-oxidant molecules in 
cells. SAMe can also take part in radical reactions via its adenosine group and generate the 5´-
deoxyadenosyl radical, which is a powerful oxidizing agent (Figure 4). On the other hand, 
aminopropylation is involved in the synthesis of polyamines, necessary for cell proliferation 
among other functions. Through this pathway, SAMe is decarboxylated and its aminopropyl 
group is transferred, first to putrescine to form spermidine and 5´-methylthioadenosine 
(MTA) and then to spermidine to form spermine and a second molecule of MTA. The two 
molecules of MTA generated during this process exert an inhibitory effect on polyamine 
synthesis and consequently, on methionine synthesis as well [103]. The MTA molecules are 
then eliminated in order to restore the methionine levels of the cell (Figure 4).  
An integrated view of SAMe metabolism combine methylation, transsulfuration and 
amynopropilation pathways. Importantly, these reactions can affect a wide spectrum of 
biological processes ranging from metal detoxification and catecholamine metabolism to 
membrane fluidity, gene expression, cell growth, differentiation, and apoptosis [104]. 
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Figure 4. Schematic view of Methionine cycle  metabolism. Methionine adenosyltransferase is involved in 
methionine cycle. SAMe participates in multiple biological processes, including methylation, transsulfuration 
and amynopropylation pathways. During methylation, MAT converts methionine to SAMe using ATP as co-
substrate. When the methyl group of SAMe is transferred to the acceptor substrates, S-adenosylhomocysteine 
(SAH) is generated, which is then hydrolyzed to form homocysteine (Hcy). Moreover, when SAMe is 
decarboxylated to transfer its aminopropyl group for polyamines synthesis, 5´-methylthioadenosine (MTA) is 
generated as a by-product. 
 
Although all mammalian cells synthesize SAMe, the liver is where the bulk of SAMe is 
generated, as it is the organ where about 50% of all dietary methionine is metabolized and 
where up to 85% of all transmethylation reactions take place [105][106]. Thus, SAMe 
regulation is very important for liver homeostasis. Abnormal MAT activity is linked to many 
diseases outside and inside the liver. Indeed a failure in SAMe regulation can lead to fatty 
liver disease, cirrhosis or hepatocellular carcinoma (HCC) among others [100].  
 
 
3.4.3.   CATECHOL-O-METHYL TRANSFERASE (COMT) 
COMT is a enzyme that catalyzes the transfer of a methyl group from SAMe to one of the 
hydroxyl groups of a catecholamine (Figure 5) [107], [108]. By means of this reaction, the 
general function of COMT is the elimination of biologically active or toxic hydroxylated 
metabolites and catechols. In this line, COMT acts as an enzymatic detoxicating barrier 
between the blood and other tissues shielding against the detrimental effects of xenobiotics 
[109]. 
Catecholic compounds belong to a heterogenous group of reactive molecules that participate 
in chemical and biological reactions such as redox cycling, production of reactive oxygen 
species (ROS) or DNA and protein damage [110]. In mammals, catechols can occur as 
cathecol drugs (some dietary and medicinal products), metabolites in the degradation of 
cathecolestrogens or other endogenous compounds, such as cathecholamine neurotransmitters 
or regulators of endothelial permeability. So, catechol-metabolizing system has a potential 
pathophysiological and pathogenic significance in estrogen-induced hormonal cancers, in the 
INTRODUCTION 
 
49 
 
development of degenerative brain disorders as Parkinson’s disease or depression, as well as 
in the development of cardiovascular diseases [111].  
 
 
Figure 5. The basic function of Catechol‐O‐Methyltransferase. Enzymatic O‐methylation of the catechol 
substrate to 3‐Methoxy (major route) or 4‐Methoxy (minor route) products in the presence of Mg2+ and SAMe 
[109]. 
Among cathecolestrogens, 17-beta estradiol and salvianolic acid A (SAA) are found. 17-beta 
estradiol [112] is an essential estrogen hormone for sexual and reproductive development, 
mainly in females, although it also has important effects in many other tissues including liver. 
In this regard, it can lead to cholestasis by inducing a reversible inhibition of bile flow. 
Therefore, 17-beta estradiol is a toxicologically active metabolite that requires to be removed 
by COMT [113]. Concerning SAA, COMT is also responsible for methylated transformation 
of this phenolic acid metabolically unstable. Interestingly, metabolites derived from O-
methylation of SAA display high antioxidant potency against liver lipid peroxidation [114]. 
Moreover, considerable evidence has also demonstrated the potent protective effects of SAA 
against ischemia-induced injury [115][116]. 
Among cathecholamine neurotransmitters, dopamine (DA) and norepinephrine (NE), also 
called noradrenaline are found. DA and NE neurotransmitters play essential roles in 
controlling several forebrain functions. Consequently, perturbations of these neurotransmitters 
may contribute to the pathophysiology of neuropsychiatric disorders. [117]. According to this, 
the role of NE and DA neurotransmitters in the mechanism of action of antidepressant drugs 
as well as of drugs for Parkinson’s disease prompted extensive studies.  
In Parkinson’s disease, dopaminergic neurons in the brain are gradually destroyed, leading to 
a DA deficiency and to the onset of symptoms of Parkinson’s disease [118]. To overcome 
this, an option is to administrate DA precursors such as Levodopa (L-DOPA), the most 
effective medication in Parkinson’s disease [119]. However, L-DOPA is removed by COMT. 
Thus, in the late 1980s, potent and selective COMT inhibitors were introduced [120]. In this 
way, when L-DOPA is administered together with COMT inhibitors, the peripheral 
metabolism of L-DOPA diminishes, increasing its bioavailability [121]. Tolcapone, for 
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instance, is a selective COMT inhibitor that extends the duration of action of L-DOPA. But it 
has been observed to cause hepatotoxicity such as cholestatic injury which is reflected by an 
abnormal increased level of liver transaminases. Moreover, Tolcapone also caused 
hepatocellular injury since the mitochondrial ATP/ADP ratio is also decreased [122]. 
With reference to NE neurotransmitter, it produces wide-ranging effects on many areas of the 
body and is often referred to as a 'fight or flight' chemical, as it is responsible for the body's 
reaction to stressful situations. It triggers the release of glucose into the blood stream and 
increases blood pressure, heart rate, mental alertness and respiratory rate. Depression, anxiety, 
arterial hypotension, heart rate issues, and many other illnesses can be attributed, at least 
partially, to NE deregulation. In this regard, arterial hypotension occurs frequently in patients 
with acute liver failure (ALF). Treatment with NE and DA in patients with ALF is widely 
used as a vasopressor medication [123]. Moreover, NE concentrations in plasma are elevated 
in patients with cirrhosis [124]. 
Although COMT can be found in many tissues, the liver is the most important site for the 
metabolism of circulating catechols containing molecules [107]. Indeed, the liver exhibits 
clearly the highest COMT activity and protein levels followed by kidney, intestinal tract, heart 
and brain [125]. Consistent with this, COMT has been recently reported as a biomarker of 
liver injury. In the early stages, even before the current standard liver biomarker, alanine 
transaminase (ALT ) and histopathology indicate liver injury, COMT levels change 
significantly in both liver tissue and plasma [126]. 
Given the importance of the processes in which COMT is involved, the interest in this 
enzyme has considerably increased. Thus, more reliable, sensitive and rapid analytical COMT 
assays are needed, for example, to test in vitro efficacy of new COMT inhibitor candidates, to 
the determination of the structure-activity relationship of COMT or to measure COMT 
activity in various human disorders including schizophrenia, kidney disease, hypertension, 
Parkinson´s disease, and estrogen-induced cancers [107], [127]. According to COMT 
inhibitors, their efficacy is commonly determined in clinical studies and therefore, good 
sensitivity analytical method is required. To do that, there is a great variation in analytical 
methods for COMT activity measurement. Yet, High Performance Liquid Chromatography 
(HPLC) methods and radiochemical assays are the most commonly used methods[108], 
[128]–[132].  
In this doctoral thesis a novel method has been developed for the determination of COMT 
activity by UPLC-MS, using two different endogenous substrates (DA and NE) (Figure 6). 
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Figure 6. Cathechol-O-Methyltransferase catalyses methylation of Dopamine and Norepinephrine. (A) 
The methyl group of SAMe is transferred to Dopamine forming 3-methoxytyramine (B) or to Norepinephrine 
forming Normetanephrine in a reaction catalyzed by COMT.  
Overall, the alteration in protein expression of the studied enzymes [95] together with their 
presence in hepatic EVs, were the main reasons to study in detail their activity in diverse in 
vitro drug induce liver injury models. 
 
 
3.4.4.   METABOLOMIC PROFILING OF HEPATIC EVS 
Over the last decades there has been an important revolution in biomedical science with the 
search for single genes, transcripts, proteins or metabolites being substituted by the coverage 
of the entire genome, transcriptome, proteome and metabolome. Genomics, trancriptomics 
and metabolomics are considered important tools for interpreting and understanding the 
complex biological processes given their capability to measure changes in multiple entities 
simultaneously, providing an overview of different physiological or pathological conditions 
[133].  
From these “omics” technologies, metabolomics is the most recently developed and involves 
the measurement of hundreds to thousands of small molecules called metabolites (<2000 Da). 
These metabolites include molecules from different chemical nature, such as carbohydrates, 
vitamins, lipids and amino or fatty acids [134]. Metabolomics allows the qualitative and 
quantitative measurement of the metabolic response of a biological system to physiological or 
pathological stimuli.   
Metabolomics can be divided into two different types, targeted (metabolic target analysis) and 
untargeted (metabolic profiling) [135][136]. The use of targeted approaches in research is 
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quite old, and appeared long before the emergence of the “metabolomics” terminology [135]. 
This analysis includes the identification and quantification of a small set of metabolites using 
the most suitable analytical techniques for those compounds to avoid interferences [137]. The 
chemical identities of the metabolites to be assayed are known before data acquisition 
commences and this is a significant advantage with regards to metabolic profiling. In this 
regard, in this doctoral thesis, targeted metabolomics has been applied to the study of COMT 
and MAT enzymatic reactions. 
In contrast, in metabolic profiling, the aim is to provide a holistic picture of the system. From 
the metabolite it is infered the protein involved in the regulation of that metabolite, and 
therefore the transcript and the gene. A large number of metabolites can be quantified [138] 
from cells, tissues or biofluids to generate metabolic profiles [139]. Then, the biological 
relevance of these metabolic profiles can be evaluated via pathway analysis. The combination 
of metabolomics and software specialized in visualizing cellular pathways, offer a tool to 
identify and integrate the different metabolic pathways that are affected by a determined 
stimuli [140]. Interestingly, comparisons of such profiles from different genotypes are being 
used to identify specific metabolic changes leading to the understanding of physiology, 
toxicology and disease progression. Overall, both, targeted and untargeted metabolomics, 
reveal the expected behavior of known metabolites, but only untargeted metabolomics  allows 
also the detection of synergic effects between variables which cannot be observed at an 
individual level [141].  
The metabolome is highly dynamic, so it reflects the actual biological state given the rapid 
metabolic response to microenvironment changes [142]. This is particularly important for the 
assessment of rapid and progressive diseases. In this regard, application of metabolomics is 
growing rapidly covering a wide range of applications [143][135] including: disease 
diagnosis, drug discovery and development, pharmacometabolomics and personalized 
medicine, nutrigenomics, metabolic engineering/biotechnology and toxicology [137]. The 
basis of all these applications has a common aspect; alterations in metabolism due to a 
functional response of a given condition, results in an alteration in the metabolic profile, 
leading a characteristic patterns, which could give new insights into the underlying biological 
state [135]. 
In summary, metabolomics can help to elucidate different metabolic profiles that will 
ultimately give information about different pathways in which a specific phenotype or 
biological system is implicated. Moreover, UPLC-MS based metabolomics is a powerful tool 
for biomarker discovery in hepatic EVs that, at the end, could allow the development of novel 
diagnostic methods and therapies. 
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4.   HYPOTHESIS AND OBJECTIVES 
It is reported that hepatic EVs contain relevant enzymes involved in drug metabolism such as 
CES, cytochromes P450 or UGTs. Interestingly, some of these enzymes not only can 
contribute to drug metabolism but also in DILI development. Furthermore, these families of 
proteins are target of autoantibodies in several autoimmune diseases, causing immune-
mediated liver injury. Based on these data, the possible role of hepatic EVs in DILI is 
hypothesized. Basing on this hypothesis, hepatic EVs could constitute a powerful tool for 
DILI biomarker discovery. In this regard, the first objective of this study is to characterize the 
secretion of hepatic EVs in different DILI in vitro models. At the same time, their putative 
role as liver injury indicators is also evaluated. With this aim, different molecular approaches 
were employed such as immunostaining, Western Blot Analysis, Cryo-Electron Microscopy 
(Cryo-EM), particle tracking analysis (NTA) or Raman tweezers microspectroscopy (RTM).  
It is known that there are several drug metabolizing enzymes contained in hepatic EVs but, 
are they active? To address this question, the second objective of this study is to analyze by 
UPLC-MS technology specific enzymatic reactions. With this aim, an UPLC-MS based 
enzymatic activity determination and quantification method was developed for each of the 
studied enzymatic reactions. Moreover, these methods could be used to prevent DILI in a 
personalized manner by measuring these enzymatic activities in circulating hepatic EVs. In 
this way, an individual hepatic response could be estimated in order to determine drug optimal 
dosis.  
Finally, the third objective of this study is to elucidate/characterize the metabolic profile of 
MLP-29 murine cell line derived EVs through UPLC-MS-based metabolomics in order to 
identify pathways and functions where these vesicles are involved. Moreover, metabolomics 
as a tool for biomarker discovery on hepatic EVs is evaluated since alterations in metabolism 
(metabolites downregulation or upregulation) due to a functional response of a given 
condition such a drug overdose, results in an alteration in the metabolic profile, leading a 
characteristic pattern that could give new insights into the underlying biological state. In this 
regard, the screening of biomarkers candidates contained in hepatic EVs would enable the 
simultaneous profile of a large number of metabolic signatures in a given condition.  
In summary, the main objectives of this thesis are: 
1. To characterize the secretion of hepatic EVs in different DILI in vitro models and 
evaluate their role as putative low-invasive liver injury indicators. 
 
2. To demonstrate through UPLC-MS that hepatic EVs carry active enzymes.  
 
3. To characterize the metabolic profile of EVs-derived from MLP-29 murine hepatic 
cell line by using UPLC-MS based metabolomics in order to investigate the 
pathways in which these vesicles are involved and evaluate metabolomics as a tool 
for biomarker discovery in hepatic EVs.  
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5.   EXPERIMENTAL PROCEDURES 
5.1.    REAGENTS AND CELL CULTURE 
All chemical reagents were HPLC grade and suppliers are indicated in the specific description 
of each procedure. 
Next are listed antibodies employed in this doctoral thesis:  
 Mouse monoclonal antibodies were purchased from the indicated vendors: anti-Rab8 
(clone 4/Rab 4), anti-Hsp90 (clone 68), anti-flotillin-1 (clone 18), anti-CD63 (clone 
H5C6) and anti-BiP/Grp78 from BD Biosciences; anti-TSG101 (4A10) from Santa Cruz 
Biotech and anti-CD81 (Eat2) from AbD Serotec.  
 Rabbit polyclonal antibodies were acquired from the indicated vendors: anti-LIMP II 
(ab16522) and Cyp 2d1 (ab22590) from Abcam; anti-COX IV (3E11) from cell signaling 
and anti- MAT1A was developed in-house. 
 
 Goat polyclonal antibodies were acquired from the indicated vendors: anti-CES (M-14) 
from Santa Cruz Biotech and anti-COMT (ab51984) from Abcam. 
 Horseradish peroxidase (HRP)-conjugated secondary antibodies anti-mouse, rabbit, goat, 
were purchased from GE Healthcare.  
 Cy3-conjugated secondary antibodies anti-mouse (715-165-150) and anti-goat (705-165-
147) were purchased from Jackson Immuno Reseach. 
 Alexa 488-conjugated secondary antibodies anti-mouse (A21202) and anti-rabbit 
(A21206) were purchased from Molecular Probes. 
 Fluorescein isothiocyanate (FITC)-conjugated Phalloidin (P5282) employed to bind F-
actin was purchased from Sigma-Aldrich. 
Cell tissue cultures employed in this work were primary rat hepatocytes and MLP29 liver-
derived murine cell line. Primary hepatocytes were obtained by perfusion of rat liver (see 
procedure below). MLP29 was provided by Dr. E. Medico [144]. Suppliers of cell culture 
reagents are indicated in the specific description of the procedures. 
 
5.2.    ANIMAL EXPERIMENTATION  
Fourteen weeks old male Wistar rats (body weight 300-400 g), were maintained in an 
environmentally controlled room at 22°C on 12 h light/dark cycle and provided with standard 
diet (Rodent Maintenance Diet, Harlan Teklad Global Diet 2014) and water ad libitum. All 
surgery required for primary hepatocytes preparation was performed under anaesthetic gas 
Isoflurane (IsoFLO, Abbott Laboratories), and all efforts were made to minimize suffering. 
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For in vivo model of liver damage in RNA assay/analysis, rats received an intraperitoneal 
injection of 1 g/kg/5 ml of D(+)-galactosamine hydrochloride (GalN, Sigma-Aldrich). A 
control group of animals received the same volume of saline solution. Blood samples from 
each animal were drawn 18 h after the injection, and the sera were transferred to fresh 
Eppendorf tubes and stored at -80°C. 
All animal experimentation was conducted in accordance with the Spanish Guide for the Care 
and Use of Laboratory Animals, and with International Animal Care and Use Committee 
Standards. All procedures were approved by the CIC bioGUNE ethical review committee 
(Permit Number: P-CBG-CBBA-3610) accredited by AAALAC organizations. 
 
5.3.   CELL VIABILITY ANALYSIS 
Cell viability was measured with a benchtop automated cell counter (Countess
TM
, Life 
technologies) that performs cell count and viability (live, dead, and total cells) measurements 
using trypan blue staining. Briefly, cell sample was mixed 1:1 with trypan blue. A fraction of 
10 μL of the sample mixture was then loaded into a Countess™ cell counting chamber slide. 
The camera of the equipment acquires cell images from the sample on the slide and the image 
analysis software automatically analyzes acquired cell images, and measures cell count and 
viability based on trypan blue exclusion method.  The measurement provides live and dead 
cell concentration (per mL), total cell concentration (per mL) and viability (% of live cells). 
 
5.4.    IMMUNOFLUORESCENCE STAINING 
Primary rat hepatocytes were seed to 50–80% confluence on glass coverslips and after 
incubation at 37ºC for a period of time under indicated conditions, cells were fixed for 10 min 
with 2% formaldehyde in Dulbecco‟s modified phosphate-buffered saline (DPBS, Gibco) and 
then washed with DPBS. Successive incubations with primary and fluorophore-conjugated-
secondary antibodies diluted in a PBS solution containing 0.1% BSA and 0.1% saponine were 
carried out for 30 min. After each incubation period, unbound antibodies were removed by 
washing the coverlips in PBS. Finally, the coverslips were mounted onto glass slides on 
Fluoromont G (Southern Biotechnology Associates, Birmingham, AL) containing 0.7 g/ml 
4',6-diamidino-2-phenylindole (DAPI) to stain DNA (nucleus). All procedure was carried out 
at room temperature. All immunostainings were analyzed in a Leica Confocal microscope 
(Leica) and images were taken using a Leica confocal software. 
 
 
5.5.    WESTERN BLOT ANALYSIS  
Cell pellets of 1 × 10
6
 cells were lysed during 15 min on ice in the presence of 150 μl of lysis 
buffer (1% Triton X-100, 300 mM NaCl, 50 mM Tris-HCl, pH 7.4) before centrifugation at 
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14,000 × g for 5 min for clarification of the sample. The supernatant was transferred to a fresh 
eppendorf tube. The protein concentration of the preparations was determined by means of a 
Bradford protein assay (Bio-RadLaboratories, Inc) using bovine serum albumin (BSA) as 
standard [145]. NuPAGE® LDS Sample Buffer (Life Technologies, Inc) was added to the 
protein extract and incubated for 5 min at 37, 65 and 95ºC in order to prepare protein samples 
for denaturing gel electrophoresis. After cooling and clarification by centrifugation, samples 
were loaded and separated on 4-12% pre-casted polyacrylamide gel electrophoresis 
(NuPAGE® Bis-Tris gel, Life Technologies, Inc). Once the electrophoresis was finished, 
proteins were transferred to Polyvinylidene difluoride (PVDF) membrane and blocked for 1 h 
(5% non-fat dry milk and 0.2% Tween-20 in DPBS). PVDF membranes were incubated 1 h 
with primary antibody followed by DPBS washes and subsequently 30 min incubation with 
horseradish peroxidase (HRP)-conjugated secondary antibody. Chemioluminiscence detection 
of bands was performed using ECL Plus chemiluminiscent substrate (GE Healthcare, 
Buckinghamshire, UK). All proteins were detected under non-reducing conditions. 
Protein concentration was determined by Bradford assay (Cat. Num. 5000006, Bio-Rad 
Laboratories, Inc) using bovine serum albumin as standard. 
 
5.6.    CRYO- ELECTRON MICROSCOPY (Cryo-EM) 
For Cryo-EM, EVs preparations were directly adsorbed onto glow-discharged holey carbon 
grids (QUANTIFOIL, Germany). Grids were blotted at 95% humidity and rapidly plunged 
into liquid ethane with the aid of VITROBOT (Maastricht Instruments BV, The Netherlands). 
Vitrified samples were imaged at liquid nitrogen temperature using a JEM-2200FS/CR 
transmission cryo-electron microscope (JEOL, Japan) equipped with a field emission gun and 
operated at an acceleration voltage of 200 kV. In cryo-EM sessions, digital images were taken 
using low-dose technique by means of an ULTRASCAN 4000SP (4096 × 4096) cooled slow-
scan CCD camera (GATAN). An in-column energy filter (Omega Filter) was used to improve 
the signal-to-noise ratio of these images by zero-loss filtering. 
 
5.7.    RAMAN TWEEZERS MICROSPECTROSCOPY (RTM)  
These experiments were carried out at Pierre et Marie Curie University in Paris (France) in 
collaboration with Sergei G. Kruglik and his group. 
Raman spectra were recorded using a nearinfrared (NIR) Raman tweezers setup. In the setup, 
laser excitation light at 780 nm is provided by continuous-wave Ti:Sapphire laser (Spectra 
Physics, model 3900S) pumped by argon-ion laser (Spectra Physics Stabilite 2017).  The 
focal waist of intense laser radiation has an average power of 100 mW. The same objective is 
used to collect the Raman signal in a backscattering geometry and to deliver it onto the 
spectrograph (Acton SpectraPro 2500i). 
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Raman light is focused onto the spectrograph‟s entrance slit (semi-confocal configuration, slit 
width 30-40 µm) by an achromatic lens with f=75 mm. The Raman signal is separated from 
laser stray light by 2 Semrock RazorEdge long-pass filters (grade „„U‟‟). One filter, with 
λlaser=780 nm, is placed normally to the optical beam just before the focusing lens; another 
one, with λlaser= 830 nm, is used as a dichroic beam splitter at an angle of incidence 458:  it 
reflects laser light at 780 nm and transmits all the wavelengths longer 785 nm. Spectral 
resolution in all Raman experiments was about 5 cm-
1
. A frequency calibration was 
performed using Raman lines of toluene with 92 cm
-1
 absolute accuracy and relative 
frequency position accuracy better than 91 cm
-1
. Raman spectra were acquired using WinSpec 
software; further data treatment was performed using Igor Pro for Windows software. 
Raman spectra were acquired every 3 seconds during a sequence of 20 consecutive 
measurements: this constitutes one „„experimental set‟‟. Measurements were kept going until 
the event of optical trapping of at least several vesicles in the focus of the microscope 
objective (so-called „„vesicle set‟‟). After this event, a few more experimental sets are 
sequentially acquired for a better signal averaging. The transition from one vesicle set to 
another is accomplished by blocking the laser beam for 10 seconds, the trapped particles in 
the measurable volume being then exchanged by Brownian motion. The process of data 
treatment consists of the following successive steps: 
a) All of the recorded raw Raman spectra are visually inspected and properly selected, 
to eliminate the spectra without (or with very minor) vesicles contribution, with high 
background and poor quality. 
b) The selected raw Raman spectra are averaged and normalized on the water-bending 
band around1, 640 cm
_1
. 
c)  The contribution from PBS is subtracted. 
d) The resulting spectra are smoothed by 2 adjacent pixels, to minimize the etaloning 
effect in back illuminated NIR-CCD detector. 
 
 
5.8.    RNA ISOLATION AND QUANTITATIVE REAL-TIME PCR (qPCR) 
Selected RNAs found in EVs [70] were analyzed by quantitative polymerase chain reaction 
(qPCR) in EVs of untreated or drug-treated cells. With this purpose, EVs were isolated from 
tissue culture media using Exoquick as described in 5.11. Afterwards, RNA was isolated from 
Exoquick-precipitated material using RNeasy Mini Kit columns (Quiagen, Inc) following the 
manufacturer´s indications. RNA was eluted in 30 µl of RNase free water. The tube 
containing eluted RNA, was subsequently centrifuged at 13000 rpm during 15 seconds. RNA 
concentration was measured by means of Nanodrop spectrophotometer (Thermo scientific, 
Inc). Subsequently, cDNA was synthesized from 10 µl of eluted RNA using the Quanta 
cDNA SuperMix (Quanta bioscience, Inc). Briefly, reaction reagents (qScript cDNA 
SuperMix 5X, RNA template and RNase/DNase-free water) are combined and placed into 0.2 
mL microtube. After mixing by vortex, the sample was centrifuged briefly to collect 
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components at the bottom of the reaction tube. Then, it was subsequently incubated during 5, 
30 and 5 min at 25 ºC, 42ºC and 85ºC respectively and holded at 4ºC. Samples were stored at 
-20ºC if not use immediately. 1/5th to 1/10th of the cDNA synthesized was employed for 
PCR amplification using Taq polymerase (Biotools B&M Labs) according to the 
manufacturer‟s protocol and an iCycler thermocycler (Bio-Rad Laboratories Inc). 
Next, for relative quantification of genes, qPCR was performed in duplicates using SYBR 
Green PCR Master Mix (Bio-Rad Laboratories Inc) in an iCycler thermocycler. First, reaction 
master mix for all qPCR reactions was prepared which contains; SYBR Green Master Mix, 
forward and reverse primers and nuclease-free water. Then, equal aliquots of the master mix 
were dispensed into each PCR tube. cDNA templates were then added to the qPCR tubes 
which already contain reaction set up and mixed. Then, formed air bubbles were removed 
from the reaction mixture and the thermal cycling protocol was programmed in iCycler 
thermocycler according to manufacturer´s protocol. qPCR tubes were loaded and the qPCR 
run. 
Primers used for cDNA amplification were designed using Primer3 [146] and the selected 
sequences are listed in the Table 2. 
 
          Table 2. List of primers used for DNA amplification 
 
 
 
The efficiency of each set of primers was determined by serial dilution of the template cDNA. 
The theoretical value obtained with the iCycler software was 100±5% (Efficiency (%) = 100X 
[10(-1/slope) –1]; Bio-Rad Laboratories Inc).  
Fold changes respect to untreated cells were calculated using the formula 2-Ct, where Ct = 
Ct treated - Ct untreated. 
5.9.    RAT LIVER EXTRACT PREPARATION 
Liver extract preparation was carried out following protocol described in Van-Liempd et al 
2013 [147]. Liver tissue aliquots of approximately 50 mg from WT rat were lysed with a  
Precellys
®
24 tissue homogenizer (Thermo Fisher Scientific Inc. MA, USA) using 500mg of 
soft tissue homogenizing beads (CK14,Thermo scientific) in standard 2mL tubes 
(Precellys,Thermo scientific). Each sample was lysed in 2 x 20 second cycles at 6000 rpm in 
500 µL of 50 mM HEPES/150 mM KCl pH 8 in case of measurement of MAT activity, and 
50 mM sodium phosphate buffer pH 7.4 in the case of measurement of COMT activity. All 
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the buffers contained 10% Glycerol. Subsequently, 400-450 µL of the resulting homogenate 
was transferred to a fresh Eppendorf
® 
tube and centrifuged at 15,000 × g during 15 min at 
4°C. Supernatant was transferred to a fresh tube and place at -80 °C for 20 min. The chilled 
supernatant was stored at LN2 if not used immediately. 
Protein concentration was determined by Bradford assay, using bovine serum albumin as 
standard. 
 
5.10.    RAT MICROSOMES PREPARATION 
For microsomes preparation, fresh or cultured rat hepatocytes were collected and centrifuged 
at 800 rpm 5 min at 4°C.  The obtained pellet was resuspended in 50 mM HEPES/150 mM 
KCl pH 8 in the case of measurement for MAT activity and in 100 mM Tris-HCl buffer pH 
7.4 in the case of measurement for COMT activity. All the buffers contained 10% Glycerol. 
The suspension was transferred to a standard 2mL tube containing 500 mg of soft tissue 
homogenizing beads. The solution was lysed with a Precellys
®
24 tissue homogenizer in 2 x 
20 second cycles at 6000 rpm. The resulting homogenate (400-450µL aprox) was transferred 
to Eppendorf
® 
tubes and centrifuged at 15,000 × g during 15 min at 4°C. Supernatant was 
then ultracentrifuged at 100,000 x g during 60 min at 4°C. Resulting microsomal pellet was 
solubilized in the corresponding buffer for measurements of each enzyme (MAT and COMT) 
and stored at LN2 if not used immediately.  
Protein concentration was determined by Bradford assay, using bovine serum albumin as 
standard. 
 
5.11.    PRODUCTION AND ISOLATION OF EVs SECRETED BY PRIMARY        
HEPATOCYTES 
Rat hepatocytes (purity >95%) obtained from livers of 14 week old healthy Wistar male rats 
were purified by two-step collagenase perfusion technique which involves sequential 
perfusion of the liver with ethylenediaminetetraacetic acid (Sigma-Aldrich, St. Louis, MO, 
USA) and collagenaseType I (Worthington Biochemical Corp, Lakewood, NJ) [148]. Rat 
hepatocyte suspension was centrifuged at 400 rpm 3 min and plated in 24 collagen-coated 
dishes (150 mm) with collagen type I from rat tail (BD Biosciences, San Jose, CA) at 20 
million cells per dish. Cells were cultured in complete Dulbecco‟s modified eagle medium 
(DMEM, Gibco, Life technologies, Heidelberg, Germany) supplemented with 10% (v/v) fetal 
bovine serum (Gibco), streptomycin (0.1 mg/L, Lonza, Walkersville, MD, USA), penicillin 
(100 u/mL, Lonza) and amphotericin-B (0,25 µg/mL, Lonza) for 4 h at 37°C and 5% CO2. 
Then, cells were washed twice with DPBS and incubated for 36h in complete DMEM 
containing 25 mM HEPES and previously depleted from contaminating vesicles by overnight 
centrifugation at 100,000 × g, 4°C. For drug treatments the 24 collagen-coated dishes were 
divided in 4 groups (6 dishes each group) and incubated individually with no additives, 
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diclofenac Sodium (400 µM, Sigma-Aldrich), acetaminophen (10mM, Sigma-Aldrich), or D-
galactosamine (10mM, Sigma-Aldrich). After 36h incubation, media was collected and EVs 
isolated. In all cases, the 36 h-conditioned medium was centrifuged at 500 × g during 10 min 
and the resultant supernatant was filtrated through a 0.22 μm pore size filter system (Corning, 
NY USA) to remove large debris while keeping small membranes (under 220 μm) for further 
purification by ultracentrifugation. This step ensures a high enrichment of the preparation on 
small EVs. Filtrated supernatant was transferred to 50 mL centrifuge polycarbonate tubes 
(Beckman Coulter Inc, Brea, California) and ultracentrifuged 30 min at 10,000 × g 4°C to 
remove remaining cell debris. The resultant supernatant was transferred to a fresh tube and 
centrifuged at 100,000 × g 4°C during 75 min to pellet EVs. To eliminate contaminating 
proteins, the supernatant was completely removed, pellets resuspended in 1 mL of DPBS and 
pooled in a single centrifuge tube. More DPBS is added to fill 50 mL and ultracentrifuged at 
100,000 × g 4°C during 75 min. Supernatants were removed and pelleted EVs resuspended in 
50 mM sodium phosphate buffer pH 7.4 in the case of measurements of COMT activity, in 50 
mM HEPES/150 mM KCl pH 8 in the case of measurements of MAT or PBS for any other 
use. In the case of EVs destined to enzymatic measurements buffers contained 10% glycerol. 
Finally, EVs suspensions were split in aliquots to avoid repeated cycles of freezing and 
thawing. If not used immediately aliquots were frozen at -80ºC or liquid nitrogen in the case 
of preparations destined to enzymatic measurements. 
For the analysis of RNAs present in hepatic EVs, the vesicles were isolated using Exoquick 
(SBI System Biosciences). After the filtration (0.22 μm) step of the conditioned media, 1 mL 
aliquots were collected and centrifuge at 3,000 × g for 30 min. Supernatant was then 
transferred to a sterile tube and Exoquick reagent was mixed 1:1 with the media.  
Subsequently, the mixture solution was incubated at 4°C overnight and centrifuged at 1,500 x 
g for 30 min. After centrifugation, supernatant was aspirated and residual ExoQuick solution 
spined down by centrifugation at 1500 × g for 5 min. Finally, the pellets containing EVs were 
resuspended in 1/10 of original volume using PBS. 
 
 
5.12.    PRODUCTION AND ISOLATION OF EVs SECRETED BY MLP-29   
MURINE CELL LINE 
MLP-29 cells were seeded at 15-30 million cells per dish into 150 mm dishes. Cells were 
cultured with complete DMEM [10% (v/v) Fetal Bovine Serum, Streptomycin (0.1 mg/L), 
Penicillin (100 u/mL) and Amphotericin-B (0,25 µg/mL)] for 24 h at 37°C and 5% CO2. Cells 
were then washed twice with DPBS and incubated in complete DMEM medium containing 25 
mM HEPES previously depleted from contaminating vesicles by overnight centrifugation at 
100,000 × g, 4°C. After 72h incubation, media was collected, and EVs isolated by differential 
ultracentrifugation as described previously for primary hepatocytes [149]. EVs were 
suspended in DPBS to between 1/700th and 1/2,000th the original volume of media, 
aliquoted, and stored at -80°C if not used immediately.  
EXPERIMENTAL PROCEDURES 
 
63 
 
As controls for the experiments destined to the metabolic profiling of hepatic EVs, the same 
number of dishes of 150 mm of diameter without cells but containing the same medium 
(complete DMEM-25mM HEPES exosome-depleted) were incubated in same conditions 
(incubation time, CO2 and 37ºC) than the dishes containing cells. After the incubation period, 
the media was collected and processed as previously described for the EVs preparation 
containing cells. 
 
 
5.13.    FRACTIONATION OF EVs ONA CONTINUOUS SUCROSE DENSITY 
GRADIENT 
For some experiments, EVs were obtained from rat hepatocytes treated with hepatotoxic 
drugs (10mM APAP, 10mM GalN and 400µM DCF) and fractionated in a sucrose density 
gradient [149]. Briefly, in a tube suitable for ultracentrifugation (Beckman centrifuge tube 
tube, Cat. No. 344059, SW40 Ti rotor), 6 ml of 0.25 M sucrose solution (20mM HEPES, 0.25 
M protease-free sucrose, pH 7.4) were poured on top of 6 ml of a 2 M sucrose solution 
(20mM HEPES, 2 M protease-free sucrose, pH 7.4). Subsequently, a continuous 0.25-2 M 
sucrose gradient was slowly performed by means of a gradient maker device (Gradient 
Master, Biocomp Instruments, Inc). Once the gradient was pre-formed, EVs prepared by 
differential ultracentrifugation (see section 5.11) was poured carefully on top of the gradient 
and ultracentrifuged overnight (16 h) at 210,000 × g, 4°C, in a SW40 Ti swinging bucket 
rotor. Then 1 mL fractions were collected from top to bottom by using autodensity-flow 
gradient fractionator (Labconco, Kansas City, MO, USA). Subsequently, each fraction was 
diluted in 2 mL of 20 mM HEPES (pH 7.4), placed into a polycarbonate thick wall tube (Cat 
No 362305, Beckman Counter) and ultracentrifuged during 1 h at 110 000 × g, 4°C, in a 
TLA-110 rotor. Finally, supernatants were aspirated and the pellets were resuspended in 25 
μL of PBS and frozen at −80°C if not use immediately. Additionally, 10 μL of each fraction 
were used for measurement of the refractive index by means of a refractometer (Abbe 2WAJ, 
PCE Americas, Inc) to obtain the density value. 
 
5.14.    NANOPARTICLES TRACKING ANALYSIS (NTA)  
Size distribution and concentration within EVs preparations were analyzed using a NanoSight 
LM10 system (NanoSight, Amesbury, U.K.), which is equipped with a fast video capture and 
particle-tracking software. In this system, vesicles are visualized by light scattering using a 
light microscope NTA software tracks the brownian motion of individual vesicles and 
calculates their size and total concentration.  
NTA postacquisition settings were kept constant for all samples, and each video was analyzed 
to give the median vesicle size, and an estimate of the concentration [150]. 
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5.15.    DETERMINATION OF CES ACTIVITY BY USING A FLUOTOMETRIC 
ASSAY 
Fluorometric assay was performed using the protocol followed by Stacey L et al, 2006 [151]. 
Fluorescein formation was measured using a spectrofluorometer (SPECTRAmax Gemini 
plate reader; Molecular Devices Corp, Sunnyvale, CA) at excitation and emission set at 490 
and 520 nM, respectively. Experiment was conducted in 96-well flat bottom plates in a final 
volume of 200 µl, containing 198 µl of potassium phosphate buffer (0.1 M, pH 7.4) and 1 µl 
of EVs sample. The plates were preincubated at 37°C in a fluorometer for 3 min. Reaction 
was initiated by adding 1 µl of the fluorogenic substrate (fluorescein diacetate) at a final 
concentration of 100 µM . The reaction product (fluorescein) was measured for 10 min at 60 
second intervals. 
 
 
5.16.    MEASUREMENTS OF MAT AND COMT ACTIVITIES BY UPLC-MS 
5.16.1.    INCUBATION CONDITIONS 
Previous to COMT and MAT enzymatic activity evaluation, incubation conditions of the 
enzymatic reaction had to be optimised. This involves the use of cofactors as well as the 
adjustment of different parameters such as pH, temperature or incubation time of the reaction 
mixture. It also has to be taken into consideration other factors such as the stability of the 
compounds that take part in the reaction. 
The enzymatic reactions were studied in samples from different origin (Figure 7): Frozen rat 
liver extract, microsomes coming from non-cultured rat hepatocytes (Microsomes t0), 
microsomes coming from untreated rat hepatocytes cultured for 36 h (Microsomes t36) and rat 
hepatocytes cultured for 36 h treated with 400 µM diclofenac in the case of COMT activity 
and also treated with 10 mM acetaminophen and 10 mM galactosamine in the case of MAT 
activity. 
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Figure 7. Experimental design to perform the stydy of the enzymatic activities. This figure shown liver 
extract, microsomes and EVs obtention procedures carried out to study the enzymatic activities carboxylesterase 
(CES), methyl-adenosyl-transferase (MAT) of cathecol-O-methyl transferase (COMT). 
 
 
Incubation conditions for MAT activity 
Enzymatic assays after optimization was carried out in a final volume of 250 µL of 50 mM 
HEPES/ 150 mM KCl pH 8 incubation buffer containing; enzyme provider (liver extract, 
microsomes or EVs), 5 mM L-Methionine, 10 mM MgCl2, 5 mM DTT, 5 mM ATP and 
protease inhibitor. The reaction mixture was incubated for 2 h in a water bath at 37°C. 
Standard stock solutions of L-Methionine (10 mM), ATP (25 mM), protease inhibitor 
(1x10000) and Dithiothreitol (DTT, 1M) were prepared in incubation buffer and MgCl2 (1000 
mM) in water. 
Controls-. Not incubated samples were prepared in parallel 
 
Incubation conditions for COMT activity 
Enzymatic assay after optimization was carried out in final volume of 300 µL of 50 mM 
sodium phosphate buffer pH 7.4, 2 mM MgCl2 and 200 μM SAMe (Abbott S.r.l, Campoverde, 
Italy) without or with 2 mM DA (Sigma-Aldrich) or 0.1 mM NE (Sigma-Aldrich). Reaction 
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mixture was incubated for 1 h at 37°C in a water bath. Standard stock solutions of DA and NE 
(10 mM) were prepared in incubation buffer and MgCl2 (1000 mM) in water. 
Controls-. Three different types of controls were run with each experiment: (a) DA (2 mM) or 
NE (0.1 mM) in 50 mM sodium phosphate buffer pH 7.4, (b) Rat liver extract/ Microsomes/ 
EVs incubated in 50 mM sodium phosphate buffer pH 7.4,and (c) Rat  liver extract/ 
Microsomes/ EVs incubated with DA (2 mM) or NE (0.1 mM) in absence of SAMe and 
MgCl2. 
COMT and MAT enzymatic reactions were then stopped by the addition of 1 mL of MeCN/ 
Water (75/25; v/v%). Then, samples were vortex-mixed for 30 min (4°C) and centrifuged at 
15,000 × g for 30 min (4°C) to precipitate the proteins. Subsequently, the supernatant (1.1 
mL) was reduced to dryness with a speedvac (miVac concentrator, Genevac SP Scientific, 
USA) and samples reconstituted in 1 mL of ammonium phosphate 10 mM in the case of 
COMT activity, and in 1 mL of ammonium sulphate 0.01M in the case of MAT activity. 
Finally they were transferred to solid-phase extraction (SPE) cartridges to clean the samples 
before injected in the UPLC-MS system. Given the different chemical nature of the analyzed 
compounds, different SPE method was employed for each activity assay. As described below, 
a SPE Oasis weak cation exchange (WCX) cartridges in the case of COMT activity and Bond 
Elute cartridges containing 100 mg of Phenylboronic acid (PBA) in the case of MAT activity 
were employed. 
 
5.16.2.    SOLID-PHASE EXTRACTION (SPE) 
SPE was used to process the samples prior to UPLC–MS analysis. The presence of 
interferences in the original sample matrix can result in instrument downtime due to a buildup 
of contamination with each injection [152]. In addition, when a saline solution is injected, the 
formation of the analyte ion could be suppressed by interferences in the sample matrix and the 
signal strength could be greatly diminished. If the interferences are removed as part of the 
sample preparation, then the analytes of interest could be analyzed with a more robust 
method. In this regard, protein precipitation is the most widely employed preparation 
technique in enzymatic assays, coupled to UPLC-MS. However, it was not enough since 
deposit of salts were found in the ion source and cone of the mass spectrometer that was 
translated in decreased sensitivity. Therefore, it was necessary to perform an “extra-clean” 
step of the samples prior to their injection into UPLC-MS system using SPE in addition to 
PPT method. 
SPE is a sample preparation technology that uses solid particles and chromatographic packing 
material contained in a cartridge to chromatographically separate the different components of 
a sample [152]. The first step to develop a SPE method is based on the analytes chemical 
characteristics. Then, chromatography and SPE strategy can be chosen.  
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The general SPE procedure has to provide sample extracts not only free of interfering matrix 
components but also concentrated enough for analytes detection. The protocol consisted of 5-
step including conditioning, equilibration, sample loading, washing and eluting the compound 
of interest [153]. A vacuum manifold system (20 pos, 13x75 mm tubes, Waters Corp., 
Manchester, UK) was used to house the cartridges.  
Analyte Recovery-. The recovery (or extraction efficiency of SPE method) was determined by 
measuring the response of blank matrix (rat liver extract) spiking analytes before SPE (pre-
spiked samples) (Figure 8B) and after SPE (post-spiked samples) (Figure 8C). Non-spiked 
samples were also prepared (rat liver extract in buffer). The recovery was calculated as 
follows: 
%R   Recovery (%) =      ratRRat liver extract spiked with the analyte of interest before SPE (Pre-spiked sample) 
Rat liver extract spiked before UPLC-MS (Post-spiked sample) 
 
The recovery value must be > 50% to be  in acceptable range for routine UPLC-MS analysis 
[154].  
Bond Elut cartridges containing 100 mg phenylboronic acid (PBA) bonded silica from 
Agilent Technologies (Santa Clara, CA, USA) and Oasis WCX Solid-Phase Extraction from 
Waters Corporation (Milford, USA) was used for MAT and COMT enzymatic assays 
respectively. 
After incubation period, resulting supernatants were reduced to dryness with a speedvac and 
reconstituted in appropriate solution depending on the SPE procedure employed for each 
enzymatic assay. Samples were then transferred to the corresponding SPE cartridges and run 
through them. The cartridges were then subsequently washed and analytes eluted and 
evaporated using a speedvac centrifuge. Finally, residues were reconstituted in mobile phase 
and transferred to an autosampler vial for injection in the UPLC-MS system. A total volume 
of 2 µL was injected into the UPLC-MS system. 
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Figure 8.  Preparation of standard and test samples for evaluation of Solid phase extraction method 
recovery. (A) Analytes in solution (B) Analytes spiked in matrix before SPE and (C) Analytes spiked in matrix 
after SPE  
5.16.3.   CALIBRATION CURVE AND QUALITY CONTROLS  
For quantification of products related with the enzymatic reactions, a matrix-spiked 
calibration curves were obtained for each assay.  
In the case of MAT enzymatic assay, standard stock solutions of the enzymatic components, 
10 mM SAMe (Abbort S.r.l, Campoverde, Italy) and 10 mM SAH (Abbort S.r.l, Campoverde, 
Italy),  were prepared in formic acid 0.1 % and 10 mM MTA (Sigma-Aldrich; St. Louis, MO, 
USA) in MeCN/Water/Formic Acid (75/23.8/1.2; v/v/v%).  Working solutions were prepared 
by appropriate dilution in mobile phase (Acetonitrile (ACN)/ Water/ Formic acid 
(60/39.9/0.1; v/v/v %)). For the calibration curve different concentrations of these compounds 
were used: 0.005, 0.01, 0.05, 0.1, 0.25, 0.5, 1, 2.5, 5, 10, 25 and 100 µM. Three non-spiked 
samples were used to calculate a baseline signal for the analytes. For quality controls (QCs) 
two concentrations were used, 1 and 10 µM. Calibration samples (non-spiked and spiked 
samples) were individually prepared in 50 mM HEPES/150 mM  KCl  buffer pH 8 containing 
5 mM ATP, 5 mM Met, 5 mM MgCl2, protease inhibitor and 0.25 mg of protein (rat liver 
extract). After adding 1 mL of MeCN/Water/Formic Acid (75/23.8/1.2; v/v/v%)  to stop the 
reaction, samples were vortex-mixed for 30 min (4°C) and centrifuged at 15,000 × g for 30 
min (4°C) to precipitate the protein. To evaporate the organic solvent, the supernatant (1.1 
Matrix
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mL) was reduced to dryness with a speedvac centrifuge. Then, the residues were reconstituted 
in 1 ml of (NH4)2SO4 0.01 M at pH 7.5 and transferred to SPE-PBA cartridges. 
In the case of COMT enzymatic assay,  standard stock solutions of the enzymatic products 
(10 mM 3-MT and 10 mM NMN) were prepared in Acetonitrile (MeCN)/ Water/ Formic acid 
(60/39.9/0.1; v/v/v %). For the calibration curve different concentrations were used: 0.005, 
0.01, 0.05, 0.1, 0.25, 0.5, 1, 2.5, 5, 10 and 25 µM. Two non-spiked samples were used to 
calculate a baseline signal for the analytes. For Quality Controls (QCs), two concentrations 
were used, 1 and 10 µM. Calibration samples (non-spiked and spiked samples) were prepared 
individually in 300 µL 50 mM sodium phosphate buffer pH 7.4 containing 0.25 mg of protein 
(from rat liver extract) and 2 mM MgCl2. Subsequently, 1 mL of MeCN/Water (75/25; v/v%) 
was added to the mixture reaction and then vortex-mixed for 30 min (4°C) and centrifuged at 
15,000 × g for 30 min (4°C) to precipitate the protein. To evaporate the organic solvent, the 
supernatant (1.1 mL) was reduced to dryness with a Speedvac centrifuge). Then, the residues 
were reconstituted in 1 mL of 1% ammonium phosphate 10 mM (aprox. pH 7.4) and 
transferred to SPE cartridges. 
 
5.16.4.   LIQUID CHROMATOGRAPHY AND MASS SPECTROMETRY (UPLC-  
MS) CONDITIONS 
UPLC conditions   
The substrates and products of the reactions were measured and chromatographically 
separated with an ACQUITY UPLC system (Waters Corp, Milford, USA). The system was 
equipped with two binary solvent pumps, a cooled autosampler (4°C) with a 10 μL injection 
loop and a column oven (40°C). An Acquity UPLC BEH AMIDE column, 1.7 µm (Waters 
Corp.) was used for separation of the analytes. Samples were injected (Vload 2 μL; partial loop 
fill mode) from deactivated total vials (Waters Corp.). A gradient was used to separate the 
analytes; solvent A consisted of 99.5% water, 0.5% formic acid and 20 mM ammonium 
formate while solvent B consisted of 29.5% water, 70% MeCN, 0.5% formic acid and 1 mM 
ammonium formate. The gradient was as follows: from 5% A to 50% A in 2.4 min in curved 
gradient #8, from 50% A to 99.9% A in 0.2 min, constant at 99.9% A for 1.6 min, back to 
05% A in 0.3 min and constant at 5% A for 0.5 min. The flow rate was 0.25 mL/min.  
MS conditions 
 A SYNAPT HDMS G2 Time of Flight (ToF) mass spectrometer (Waters Corp.) was used for 
the detection of the analytes. The ToF was operated in positive electrospray ionization mode 
(ESI+). The following source parameters were used for the analysis: capillary voltage 25 V, 
sample cone voltage 25 V, extraction cone voltage 5 V, desolvation temperature 450°C, 
source temperature 120°C, cone gas flow 5 L/h and desolvation gas flow 600 L/h. Ion optics 
were tuned to a resolution of 22.000 (FWHM) for m/z 556. In order to guarantee mass 
accuracy, leucine-enkefaline solution (2 μg/mL in MeCN/Water (50/50; v/v %) and 0.1% 
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formic acid) was infused into the source via a second ESI probe at 10 µL/min and used as a 
lock mass. Every 30s a lock mass was recorded for 0.5 s. Analyte spectra were automatically 
corrected for fluctuations in the lock mass. 
Initially, to develop the UPLC-MS method ToF (in the MS), it was operated in Full Scan 
Mode (50-1200 Da) with a 0.2 s scan time. Then, in order to reach an optimized lower Limit 
of Detection (LLOD) for 3-MT/NMN and SAH/MTA in the case of COMT and MAT 
enzymatic activities respectively, the ToF was operated in Enhanced Duty Cycle (EDC) 
mode. In EDC mode, the expulsion of ion bunches from the transfer T-Wave
TM
 collision cell 
and the pusher of the ToF analyzer were synchronized so that the duty cycle is optimal for a 
given m/z. 3-MT, NMN, SAH and MTA were measured in a scan function optimized for m/z 
151, m/z 166, m/z 385 and m/z 298 respectively. The scan rate for these scan functions was 
0.2 s. 
 
5.16.5.    ANALYTICAL METHOD 
After sample cleaning and prior to data analysis, several parameters of the method were 
determined to establish the sensitivity and specificity of the developed enzymatic activities. 
Specificity  
This parameter measures the ability of the method to detect potential interferences and 
differentiate and quantitate the analyte in the presence of other endogenous constituents in the 
sample. If any inspecificity is present, it will interfere in the detection and quantification of 
the analyte of interest. 
The specificity of the method was determined by the retention time, accurate mass (3 decimal 
places) and isotope patterns of the analytes. The latter two are indicative of the elemental 
composition of the analyte. Theoretical values for both, accurate mass and isotope pattern, 
were calculated with MassLynx software. In order to obtain the proper retention times, blank 
matrix was spiked with analytes. The retention times of those intensities that increased in the 
mass window of the theoretical mass were taken as the retention times of the analytes. After 
comparing theoretical masses and measured masses, the mass error was around 1 mDa that 
provides the necessary specificity. 
Linearity of calibration curves and Lower Limit of Quantification (LLOQ)  
As the majority of instrumental methods of analysis, chromatography is not an absolute, but 
a relative technique. The response for a sample component must be compared with the 
response of a suitable reference (for example with a substance that closely resembles the 
sample) and with a known amount of the analyte. Usually, the comparison is based on a 
calibration curve extending over a concentration range corresponding to the variation of the 
analyte content in the samples. Once the calibration curve has been constructed, the 
concentration of an unknown sample can easily be extrapolated [155]. 
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To calculate the absolute amount of formed product, the average of the baseline signals was 
subtracted from the signals of the serially diluted calibration samples. The calibration curve 
was obtained over the concentration of a variable range specific of each enzyme.  
Power-fit function was used to determine the relation between the signal (peak area) and 
sample concentration. [signal] = a*[concentration]^b) where a and b are determined by linear 
regression of the log-transformed values of the concentrations and their associated signals. It 
gives the least deviation from the theoretical values, especially at low concentrations. Once 
the sample concentrations were calculated they were converted to amount of product (nmol) 
obtained per mg of protein employed in 1 h incubation. 
The sensitivity expressed as LLOQ was defined as the lowest quantifiable concentration on 
the calibration curve with an acceptable accuracy ( ±15%) and a precision below 15% [156]. 
The deviation from theoretical curve concentration for the LLOQ level should not be more 
than 20%. 
Precision and Accuracy  
These parameters are indispensable criteria in the assessment of an analytical method. 
Monitoring QC during sample analysis is essential to ensure the validity of reported results. 
The accuracy and precision of the method were assessed by determining QC samples at two 
concentration levels.  
Precision was assessed by the relative standard deviation of the analytes (%CV) for either 
high or low QC samples;  
%CV=100*SD/average 
Accuracy was calculated by determining the %deviation of the theoretical values at the QC 
levels: 
%dev=100*((calculated concentration)-(theoretical concentration))/(theoretical 
concentration)) 
5.16.6.    DATA ANALYSIS OF UPLC-MS RESULTS PROVIDED BY MAT AND 
COMT ACTIVITY ASSAYS 
After samples injection in UPLC-MS system, MAT and COMT activities were determined as 
follows.  
Extracted ion traces were obtained for 3-MT (m/z 151.0759), NMN (m/z 166.0868), SAH (m/z 
385.1294) and MTA (m/z 298.0974) with a 20 mDa window and subsequently smoothed (2 
points, 2 iterations) and integrated with QuanLynx software (Waters Corp.). 
Then, to calculate the absolute amount of the products, the average of the baseline signals was 
subtracted from the signals of the serially diluted calibration samples. Subsequently, Power-fit 
function ([Signal] = a x [concentration]
b
) where a and b are the fitted constants) was used to 
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determine the relation between the signal (peak area) and sample concentration. Once the 
sample concentrations were calculated they were converted to amount (nmol) of product 
formed per mg of protein employed in 1 h incubation. The amount of products detected in the 
controls was subtracted from the total amount of product obtained in incubated samples. 
 
5.17.    METABOLIC PROFILING OF HEPATIC EVs BY UPLC-MS   
METABOLOMICS 
5.17.1.   SELECTION OF METABOLITES EXTRACTION METHOD  
Due to the limiting amount of EVs samples, the experiments to select an optimal metabolites 
extraction method were performed only with cell extracts. Three extraction methods were 
tested. Each pellet of cells was suspended in a final volume of 500 µl of a variable solvent 
that depends on the selected extraction method: 
 
- 500 µl MeOH/H2O (50%  v/v)  
- 250 µl MeOH/H2O (50% v/v) + 250 µl Chloroform  (“Biphasic method”) 
- 500 µl Isopropanol  
Twelve cell pellets were mixed and split again into three groups (4 aliquots x 3 extraction 
methods). Mixtures were vortex for 10 seconds and subsequently sonicated during 15 min on 
ice. The resulting homogenate was then agitated at 1400 rpm for 30 min, 4°C and 
subsequently centrifuged at 13,000 rpm for 15 min, 4°C. After centrifugation, 400 µl of the 
supernatant was collected and placed at -80 °C for 20 min. In the case of 
MeOH/H2O/Chroroform (50:50:50, v/v/v) extraction method, two phases were formed (of 
200 µl each) which were collected to independent Eppendorf tubes and placed at -80 °C for 
20 min. Organic solvent was then evaporated by centrifugation in a speedvac 2 h at 4ºC. 
Finally, the obtained pellet was solubilized in 200 µl of mobile phase (ACN)/ Water/ Formic 
acid (60/39.9/0.1; v/v/v %)). A total volume of 2 µl was injected into the UPLC-MS system. 
 
5.17.2.   BIPHASIC METABOLIC EXTRACTION OF CELLS AND EVs  
Five preparations of 100 µl each containing EVs (140 µg) were prepared from MLP29 cells 
and used to obtain the metabolome of hepatic EVs. In parallel, three cells suspension of 100 
µl each of them, containing 1 million of cells were employed for the characterization of the 
metabolic profile of the cells.  
In addition, control samples obtained from tissue culture media incubated in the absence of 
cells under same conditions and subjected to same EV isolation procedure, were employed to 
remove contaminant metabolic signals rising for the media [157]. 
The extraction method employed for metabolites extraction was MeOH/H2O/Chloroform 
(50:50:50, v/v/v) as indicated above. Briefly, 400 µl of MeOH/H2O (50:50) was added to each 
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aliquot to reach a final volume of 500 µl. Then, 500 µL of Chloroform was added and the 
resultant mixture was vortex for 10 seconds and sonicated during 15 min on ice. The resulting 
homogenate was then agitated at 1,400 rpm for 30 min, 4°C and subsequently centrifuged at 
13,000 rpm for 15 min at 4°C. After centrifugation, supernatant was collected and the two 
layers formed (aqueous and organic layer) were collected in independent Eppendorf tubes and 
placed at -80 °C for 20 min. Organic solvent was then evaporated by centrifugation under 
vacuum conditions by 2 h at 4ºC. Finally, the obtained pellet was suspended in 100 µl of 
mobile phase (ACN/ Water/ Formic acid (60/39.9/0.1; v/v/v %)) and injected into the UPLC-
MS system. 
 
5.17.3.   ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY – MASS    
SPECTROMETRY CONDITIONS 
UPLC conditions 
 
Extracted metabolites were measured with a UPLC system (Acquity, Waters, Manchester) 
coupled to a Time of Flight mass spectrometer (ToF- MS, SYNAPT G2, Waters Corp.). Two 
different types of chromatography were used to separate different classes of metabolites.  
 
First the samples were injected on an AMIDE column in order to separate polar metabolites 
and subsequently on a C18 to separate apolar metabolites. A 2.1 mm x 100 mm, 1.7 µm BEH 
AMIDE column (Waters), thermostated at 40 °C, was used to separate the analytes. Solvent A 
(aqueous phase) consisted of 99.5% water, 0.5% formic acid and 20 mM ammonium formate 
while solvent B (organic phase) consisted of 99% acetonitrile, 0.5% water and 0.5% formic 
acid. The gradient was as follows: from 0.1% A to 50% A in 8 min in convex gradient ( #8), 
from 50 %A to 99.9 %A in a linear gradient (#6) of 0.2 min, constant at 99 %A for 1.20 min 
and back to 0.1 %A in 0.2 min to equilibrate. The flow rate was 250 µL/min and the injection 
volume was 5 µL. 
 
The samples were also separated on a 1 mm x 100 mm, 1.7 µm BEH C18 UPLC column, 
thermostated at 40 °C. Solvent A (aqueous phase) consisted of 99.9% water, 0.1% formic acid 
while solvent B (organic phase) consisted of 99.8 % ACN, 0.1% water and 0.1% formic acid. 
The gradient was as follows: from 95 %A to 1 %A in 8 min in a linear gradient (#6), constant 
at 1 %A for 1.4 min and back to 95 %A in 0.2 min to equilibrate. The flow rate was 140 µL/ 
min and the injection volume was 5 µL. 
Injection sequences consisted of test mixes, extraction controls, initialization runs, 
randomized sample sequences and QCs. First, the UPLC and MS performance was evaluated 
by injecting a test mix of known composition. Then, the extraction control samples were 
injected. Next, the column was equilibrated by injecting liver extract samples. After 
equilibration, the randomized sample sets were injected. After each 5 samples a QC sample 
was injected in order to check the stability of the system.  
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MS conditions 
The mass spectrometer was operated in both ESI+ and ESI- modes with capillary voltages of 
respectively 250 V and 500 V for both types of chromatography. Thus, two consecutive runs 
(positive and negative polarity) had to be performed on both columns (amide and C18). The 
settings described next, were the same for all polarities and chromatographies. The extraction 
cone voltage was 5 V and sampling cone voltage was 25 V. Source temperature was 120 ºC 
while capillary temperature was 450 ºC. Two scan functions were used; one for low collision 
energy (4 V) and one for high collision energy (30 V). Samples were measured in full scan 
mode from 50 to 1,200 Da. Polar and apolar sets were first measured in ESI+ mode and 
subsequently in ESI- mode.  
 
5.17.4.   DATA PROCESSING, MULTIVARIATE ANALYSIS AND METABOLITE    
IDENTIFICATION 
All data was processed using the MarkerLynx application manager for MassLynx 4.1 
software (Waters Corp., Milford, USA), which is a post-adquisition processing package that 
can be applied to MS data files. A list of chromatographic peak areas for the metabolites 
detected in each sample injection was generated. Both polarities and chromatographies were 
separately analyzed. The UPLC-MS data were peak-detected and noise reduced such that only 
true analytical peaks were further processed by the software. A list of intensities 
(chromatographic peak areas) of the peaks detected was then generated, using the RT-mz 
(retention time and m/z) data pairs as identifiers in a mass window of 0.02 Da and a RT 
window of 0.05 min. 
After data processing, the RT-mz signals were subjected to Principal components analysis 
(PCA) to determine metabolic profile differences between cells and EVs. In the PCA, the first 
two principal components (t[1] and t[2]) are plotted, representing the most important 
metabolic variation in the samples captured by the analysis. The final dataset was mean 
centered and log-transformed during multivariate data analysis. Selected peaks were 
tentatively identified by using the corresponding exact molecular mass and MS data for 
searching in the databases Metlin (https://metlin.scripps.edu/index.php) and HMDB 
(http://www.hmdb.ca). 
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6.   RESULTS AND DISCUSSION 
6.1   RAT HEPATOCYTES IN MODELS OF DILI 
Different hepatotoxic agents are frequently used as model substances to induce liver injury in 
animals. Nevertheless, due to scientific, ethical and also economical reasons, there is a high 
tendency to replace animal models by appropriate alternative methods. Isolated primary 
hepatocytes fulfill these requirements and they could be useful in vitro DILI model [158]. 
This model allows evaluating the injury induced by different hepatotoxicants, such as 
acetaminophen (APAP), galactosamine (GalN) or diclofenac (DCF) using different molecular 
and biochemical approaches [20]. Hepatocytes cultured on collagen-coated dishes de-
differentiate within 72h period [159][160]. Taking this into consideration, the incubation 
period of the primary hepatocytes was established in 36 h in order to have enough hepatic 
secreted EVs for their detection and analysis. Based on published works, the concentrations of 
drugs employed in this study were 10mM for APAP and GalN [161] [21] and 400µM in the 
case of DCF [162]. Using these conditions, several cellular parameters were evaluated. 
 
6.1.1.   CELL VIABILITY   
Cell viability after treatment with APAP, GalN and DCF hepatotoxicants was determined by 
trypan-blue exclusion method. Then, the obtained values were normalized to the control 
(untreated), that corresponds with 100% of viability. A slightly decrease in the cell viability in 
all treatments was observed. After treatments, cell viability ranged from 84 to 95% (Figure 
9), being this effect consistent in the 10 independent experiments examined (Figure 10). This 
small reduction in the viability, indicates that no dramatic cell death was observed under 
conditions used for this study. 
 
 
Figure 9. Cellular viability analysis of rat hepatocytes exposed to liver-damaging drugs. Cell viability of 
primary rat hepatocyte was evaluated by trypan-blue exclusion method after cultured during 36h in the presence 
of APAP (10 mM), GalN (10 mM) or DCF (400µM). Error bars represent standard error (n = 10), ** denotes 
p<0.01 with respect to the control. 
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Figure 10. Reproducibility analysis of cellular viability in independent rat hepatocytes preparations. . 
Primary rat hepatocytes (RH) were incubated during 36 hours in the presence of the hepatotoxic compounds and 
cell viability was determined by trypan-blue exclusion method. Note the reproducibility in terms of cell viability 
among all preparations. 
 
6.1.2.    CELL MORPHOLOGY 
In agreement with the low effect on cell viability under assayed conditions, the number of 
attached cells remains very similar in all APAP, GalN and DCF treatments as can be observed 
in the inmunofluorecence analysis (Figure 11). The effect of the different treatments on the 
hepatocyte morphology was studied by examining sub-cellular localization of different 
proteins by confocal microscopy (Figure 11).  
To evaluate the effect on the morphology of the cells it was firstly studied the cytoskeleton by 
staining F-actin with fluorescently labelled phalloidin. As it can be observed, there were no 
significant morphological alterations in cells treated with the different hepatotoxicants 
compared to untreated hepatocytes. In particular, a slightly increase in the fluorescence 
intensity was observed in DCF-treated hepatocytes, indicating changes in the amount of F-
actin (Figure 11, Panel A). 
It was also evaluated the effect on the intracellular distribution of enzymes that have been 
described to be present in hepatic EVs [69], such as Ces1d, P450 2d1, MAT and COMT. In 
the case of the drug-metabolizing enzyme Ces1d, there was no significant alteration neither in 
their abundance or intracellular cytosolic localization (Figure 11, Panel B). 
Which regards to cytochrome P450 2d1 (rat ortholog of human P450 2D6), which takes part 
in the metabolism of APAP [163], GalN [95] and DCF [164], the cellular staining was mostly 
associated to plasma membrane. In this case, as occur with Ces1d, there was no significant 
alteration neither in localization or intracellular abundance after treatment with the 
hepatotoxicants (Figure 11, Panel C). 
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COMT, which is involved in the elimination of biologically active or toxic catechols and 
some other hydroxylated metabolites, presents a marked membrane distribution in both, 
untreated and treated hepatocytes. In this case, an increase in the intracellular content of this 
enzyme was observed in APAP and GalN-treated hepatocytes respect to the control (Figure 
11, Panel D). 
Finally, MAT enzyme is involved in the regulation of the central metabolite S-
adenosylmethionine (SAMe). Its distribution was mostly cytoplasmic although a marked 
membrane localization in APAP-treated hepatocytes was clearly observed (Figure 11, Panel 
E). 
Next, the effect of the different treatments on intracellular localization of proteins that are 
considered markers of EVs such as Cd81 and LIMP II proteins was evaluated. In the case of 
Cd81, untreated cells showed both, plasma membrane and intracellular vesicular localization. 
However, in cells treated with APAP and GalN, Cd81 was localized mostly in the plasma 
membrane losing its intracellular vesicular pattern (Figure 11, Panel F). On the other hand, 
LIMP II was preferentially localized in intracellular vesicles in all the cases, although the 
distribution of the vesicles was more perinuclear in untreated cells than in the treated 
hepatocytes. In this case, it was also possible to appreciate that the abundance of the protein in 
APAP and GalN-treated hepatocytes was reduced compared to untreated or DCF-treated cells 
(Figure 11, Panel G).  
All these results show that liver-damaging compounds have different effects on the abundance 
and/or in the intracellular distribution of different proteins. This indicates that different 
responses are carried out in hepatocytes depending on the induced liver damage. 
   
 Panel A: F-Actin 
 
Figure 11. Confocal analysis of primary rat hepatocytes in DILI conditions. Untreated- or cells-treated with 
the hepatotoxins during 36 hours were formaldehyde-fixed and processed to analyze indicate markers.  The 
images were captured by confocal microscopy under similar conditions. Scale bar: 40µm. 
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 Panel B: CES3 
 
 
 Panel C: Cyp 2d1 
 Figure 11 (continuation) 
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 Panel D: COMT 
 
 
 Panel E: MAT1A 
 Figure 11 (continuation) 
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 Panel F: Cd81 
 
 
 Panel G: LIMP II 
 Figure 11 (continuation) 
 
6.1.3.    WESTERN BLOT ANALYSIS 
The effect of the APAP, GalN and DCF drugs on the intracellular content of hepatocytes was 
also evaluated by Western-blotting, focusing the study on protein markers of EVs (LIMP II, 
Hsp70, Hsp90, Rab8, Flotillin-1 and Cd63) and on an intracellular compartment as the 
mitochondria (Cox IV). Several enzymes that were previously detected in hepatocyte-derived 
EVs (Ces1d, MAT, COMT) were also analyzed [69]. 
Consistent with the results obtained in the confocal microscopy analysis, similar differences 
were found in the behaviour of the proteins analyzed by Western-blotting, suggesting again 
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different responses of the hepatocytes to the tested drugs. While cellular levels of Cd63 and 
Hsp70 decreased in all treatments, the levels of Ces1d increased in GalN- and DCF-
treatments and the levels of Flotillin-1 and COMT increased only in GalN-treated hepatocytes 
(Figure 12). It is also important to highlight that APAP-treatment caused a drastic reduction 
in the cellular levels of most of the assayed proteins, suggesting that this drug, under these 
conditions, provokes the most severe effects. This is in agreement with the cell viability 
results (Figure 9), where APAP caused the highest drop in cell viability. Interestingly, the 
only protein that increased in the cells exposed to APAP was the mitochondria marker Cox IV 
(Figure 12), in accordance with the proposed mechanism of APAP toxicity that implies 
mitochondria dysfunction [24] [25]. 
 
 
 
 
 
Figure 12. Western-blot analysis of primary rat hepatocytes and their corresponding secreted EVs. Protein 
extracts (10ug) prepared from rat hepatocytes and secreted EVs were analyzed by Western-blotting after the 
exposure of indicated drugs, using antibodies against the following proteins: LIMP II, Hsp 70, CES3, Flotillin-1, 
COMT, Rab8, COX IV, Hsp90 and CD63. Two representative preparations are shown and molecular weights are 
indicated in KDa. 
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6.2.   EVs SECRETED BY PRIMARY RAT HEPATOCYTES IN MODELS OF DILI 
 
MOLECULAR CHARACTERIZATION  
EVs derived of rat hepatocytes after exposure to APAP, GalN and DCF hepatotoxic drugs 
were isolated by differential ultracentrifugation and analyzed by NTA, Cryo-EM, Western-
blotting and RTM. The use of these complementary techniques allows a rapid characterization 
of EVs using small amount of material. NTA is valuable for studying the size distribution and 
concentration, Cryo-EM for morphological characterization (vesicle heterogeneity) [165], 
while Western-blotting and RTM provides information about the protein and global chemical 
composition, respectively [166]. 
 
6.2.1.   EVs SIZE, MORPHOLOGY AND CONCENTRATION ANALYSIS 
Nanoparticle Tracking Analysis (NTA) is a simple and rapid method to determine  
nanoparticles size distribution and concentration [150]. 
The NTA analysis of EVs from untreated hepatocytes showed two main vesicles populations 
with 70% of the vesicles ranged on average size of 110 and 180 nm. Regarding EVs released 
by hepatocytes after exposure to different hepatotoxic drugs, a modification in the size 
distribution of the vesicles could be observed. In the case of GalN and DCF treatments, 50% 
of the vesicles maintain these two main vesicle populations, although they are not so 
pronounced as in untreated cells. Nevertheless, in the case of APAP treatment there is a clear 
main population on average size of 130 nm consisting of 50% of vesicles (Figure 13B). This 
result indicates that under these experimental conditions, the hepatotoxins provoke changes in 
the populations of secreted-vesicles.  
In all treatments, Cryo-EM images revealed a membrane vesicles limited by a lipid bilayer 
(Figure 13A). In the case of DCF-treated hepatocytes, in addition to rounded vesicles, there 
was amorphous non-vesicular material in the EVs purifications in comparison with the rest of 
the conditions (Fig. 13A, DCF-treatment). It is important to highlight the high heterogeneity 
of vesicles observed in all the preparations in terms of size and shape. Also in many cases it 
was possible to observe vesicles inside the vesicles (Fig. 13A, APAP and GalN-treatment). 
In summary, these analyses together revealed heterogeneous EVs populations in terms of size 
and morphology and suggest that the hepatotoxic treatments alter the size distribution of EVs.  
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Figure 13. Ultrastructural characterization of EVs in DILI models. Comparison of cryo-electron  
microscopy and Nanosight Tracking Analysis of hepatic EVs after treatment with different hepatotoxic drugs. 
(A) EVs were analyzed by Cryo-EM. Images show electron micrographs of membrane vesicles of different sizes 
and morphology. Scale bar: 100 nm. (B) NTA analysis showing vesicles size distribution (n=10).  
 
 
NTA also allows the quantification of the number of vesicles present in the preparations. As 
can be observed in the Figure 14, the amount of secreted vesicles increased significantly in 
treated hepatocytes; 4.5, 3.8 and 3.5 fold in APAP-, GalN- and DCF-treated hepatocytes 
respectively compared to the level of secretion observed in untreated cells.  
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Figure 14. Total number of particles secreted in DILI models. The total number of secreted vesicles 
contained in each rat hepatocytes preparation after EVs isolation was estimated by means of Nanosight Tracking 
analysis. The mean number of secreted vesicles from untreated, APAP, GalN and DCF-treated hepatocytes was 
2.19·1010, 9.79·1010, 8.41·1010 and 7.68·1010 vesicles respectively.  Error bars represent SE (n = 10), * denotes 
p<0.01. 
 
The total number of secreted vesicles estimated by NTA was then compared with the total 
protein amount of EVs estimated by means of Bradford assay. As shown in Figure 15, the 
total protein amount of hepatic EVs obtained after each treatment correlates with the number 
of secreted vesicles (see Figure 14). APAP was the treatment with highest values for number 
of secreted vesicles and amount of protein, followed by DCF, GalN and control in decreasing 
order.  
 
 
Figure 15. Total protein amount of EVs secreted in DILI models. The total protein amount contained in EVs 
preparation was determined by means of Bradford assay. The mean protein amount of hepatic EVs control and 
after treatment with APAP, GalN and DCF was 150, 550, 451 and 450µg respectively.  Error bars represent SE 
(n = 10), * denotes p<0.01. 
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In order to estimate the purity of each preparation of vesicles, it was used the method 
described by Webber J and Clayton A, 2013 [167]. In this study is hypothesized that vesicle 
preparations that are more pure exhibit a relatively high ratio of particles to protein 
(NTA/Bradford). Thus, the presence of contaminating proteins in the samples would decrease 
this ratio. The ratio (NTA/Bradford) of EVs isolated from untreated and treated hepatocytes 
were 0.22 and 0.03 respectively. Thus, the ratio is more than 7-fold higher in EVs control than 
in EVs coming from treated cells. This result suggests that although there is an effect in the 
number of secreted vesicles under DILI conditions, there is even a higher effect in the release 
of protein aggregates.  
 
6.2.2.   WESTERN BLOT ANALYSIS 
Until now, several proteins have been identified as EVs markers, including Cd63, Hsp70, 
Hsp90, Rab8, Flotillin-1 and LIMP II among others. In this work, the expression of these 
proteins was analyzed by Western blot in both untreated and treated hepatocytes as well as in 
their derived EVs (Figure 12). 
In the case of Hsp70 and Hsp 90, there is a decreased expression of these proteins in the 
treated cells that is accompanied by an increase in the corresponding EVs. Regarding Rab 8, 
there is a significant protein expression decrease in APAP-treatment in both cells and EVs. In 
contrast, for GalN- and DCF-treatments, there is an increase in the levels of this protein in 
EVs. 
In the case of Flotillin-1, its expression is significantly reduced in both, cells and EVs in 
APAP- and DCF-treatments. In contrast, in the case of GalN-treatment such expression is 
increased. Which regards Cd63, there is a significant decrease in protein expression in treated 
hepatocytes for both, cells and EVs. LIMP II protein expression levels decreased notably in 
EVs in APAP- and DCF-treatments and, at less extent, in GalN-treatment.  
In the case of Ces1d, there are increased protein expression levels in GalN- and DCF-treated 
hepatocytes derived EVs. Finally, COMT protein expression levels were clearly increased in 
EVs from GalN-treated hepatocytes. 
In summary, the different levels of proteins observed in the different treatments suggest that 
different regulation processes are carried out in response to APAP, GalN and DCF induced 
liver damage.  
 
6.2.3.   EVs OVERALL COMPOSITION ANALYSIS 
Once analyzed vesicles size, amount and morphology, it was wanted to fulfill hepatic EVs 
characterization analyzing their general composition.  
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Western blotting, as seen previously, allows analyzing the expression of determined proteins 
but it does not give information about the overall composition including proteins, lipids and 
nucleic acids. Yet, this analysis is possible using RTM [166]. Thus, changes in EVs global 
chemical composition in our DILI models were analyzed by RTM technology in collaboration 
with Sergei G. Kruglik and his group in Pierre et Marie Curie University in Paris (France). 
RTM is the technique of choice for global chemical study in a time scale of few seconds of 
trapped EVs. It monitors variations in vesicular composition. In this case, EVs preparations 
were analyzed in duplicate. As can be observed in Figure 16, there is not significant shift 
variation when comparing each point of the curve of the duplicates, indicating the high 
reproducibility of the technique. 
 
Figure 16. Raman tweezers microspectroscopy technique applied to study EVs global composition in 
DILI models. Raman spectrum represents the average signal corresponding to the total number of vesicles 
trapped in the focus of the microscope. All spectra were corrected for the PBS contribution. Shift is given in 
terms of spectral resolution (cm-1).  
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Figure 17 shows the proposed interpretation of Raman spectrum originated from the EVs 
released by untreated rat hepatocytes. It appears that vesicles composition is heterogeneous, 
with different proportions of the chemical compounds. The main Raman signatures of lipids, 
proteins and nucleic acids are identified (arrows).  
 
 
 
 
Figure 17. Average Raman spectra interpretation for rat hepatocytes derived EVs. Position, frequencies 
and bands interpretation for the major spectral differences are indicated by arrows. Raman spectrum represents 
the average signal corresponding to the total number of the vesicles trapped (n=2) Background was subtracted 
from both spectra to facilitate the comparison.  Shift is given in terms of spectral resolution (cm-1). 
 
 
In Figure 18, the Raman spectrum corresponding to each treatment is represented. On these 
data, it is possible to characterize differences in composition between treatments. The higher 
RTM shift differences (black line), the bigger the alteration in EVs composition. In this 
regard, APAP-treated hepatocytes derived EVs have the major change in composition relative 
to untreated cells, showing more prominent lipids signatures than the control. Moreover, the 
amino acid tryptophan has also higher contribution in APAP-treatment (Figure 18A). 
Interestingly, in the Western blot analysis, APAP has a detrimental effect in the expression of 
the majority of the analyzed proteins (see Figure 12).  On the other hand, in GalN- and DCF-
treated hepatocytes derived EVs there is a decrease in general lipid contribution with respect 
to the control, although at less extent compared to APAP-treatment. Finally, regarding nucleic 
acid composition, there are not significant changes in the treatments with respect to control. 
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Figure 18. Analsyis of overall composition of hepatocytes-secreted EVs in DILI models. Comparison of 
the similarity/ variability of RAMAN spectra between untreated and treated hepatocytes is shown. (A) Control 
vs APAP, (B) control vs DCF and (C) control vs GalN is compared. Shift or composition differences between 
different treatments is given in terms of spectral resolution (cm-1). Raman spectrum represents the average 
signal corresponding to the total number of the vesicles trapped. All spectra were corrected for the PBS 
contribution. 
 
These results also suggest that different regulatory processes are carried out in response to 
APAP, GalN and DCF induced damage. Indeed, the general composition, amount and cargo 
of EVs has been observed to vary according to induced liver damage reflecting in this way the 
physiological condition of the liver [33]. In this regard, APAP is the treatment with the 
highest number of secreted vesicles, the most detrimental effect in the expression of most of 
the analyzed proteins and also with the highest alteration in overall composition, suggesting a 
severe liver damage. 
Overall, it seems plausible to discriminate between different DILI treatments basing on EVs 
general composition analysis, strongly supporting the application of EVs as a source of non-
invasive DILI biomarkers.  
Finally, it is important to remark that the approach of a rapid characterization of EVs could be 
proposed by the joint use of the three complementary methods, NTA, Cryo-EM and RTM, 
with easy sample preparation and without the use of any added label. 
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6.2.4.    EVs RNA CONTENT ANALYSIS 
Since the demonstration that EVs cargo apart from protein and lipids also contain nucleic 
acids including both, DNA and RNA, numerous groups have analyzed the presence of genetic 
material in EVs. In this regard, it has been showed that EVs released by rat hepatocytes also 
carry RNA [70]. Remarkably, some of those RNAs were enriched in EVs respect to 
intracellular content. In particular, Albumin (Alb), retinol binding protein 4 (RBP4) and beta 
polypeptide 2-like 1 (GNB2L1) gene transcripts were analyzed due to their relevance in the 
biological context of the liver function. Briefly, albumin is synthesized in the liver and 
secreted into the serum in order to mobilize different molecules. GNB2L1 acts as an anchor or 
adaptor protein providing a platform for protein-protein interactions involved in cell-signaling 
pathways [168]. Finally, vitamin A (retinol) is absorbed in the small intestine, stored in liver, 
and secreted into circulation bound to RBP4 [169]. 
With the aim of characterizing the effects of hepatotoxic drugs in the RNA cargo of hepatic 
EVs, EVs derived from hepatocytes exposed to GalN, APAP or DCF were isolated and RNA 
contained in them was extracted for further analysis. 
As it is shown in Figure 19A, remarkable differences between the RNA cargos of EVs 
released after the different liver-damaging treatments were found. All the treatments clearly 
increased the levels of analyzed RNAs (Alb, GNB2Ll and RBP4) secreted to the culture 
media. In fact, the amounts of Alb transcript increased from 2 to more than 15-fold in 
comparison with untreated hepatocytes. In the same way, the levels of transcripts coding for 
GNB2Ll and RBP4 proteins only increased significantly after GalN and DCF treatments, 
being more pronounced in the case of DCF. In particular, the levels of GNB2Ll increased 5- 
and 20-fold after GalN and DCF treatments respectively, whereas APAP treatment had no 
effect on the expression levels of this transcript. Overall, the levels of the three transcripts 
increased with GalN and DCF treatments, whereas when treating with APAP only the levels 
of albumin transcript is increased. 
These results were further validated in the in vivo model. For this purpose, EVs from serum of 
rats treated with GalN (controls treated with saline solution) were purified using Exoquick 
reagent. As shown in Figure 19B, the amplification of RNAs associated with EVs, such as 
Alb, GNB2Ll and RBP4 was observed in GalN-injured animals, which was in agreement with 
the in vitro results. 
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Figure 19. RNA cargo of hepatic EVs in DILI models.  (A) qPCR analysis of three RNA transcripts 
(Albumine (Alb), Retinol binding protein 4 (Rbp4) and beta polypeptide 2-like 1 (Gnb2l))   released by hepatic 
EVs after exposure to indicated drugs is shown (error bars represent SD of 3 independent experiments (n = 2), * 
denotes p<0.05 with respect to the control (B) qPCR analysis of RNA cargo of EVs isolated from serum of 
untreated (U) rats and rats treated (T) with galactosamine (inducing acute liver injury). 
 
Overall, in vitro and in vivo evidences suggest that DILI, in addition to modifying protein 
content, it also modifies the RNA content of hepatocytes-secreted EVs. Therefore, these 
results suggest that RNA cargo of hepatocyte-derived EVs, such as albumin, Gnb2l or Rbp4, 
could serve as a suitable non-invasive candidate marker for liver toxicity. 
 
FUNCTIONAL CHARACTERIZATION (ENZYMATIC ACTIVITY ANALYSIS) 
 
In the previous section, focused on the molecular characterization of the hepatocytes-derived 
EVs, it was showed the presence of many metabolic enzymes including Ces1d, MAT and 
COMT that play important role in endogenous and xenobiotics metabolism. However, the 
presence of the protein does not mean that is active. Thus, the next objective was to 
demonstrate that these enzymes were active in hepatocytes-derived EVs. To determine the 
activity of Ces1d, a fluorometric assay was used. However, to determine MAT and COMT 
activities, it was required to develop in-house methods. 
 
6.2.5.    CES ACTIVITY ANALYSIS 
Firstly, it was tested if carboxylesterase (Ces1d) activity is present in hepatic EVs. To 
measure this activity, a fluorometric assay was performed using the protocol followed by 
Stacey L et al, 2006 [151]. EVs preparations were incubated at 37ºC in the presence of 
fluorescein diacetate and the formation of fluorescein by the action of Ces1d was measured in 
a fluorometer. As carboxylesterase activity was detected in control EVs, then, it was 
determined if DILI affected it in accordance to the Western blot results (see Figure 12). 
A) B)
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6.2.5.1.   Esterase Activity analysis 
Figure 20 shows the esterase activity detected in two independent preparations of EVs 
secreted by rat hepatocytes. In both preparations, EVs isolated from untreated hepatocytes 
showed esterase activity almost 2 times higher than the mock (absence of EVs). In addition, 
both independent preparations of EVs follow a similar trend.  
When analyzed the effect of DILI in EVs associated carboxilesterase activity, the lowest 
activity was detected in EVs coming from untreated hepatocytes, while in EVs from 
hepatocytes exposed to liver damaging drugs was increased 2, 3 and 5-fold in APAP, DCF 
and GalN-treatments respectively compared to control (Figure 20). These results strongly 
suggest that hepatic EVs carry active enzymes. Moreover, esterase activity is discriminative 
between different hepatotoxic treatments. 
 
Figure 20. Carboxylesterase activity in EVs from DILI models. CES activity contained in EVs is 
increased after the exposure of indicated drugs. The activity is expressed in relative fluorescent unit 
per minute (RFU/min) and expressed as fold change respect to the control. Results from two 
independent preparations are shown. 
 
6.2.5.2.   Continuous density gradient analysis 
In order to ensure that detected carboxilesterase activity comes from hepatic EVs, an extra 
purification step involving a continuous sucrose density gradient was performed to obtain 
highly pure EVs preparation. This step eliminates additional contaminants, such as proteins 
non specifically associated with EVs and large protein aggregates that could also be 
precipitated by ultracentrifugation but do not float on a density gradient [149]. To do that, 
equal amount (Bradford quantified) of EVs obtained from the control and the DILI models 
were subfractioned in sucrose density gradient. Then, all the fractions were analyzed by 
Western blotting and also assayed for CES activity. In all the cases, the carboxilesterase 
activity appears enriched in a fraction having a density of 1.21 g/ml (F9) (Figure 21B). This 
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was in complete agreement with the detection of the protein in the same fraction of the 
gradients by Western-blotting (Figure 21A). The activity was 2 and 5-fold higher in APAP 
and GalN-treatments with respect to control. 
 
 
 
 
Figure 21. Density fractionation and CES activity analysis of hepatic EVs in DILI models. (A)  Fractions 
obtained from sucrose density gradient were analyzed by Western-blotting. 5 µl of EVs sample were loaded in 
the input (13µg Control, 22.9µg APAP and 26.65µg in GalN) and 10µg of each fraction. The most abundant 
band was found in the fraction corresponding to EVs density. Treated EVs show more diversity, with vesicle 
populations fractionating at different densities than untreated. (B) EVs were sub-fractioned in a continuous 
sucrose density gradient and the esterase activity determined in each fraction. Esterase activity is expressed in 
relative fluorescent unit per minute (RFU/min), given in fold change respect to fraction 1 (F1).  
 
It is important to highlight that the density of the EVs where Ces1d was localized was not 
significantly modified by DILI treatments, indicating that not dramatic changes in global 
composition of the vesicles were provoked. 
In summary, these results correlate throughout the different assays. Both, protein expression 
levels (Western blotting) and enzymatic activity (Esterase activity measurement) increase 
with APAP, DCF and GalN-treatments in increasing order with respects to control.  
Therefore, CES activity varies depending on the induced liver damage, being able to 
discriminate between different liver injuries. 
 
ANALYTICAL METHOD DEVELOPMENT OF MAT AND COMT ACTIVITIES 
It is known the presence of COMT and MAT1A enzymes in hepatic EVs showed by 
proteomics and Western-blotting [69], but nothing about their activities in this localization 
has been reported so far. In order to address this question properly, a method to measure the 
activity of each of these enzymes using UPLC-MS technology was developed, which 
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provides high specificity and sensitivity. Following section, describes the optimization of 
several parameters of the procedure that were required before the analysis of hepatic EVs.  
 
6.2.6.    MAT ACTIVITY ANALYSIS 
6.2.6.1.   Analytical method development 
6.2.6.1.1.   Optimization of the incubation condition for the enzymatic reaction to assay     
MAT activity 
Although several studies have reported kinetic data of MAT activity in liver, the enzymatic 
reaction conditions are not well established yet. Initially, MAT activity was studied in rat liver 
extract following the protocol reported by Kim et al. 2008. Under these conditions, not 
reproducible results were obtained, being necessary to optimize several parameters of the 
enzymatic reaction including pH, ATP, salts, methionine and incubation time.  
During the optimization process, the standard conditions of the assay were performed in a 
final volume of 250 μl containing 100 mM Tris-HCl buffer pH 8.7: enzyme provider (250µg 
of rat liver extract), 5 mM ATP, 5 mM L-methionine, 150 mM KCl, 10 mM MgCl2, protease 
inhibitor (1 x 1,000) and 5 mM DTT. A reducing agent (DTT) is necessary since the oxidation 
of the enzyme produces an internal disulfide that could cause the inhibition of the enzyme 
[170]. The parameters to be optimized were modified as indicated for the specific 
experiments. 
 
pH optimization  
To determine optimal pH, Tris-HCl buffer 100 mM ranging from pH 7.4 to 9.2 was assayed 
under standard conditions (mentioned above) (Figure 22). Under these conditions, the 
enzyme reached its major activity at pHs between 8.0 and 9.2 and shown optimal activity at 
pH 8.7 (Figure 22A), which was in agreement with the value reported by Suma et al. 1986. 
The activity of the enzyme decreased above pH 9.2, suggesting that highly alkaline conditions 
may have a detrimental effect on enzyme and compounds stability. During the incubation 
period, the amount of consumed methionine was also measured (Figure 22B) at pH 8.7. In 
this way, reaction specificity was also confirmed. 
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Figure 22. Optimization of pH for MAT enzymatic activity.(A) The enzymatic assay was performed at 37°C 
in 100mM Tris-HCl buffer at different pHs (7.4, 8.0, 8.7 and 9.2) and time points (0, 30, 60, 90 and 120min). (B) 
The amount of consumed L-Methionine during the reaction was measured at pH 8.7 and different time points (0, 
30, 60, 90 and 120min). The reaction mixture contained the following components in a final volume of 250 μl: 
250 μg of protein (rat liver extract), 5 mM ATP, 0.1 mM methionine, MgCl2 5 mM, KCl 50 mM, 5 mM DTT 
and protease inhibitor (1x1,000). MAT activity is expressed as Σ products (SAMe and SAH) in nmol/0.25mg 
protein.  
 
Optimization of temperature of incubation for the reaction 
Once fixed the pH, the optimal temperature of the enzymatic activity was determined under 
standard assay conditions, incubating the reaction mixture at increasing temperatures ranging 
from 27°C to 52°C. The highest MAT activity at pH 8.7, was obtained at 37°C (Figure  23A). 
Rat liver basal temperature is 39.3°C [171],  which is found in the range of MAT enzymatic 
activity optimum temperature (37°C-42°C). MAT denaturation studies on recombinant rat 
liver MAT activity, showed its irreversibility at temperatures between 47–51°C [172], which 
is in agreement  with obtained results. In addition, SAMe is thermolabile, which could be 
translated in a partial decay of SAMe during prolonged incubation periods at high 
temperatures. In this regard, SAMe would be cleaved into MTA and homoserine by a 
nucleophilic attack of the carboxylate group which, at the end, would complicate the 
analytical study of SAMe [173]. During the incubation period, the amount of consumed 
methionine was also measured at 37°C (Figure 23B). In this way, reaction specificity could 
also be confirmed. 
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Figure 23. Optimization of temperature reaction for MAT activity. (A) The enzymatic assay was performed 
at 37°C in 100mM Tris-HCl buffer at pH 8.7 at different temperatures (27, 32, 27, 42, 47 and 52°C) and 
timepoints (0, 30 and 60 min). (B) The amount of consumed L-Methionine during the reaction was measured 
(nmol/0.25mg prot) at 37°C and different timepoints (0, 30 and 60 min) The reaction mixture was incubated 
under standard assay conditions; 250 μg of protein (rat liver extract), 5 mM ATP, 0.1 mM methionine, MgCl2 5 
mM, 50 mMKCl, 5 mM DTT and protease inhibitor. MAT activity is expressed as Σ products (SAMe and SAH) 
in nmol/0.25mg protein. 
 
Optimization of divalent (Mg
2+
) and monovalent (K
+
) cations content in the  reaction. 
MAT activity requires both Mg
2+
 and K
+ 
cations for maximal activity [101], [174] given that 
the mechanism of hydrolysis of the ATP requires these cations. When these cations are in 
high concentrations, MAT activity could be inhibited due to the effect of high ionic strength 
[175]. The Figure 24 shows the effect of combined concentrations of Mg
2+
 and K
+
 cations in 
MAT activity. The optimal salts concentrations were established at 10 mM MgCl2 and 150 
mM KCl. 
 
Figure 24. Optimization of divalent (Mg
2+
) and monovalent (K
+
) cations content in the reaction. Effect of 
Mg2+ and K+ on enzyme activity of MAT was evaluated in Tris-HCl buffer (100 mM, pH 8.7) at 37°C for 60 
min. The reaction mixture was incubated under standard assay conditions (250 μg of protein from rat liver 
extract, 5 mM ATP, 0.1 mM methionine, 5 mM DTT and protease inhibitor), using different concentrations of 
MgCl2 (5, 10 and 20 mM) and  KCl (150 and 250 mM) in a final volume of 250µl. MAT activity is expressed as 
Σ products (SAMe and SAH) in nmol/0.25mg protein/1h. 
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Optimization of L-methionine concentration in the reaction assay 
Optimal L-methionine concentration for MAT enzymatic activity was determined under 
standard assay conditions, incubating L-methionine at increasing concentrations ranging from 
0.1 to 10 mM. As can be observed in the Figure 25, the highest MAT activity efficiency was 
reached when incubating rat liver extract with 5 mM L-methionine. 
 
 
Figure 25.  Optimization of L-methionine concentration for MAT activity. The enzymatic assay was 
performed in Tris-HCl buffer (100 mM, pH 8.7) at 37°C for 60 min. The reaction mixture was incubated under 
standard assay conditions; 250 μg of rat liver extract, 5 mM ATP, 10 mM MgCl2, 150 mM KCl, 5 mM DTT and 
protease inhibitor in a final volume of 250 µl, using different concentrations of  L-methionine (from 0.1 to 10 
mM.). MAT activity is expressed as Σ products (SAMe and SAH) in nmol/0.25mg protein/1h. 
Optimization of ATP concentration  
Optimal ATP concentration for MAT enzymatic activity was determined under standard assay 
conditions (fixing L-methionine at 5mM), in increasing concentrations that ranging from 0.1 
to 10 mM. The highest MAT activity efficiency was reached when incubating rat liver extract 
with 5 mM ATP (Figure 26). 
 
Figure 26. Optimization of ATP concentration for MAT activity. The enzymatic assay was performed in 
Tris-HCl buffer (100 mM, pH 8.7) at 37°C for 60 min. The reaction mixture was incubated under standard assay 
conditions 250 μg of rat liver extract, 10 mM MgCl2, 150 mM KCl, 5 mM DTT, 5mM L-Methionine and 
protease inhibitor in a final volume of 250 µl using different ATP concentrations (from 0.1 to 10 mM.). MAT 
activity is expressed as Σ products (SAMe and SAH) in nmol/0.25mg protein/1h. 
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Optimization of reaction incubation time 
The incubation time was also evaluated from 0 to 3 hours; aliquots were collected every 30 
min. As can be observed in the Figure 27, during the whole tested time the reaction didn´t 
reached a maximum for MAT activity even after 3 hours incubation. Given that incubation 
times longer than two hours are not recommended because of SAMe instability in long 
incubation periods, 2-hours period was chosen as optimal to evaluated the MAT activity. 
 
 
Figure 27. Optimization of incubation reaction time for MAT activity. The enzymatic assay was performed 
in Tris-HCl buffer (100 mM, pH 8.7) at 45°C. The reaction mixture was incubated under standard assay 
conditions;250 μg of rat liver extract, 10mM MgCl2, 150 mM KCl, 5 mM DTT, 5mM ATP, 5mM L-Methionine 
and protease inhibitor (1x1,000) in a final volume of 250µl.  Different incubation periods were assayed (30, 60, 
90, 120, 150 and 180min). MAT activity is expressed as Σ products (SAMe and SAH) in nmol/0.25mg protein. 
 
As results of the optimization process, different parameters of the enzymatic reaction were 
adjusted in order to obtain the optimal enzymatic activity efficiency. The established 
conditions were  2-hours of incubation at 37ºC in a final volume of 250 µL containing 
100mM Tris-HCl buffer pH 8.7, 5 mM ATP, 5 mM L-methionine, 150 mM KCl, 10 mM 
MgCl2, protease inhibitor and 5 mM DTT. 
 
6.2.6.1.2.   Ultra performance Liquid Chromatography-Mass Spectrometry optimization 
Once the samples were incubated in the reaction mixture, it was necessary to optimize next 
steps prior to data process; UPLC-MS conditions, SPE and analytical method. 
Hydrophilic Interaction Chromatography (HILIC) was used to quantify SAMe and SAH. 
HILIC is an alternative to reserved-phase chromatography (or hidrophobic chromatography) 
and uses hidrophilic stationary phase for applications involving polar compounds such as 
these [176]. HILIC can offer a tenfold increase in sensitivity over reversed-phase 
chromatography when used with electrospray-ionization mass spectrometry detection mode 
RESULTS AND DISCUSSION 
 
99 
 
[177]. In addition, HILIC is ideal for very polar compounds that are difficult to retain in 
reversed-phase chromatography. The main products that take part in the reaction, SAMe and 
SAH, were scanned in ESI+ mode and analyzed in matrix solution (in this case, rat liver 
extract). As can be observed in the Figure 28, both compounds appear completely separated 
in the chromatogram. The spectra of SAMe and SAH were dominated by protonated 
molecules [M+H]
+
 and no significant adducts or fragments ions were observed. SAMe was 
detected at a m/z of 399.145 and a retention time of 2.99 min, and SAH at a m/z of 385.129 
and a retention time of 2.35 min (Table 3). 
 
Table 3. MAT activity derived metabolites structure and properties. In this table is shown SAMe and SAH 
m/z ratio, the retention time in matrix (rat liver extract) and molecular formula and structure of each compound. 
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Figure 28. Representative chromatograms (top) and mass spectra (bottom) obtained from rat liver extract 
spiked with SAMe (A) and SAH (B) 
 
6.2.6.1.3. Solid-Phase Extraction (SPE) method development 
In order to clean the samples before injecting them in the mass spectrometry, SPE was 
optimized to remove mostly the elevated levels of salts required to perform the enzymatic 
reaction. This step is required since high concentration of salts could interfere in analytes 
ionization and detection, in addition to shorten the lifespan of the column. 
SPE method selection 
Different protocols were combined to optimize the SPE for SAMe, SAH and MTA (see 
references Delabar et al.1999 [178], Gellekink et al. 2005 [179], Cataldi et al. 2009 [179]), 
trying different cartridge conditioning and sample pre-treatments. SPE methods based on non-
polar (Van der Waals forces), polar or ionic interactions are relatively non-specific. In 
contrast, covalent bond, is based on a specific union between a functional group of the analyte 
with the cartridge sorbent surface, which results in an increased specificity of the extraction 
method. In this regard, extraction of SAMe, SAH and MTA was performed using Bond Elute 
cartridges containing 100 mg phenilboric acid (PBA) bonded silica [180][181]. The choice of 
the PBA cartridge was based on the affinity of boronate for the cis-hydroxyl group of a ribose 
moiety, which is present in SAMe, SAH and MTA. 
The mechanism of boronate binding is illustrated in Figure 29. The immobilized PBA is first 
equilibrated with an alkaline solution to obtain the reactive boronate form, RB(OH)3
- 
(Figure 
29A). The sample is then applied and the covalent bond will be specifically formed with those 
compounds containing cis-hydroxyl group (Figure 29B). Once the compounds of interest are 
retained (SAMe, SAH and MTA in this case), contaminants will be selectively washed from 
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the bonded phase. As long as the pH of the aqueous component of the wash solvent remains 
alkaline, the covalent complex will remain intact. Finally, the compounds of interest will be 
elute by acidification of the boronate complex, which releases the diol-containing compound 
and renders the immobilized phenylboronic acid neutral (RB(OH)2) (Figure 29C).  
 
 
 
 
Figure 29. Phenilboric acid (PBA) based solid phase extraction mechanism. The three step process of borate 
binding includes equilibration, retention and elution; the sample is loaded at pH 7.5 and the analytes (SAMe, 
SAH and MTA) are bound to reactive boronate form (RB(OH)3
-). Then the chromatographic column is washed 
subsequently in order to elute contaminants present in the sample. Finally, the compounds of interest are eluted 
adding an acidic solution that disrupts analyte and sorbent binding. 
 
Buffer selection 
Apart from the SPE method selection, it is necessary to choose the appropriate buffer for 
PBA-based SPE. To ensure good extraction efficiency, the first requirement is the use of an 
alkaline pH for column conditioning and subsequent sample application. The use of buffers 
that are themselves capable of forming covalent adducts with the PBA, such as Tris-HCl 
buffer, is clearly not recommended since this will avoid the formation of the covalent bond 
between boronate (chromatographic column reactive group) and the analyte. In this regard, to 
study MAT activity, initially, as mentioned before, the protocol reported by Kim et al 2008 
[182] was followed, whom studied MAT activity using Tris-HCl buffer. Later on, due to the 
elevated contaminants (mostly salts) existing in the reaction assay, it was needed to perform 
an extra-cleaning step using PBA-based SPE, which was incompatible with Tris-HCl buffer. 
Therefore, it was decided to change Tris-HCl to HEPES buffer taking as a reference the study 
reported by Shapiro et al. 2011 [183]. They carried out a comparative study between Tris-HCl 
and HEPES-NaOH buffers at different pHs. This buffer was tested at two different pHs (7.5 
A)
B)
C)
Equilibration
Retention
Elution
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and 9.5). To choose the optimal pH, matrix effect, process efficiency and recovery was 
evaluated (see Figure 8). The matrix effect is an important issue to be addressed in method 
development, validation, and routine use of UPLC-MS. It is the alteration of ionization 
efficiency by the presence of coeluting substances in the sample of interest, having deleterious 
impact on method accuracy and sensitivity [184][185]. The presence of ion suppression was 
determined from the ratio C/A (The compound of interest added to the matrix after 
extraction/The same amount of compound injected directly in mobile phase). The data for the 
compound in mobile phase (A) provide a relative 100% response value whereas the data for 
the same amount of compound added to extracted samples (C) show the effect of sample 
matrix on MS response (ion suppression) [186].  In the Figure 30 is shown the matrix effect 
for SAMe, SAH and MTA at different pHs (7.5 and 9.5). The negative values indicate ion 
suppression. For SAMe, there is not matrix effect at pH 7.5 (0.82 %) whereas at pH 9.5 
increased notably (-8.77%) (Figure 30). Regarding SAH, there is ion suppression at both 
pHs, being higher at pH 9.5 (-5.92 at pH 7.5 and -10.48 at pH 9.5). Finally, the matrix effect 
on MTA is almost the same at both pHs (-36.96 and -36.36 for pH 7.5 and 9.5 respectively). 
Overall, there is not an important ion suppression for SAMe and SAH. 
 
 
 
 
Figure 30. UPLC-MS analysis of matrix effects for SAMe, SAH and MTA. Matrix effect for SAMe, SAH 
and MTA at pH 7.5 and pH 9.5 are shown. The negative % values indicate ion suppression.  
The efficacy of the SPE method was determined from the ratio of test solutions B/A, being B 
the mass spectrometric signal obtained before SPE extraction and A, the same amount of 
compound injected directly in mobile phase (see Figure 8). This parameter (process 
efficiency) shows the loss of signal (if present) attributable to the extraction process expressed 
in percentage (%) [186]. For SAMe, SPE efficiency was slightly higher at pH 7.5 (58.34%) 
than at pH 9.5 (53.97%).  In the case of SAH, it was notably higher at pH 7.5 (53.95) than at 
pH 9.5 (36.75%). Finally, in the case of MTA, SPE efficiency was practically the same at 
both pHs (28.64% at pH 7.5 and   28.09% at pH 9.5) (Figure 31). 
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Figure 31. SPE process efficiency for for SAMe, SAH and MTA. Solid-phase extraction (SPE) efficiency for 
SAMe, SAH and MTA is shown. The efficiencies obtained for SAMe, SAH and MTA were in decreasing order. 
 
 
Recovery Analysis 
With respect to recoveries, they were determined from the ratio of test solutions B/C, being B 
the signal obtained when the compound of interest is added to the matrix before extraction, 
and C the signal obtained when same amount of compound is added to the matrix after the 
extraction procedure (see Figure 8).  
%R   Recovery (%) =            Rat liver extract spiked with SAMe/SAH/MTA before SPE (Pre-spiked sample) 
Rat liver extract spiked before UPLC-MS (Post-spiked sample) 
 
The recovery of SAMe and SAH determined at 5 μM was 58%. This value was in the 
acceptable range for UPLC-MS analysis [187]. Nevertheless, the recovery obtained for MTA 
was 45%, under acceptable range. Low recovery efficiency together with the high matrix 
effect obtained in MTA make this method to be restricted to SAMe and SAH analysis. 
Indeed, the majority of the reported studies evaluate MAT activity quantifying simultaneously 
SAMe and SAH. 
The recovery for SAMe was very similar at pH 7.5 (57.86%) and at pH 9.5 (59.16%) (Figure 
32). Which regards to SAH, the recovery increases notably at pH 7.5 (57.35%), being under 
acceptable range at pH 9.5 (41.03%).Therefore, without taking MTA into consideration, the 
PBA-based SPE with the highest recoveries and lowest matrix effect were obtained at pH 7.5. 
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Figure 32. Recovery analysis for SAMe, SAH and MTA in the PBA-SPE method. Obtained recoveries for 
SAMe, SAH and MTA are shown. Except for MTA, obtained recoveries were in acceptable range of analysis. 
 
Overall, prior to UPLC-MS analysis, an extra-cleaning step (PBA-SPE) was applied to 
already incubated samples. 
 
6.2.6.2.   Analytical method optimization 
In order to quantify the amount of the product formed in the enzymatic reaction, it was 
required to consider the following parameters to obtain sensitive and specific determination of 
the enzymatic activity. 
 
6.2.6.2.1.   Specificity of the enzymatic assay 
It is reported that SAMe is stable at acid pH. Therefore, it was injected into UPLC-MS system 
in acidic conditions [188].  
Moreover, SAMe is formed from the union of methionine and ATP. Thus, the new SAMe 
formed after incubation can only come from enzymatic reaction.  
6.2.6.2.2.   Linearity of Calibration Curves and Lower Limits of Quantification   
(LLOQ)  
To calculate the absolute amount of obtained products (SAMe and SAH), the average of 
baseline signals were subtracted from the signals of the serially diluted calibration samples. 
The calibration curve was obtained over the concentration range of 0.025-100 µM for SAMe 
and 0.025-25 µM for SAH. 
Power fit equation was employed to determine the relation between the signal (peak area) and 
sample concentration: 
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SAMe:   [Signal] = 987.73 x [concentration]
1,0962
 (R
2 
> 0.99) 
SAH:   [Signal] = 1776.6 x [concentration]
1,0774 
   (R
2 
> 0.99) 
 
Once the sample concentrations were calculated, they were converted to amount (nmol) of 
product formed (Σ products: SAMe and SAH) per mg of protein in 1 h incubation. The 
amount of SAMe and SAH detected in the controls (not incubated) was considered 
background and subtracted from the samples. The activity of MAT was estimated by 
quantifying jointly SAMe and SAH production. The present UPLC–MS method offered a 
LLOQ of 0.025 μM for SAMe and SAH.  
6.2.6.2.3.   Precision and Accuracy of the enzymatic assay 
Accuracy and precision were deemed to be acceptable (<15%) for SAMe, SAH and MTA. 
 
6.2.7.   COMT ACTIVITY ANALYTICAL METHOD 
6.2.7.1.   Analytical method development 
6.2.7.1.1.   Optimization of the incubation condition for the enzymatic reaction to assay 
COMT activity 
Similar to MAT activity, an optimization of different parameters was required before COMT 
[189], [190] enzymatic activity evaluation. Incubation conditions of the enzymatic reaction 
had to be optimised in order to obtain the optimal enzymatic activity efficiency. This involves 
the use of cofactors as well as different parameters adjustments such as pH. Moreover, the 
stability of the compounds that take part in the reaction has to be taken also into 
consideration. 
In COMT enzymatic reaction Mg
2+
 ions are required since they are coordinated to three 
amino acid residues (Asp, Asn and Glu) in the catalytic site of COMT [191]. Therefore, Mg
2+ 
ions are routinely added to reaction mixture (2 mM MgCl2).  
COMT assays are normally performed under physiological conditions (pH around 7.4 and 
temperature 37°C). The enzyme has two-isoforms one associated to membrane (MB-COMT) 
and other soluble (S-COMT). For the measurement of MB-COMT and S-COMT activity, 
different approaches have been performed. These include the separation of the two isoforms 
by differential ultracentrifugation and the use of two different substrates such as Dopamine 
(DA) or Norepinephrine (NE) at different concentrations and pHs (7.4 for MB-COMT and 7.8 
for S-COMT) [128] (Data not shown).  
In order to simplify the assay and try to detect COMT activity in EVs, this study was focused 
on MB-COMT activity, which has higher affinity (but lower O-methylation capacity) for the 
catecholamines (DA and NE) than S-COMT [191]. 
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6.2.7.1.2.   Ultra Performance Liquid Chromatography-Mass Spectrometry optimization 
Once the samples were incubated in the reaction mixture, it was necessary to optimize next 
steps prior to data process; UPLC-MS conditions, SPE and analytical method. As same as in 
the case of MAT, with COMT, HILIC was also used to analyze DA/3-MT and NE/NMN. In 
this regard, HILIC column conditions were optimized in order to achieve the best 
chromatographic separation of the compounds of interest. Considering the strong relation 
between chromatographic conditions and mobile phase, different concentrations of 
ammonium formate were tested to see their effect on the analytes retention (Data not shown). 
In the absence of ammonium formate, the peak shapes were broad and irregular. Regular peak 
shape and identical retention time were achieved for each analyte when the salt concentration 
reached 20 mM. The pH of the buffer may also have significant influence on the analytes 
chromatographic behavior. 0.5% formic acid was used to separate the analytes. In these 
conditions, analytes of interest were positively charge and completely separated (Table 4). 
 
Table 4. COMT activity derived metabolites structure and properties. In this table is shown m/z ratio, 
retention time in matrix (rat liver extract) and molecular formula and structure of dopamine (DA), 3-
Methoxytyramine (3-MT), norepinephrine (NE) and normetanephrine (NMN). 
 
Once the analytes were properly separated, the corresponding chromatograms and mass 
spectra were obtained. The Figure 33 and Figure 34 show the mass spectra and the 
chromatograms of DA/3-MT and NE/NMN, respectively. In the spectra of DA and 3-MT, a 
loss of one molecule of ammonia was observed, forming the predominant ion [M+H-NH3]
+
, 
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whereas in the case of NE and NMN, a loss of one molecule of water was observed, forming 
the predominant ion [M+H-H2O]
+
 represented as base peak in the spectra [190], [192]. 
 
 
 
Figure 33.  Representative chromatograms (up) and mass spectra (down) obtained from rat liver extract 
spiked  with Dopamine (A) and 3-Methoxytyramine (B)  
 
Figure 34.  Representative chromatograms (up) and mass spectra (down) obtained from rat liver extract 
spiked  with Norepinephrine (A) and Normetanephrine (B). 
 
In all cases, after UPLC-MS optimization process, good chromatographic separation of the 
analytes was achieved as well as excellent mass spectrometric response. 
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6.2.7.1.3.   Solid-Phase Extraction (SPE) Method development 
SPE method selection 
In this case, given the nature of the products of the COMT activity reaction, it was chosen ion 
exchange SPE to clean the samples before UPLC-MS analysis. Thus, cationic compounds 
were isolated by using WCX bonded silica cartridges. The retention mechanism is a mix of 
ion exchange and reversed phase, which improves retention of basic analytes, having especial 
selectivity and sensitivity for strong bases. The retention is based mainly on the electrostatic 
attraction of the charged functional group on the compound to the charged group that is 
bonded to the silica surface [193] (Figure 35). 
 
 
Figure 35. Oasis WCX retention mechanism for strong bases. The retention is based mainly on the 
electrostatic attraction of the charged functional group on the compound to the charged group that is bonded to 
the silica surface. 
 
The WCX SPE material contains an aliphatic carboxylic acid group that is bonded to the silica 
surface. The carboxylic acid group is a weak anion and will isolate cations, as 3-MT and 
NMN, when both are charged. A solution having a pH that neutralizes either, the compound’s 
functional group (3-MT or NMN) and the functional group on the sorbent surface, is used to 
elute the compounds of interest. Highly selective retention enables much stronger washes, 
resulting in very clear extracts. When one of these functional groups is neutralized, the 
electrostatic force that binds the two together is disrupted and the compound is eluted. An 
acidic solution was used to elute the analytes of interest. At low pH, the sorbent is un-ionized, 
which shuts off the ion-exchange mechanism [152].  
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Recovery Analysis 
With respect to recoveries, they were determined from the ratio of test solutions B/C, being B 
the compound of interest added to the matrix before extraction and C the same amount of 
compound added to the matrix after the extraction (see Figure 8).  
The Recovery was calculated as follows: 
%R   Recovery (%) =            Rat liver extract spiked with 3-MT/NMN before SPE (Pre-spiked sample) 
        Rat liver extract spiked before UPLC-MS (Post-spiked sample) 
 
The recoveries determined at 2.5μM were 82% (for 3-MT) and 75% (for NMN). These 
recoveries were in the acceptable range for routine UPLC-MS analysis [187]. 
 
6.2.7.2.   Analytical Method optimization 
In order to quantify the amount of the product formed in the enzymatic reaction, it was 
required to consider the following parameters to obtain sensitive and specific determination of 
the enzymatic activity. 
6.2.7.2.1.   Specificity of the enzymatic assay 
To evaluate the specificity and selectivity of the method, different controls were carried out as 
follows. In the case of 3-MT, rat liver extract was incubated in buffer (Figure 36A) where no 
product was detected indicating that no endogenous compound was present in the sample. Rat 
liver extract was also incubated with DA in absence of SAMe and MgCl2 cofactors which are 
necessary for the reaction to happen. In this case, 3-MT was detected, indicating DA 
degradation during the incubation period (Figure 36B). In order to calculate the amount of 3-
MT obtained during the reaction, the amount of 3-MT detected in this control was subtracted 
from the total amount of product obtained. Finally 3-MT was incubated in buffer (Figure 
36C). 
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Figure 36.  Chromatograms obtained for 3-Methoxytyramine (m/z 151.075, tr 1.15) derived from: (A) Rat 
liver extract incubated in 50mM sodium phosphate buffer without adding DA, (B) rat liver extract incubated 
with Dopamine in absence of SAMe and MgCl2, (C) 3-Methoxytyramine in 50mM sodium phosphate buffer. 
 
Regarding NMN, the same controls as in the case of 3-MT, were performed. No endogenous 
product (Figure 37, blue) either NE degradation was detected (Figure 37, red).  Thus, no 
subtractions were needed from the controls. Rat liver spiked with NMN is also shown (Figure 
37, green).  
  
 
 
Figure 37.  Superimposed chromatogram obtained for Normetanephrine (m/z 166.086, tr 1.30) derived 
from: Rat liver extract incubated in 50mM sodium phosphate buffer (blue), rat liver extract incubated with 
Norepinephrine in absence of SAMe and MgCl2 (red) and rat liver extract spiked with Normetanephrine (green). 
Note that the product NMN is detected only in the condition where the compound is spiked into the sample 
indicating that no endogenous and no degradation of the substrate is observed under assay conditions. 
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6.2.7.2.2.   Linearity of Calibration Curves and Lower Limits of Quantification (LLOQ) 
To calculate the absolute amount of 3-MT generated by COMT activity, the average of the 
two baseline signals was subtracted from the signals of the serially diluted calibration 
samples. In the case of NMN, this subtraction was not necessary since not endogenous 
product either NE degradation was detected. The calibration curves were obtained over the 
concentration ranges of 0.01-25 µM (for 3-MT) and 0.005-25 µM (for NMN).  
Power fitting equation was used to determine the relation between the signal (peak area) and 
sample concentration: 
3- MT:   [Signal] = 10411 x [concentration]
0,9238
 (R
2 
> 0.99) 
NMN:    [Signal] = 1177 x [concentration]
0,8336
    (R
2 
> 0.99) 
 
Once the sample concentrations were calculated, they were converted to amount (nmol) of 3-
MT or NMN produced per mg of protein obtained in 1 h.   
The developed UPLC-MS methods developed offered a LLOQ of 0.01 μM for 3-MT and 
0.005 μM for NMN. 
 
6.2.7.2.3.   Precision and Accuracy of the enzymatic assay 
Precision and accuracy were deemed to be acceptable (<15%). 
 
Overall, after this comprehensive optimization of the parameters for incubation conditions, 
SPE and UPLC-MS analysis, sensitive and specific methods were successfully established for 
measuring COMT and MAT enzymatic activities. The final conditions established for the 
determination of the activities were: 
For MAT activity: Enzymatic assays after optimization was carried out in a final volume of 
250 µL of 50 mM HEPES/ 150mM KCl pH 8 incubation buffer containing; enzyme provider 
(liver extract, microsomes or EVs), 5 mM L-Methionine, 10 mM MgCl2, 5 mM DTT,  5mM 
ATP and protease inhibitor. The reaction mixture was incubated for 2 hours in a water bath at 
37°C. After incubation, samples were transferred to PBA bonded silica cartridges to clean 
them. Finally, samples were injected into UPLC-MS system; products of the reactions were 
chromatographically separated with an Acquity UPLC BEH AMIDE column and detected 
with a SYNAPT HDMS G2 Time of Flight (ToF) mass spectrometer operated in ESI+. 
For COMT activity: Enzymatic assay after optimization was carried out in final volume of 
300 µL of 50 mM sodium phosphate buffer pH 7.4 incubation buffer containing: enzyme 
provider (liver extract, microsomes or EVs), 2 mM MgCl2, 200 μM SAMe and 2 mM DA or 
0.1 mM NE. The reaction mixture was incubated for 1 hour in a water bath at 37°C.  After 
incubation, samples were transferred to WCX bonded silica cartridges to clean them. Finally, 
samples were injected into UPLC-MS system; products of the reactions were 
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chromatographically separated with an Acquity UPLC BEH AMIDE column and detected 
with a SYNAPT HDMS G2 Time of Flight (ToF) mass spectrometer operated in ESI+. 
 
MAT AND COMT ENZYMATIC ACTIVITIES ANALYSIS IN HEPATIC EVs   
The UPLC-MS based methods established above were used to analyze COMT and MAT 
activities in hepatic EVs in different DILI models. Moreover, it was also employed to 
compare hepatic EVs activities with the activities produced by microsomal (intracellular) 
preparations and liver extracts. In order to be able of correlating abundance of enzyme and 
measured activity, protein extracts of each type of sample was analyzed by Western-blotting 
(Figure 38). As can be observed, EVs markers (LIMP II, Hsp90) were detected in 
preparations. On the contrary, endoplasmic reticulum (Grp78) and mitochondria (COXIV) 
markers were not detected in EVs preparations supporting that they were not produced by 
undesired cellular lysis. Finally, we also detect the presence of the studied enzymes (CES, 
COMT and MAT) in the EVs preparations (Figure 38). 
   
 
 
Figure 38. Western-blot analysis of samples employed for measuring MAT and COMT enzymatic activity. 
Liver extract, microsomes and EVs released by non-treated and DFC-treated rat hepatocytes were analyzed by 
Western blotting using antibodies against the indicated proteins. The amount of protein was determined by 
Bradford assay and same amount of protein was loaded in all cases (10 µg) 
 
 
6.2.8.   MAT ENZYMATIC ACTIVITY ANALYSIS IN HEPATIC EVs   
MAT activity was measured by UPLC-MS in rat liver extract, microsomes obtained from 
hepatocytes previous to seed into collagen-coated dishes (t0) or after 36 hours cultivated in 
the dishes (t36) and finally in hepatic EVs. Obtained results are shown in Table 5. 
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Table 5. MAT activity in liver extract, microsomes and EVs from primary hepatocytes. Microsomes 
obtained from hepatocytes just after the liver perfusion (t0) and after 36h of incubation on collagen coated dishes 
(t36) were assayed. The amount of product obtained is expressed in nmol per mg of protein and per hour. Total 
MAT activity was estimated as Σ Products (SAM and SAH). ND; Not detected. 
 
 
 
First, it was analyzed MAT activity in liver extracts (Table 5, Figure 39) comparing the 
amount of SAMe and SAH detected when the reaction was incubated for 2 h at 37ºC (Figure 
39, in red) and without incubation (Figure 39, in green). As can be observed under 
enzymatic conditions employed in the study, there was very low amount of endogenous 
SAMe and SAH indicating that most of the detected products were newly formed by MAT 
enzymatic activity present in liver extract. Indeed, the products increased more than 44 
(SAMe) and 156-fold (SAH) due to this activity (Figure 39). 
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Figure 39.  Chromatograms of SAMe and SAH generated by MAT enzymatic activity in liver extract. (A) 
SAMe coming from enzymatic reaction (87.78 µM, in red) and endogenous SAMe (2.85 µM, in green). (B) 
SAH coming from enzymatic reaction (12.51µM, in red) and endogenous SAH (0.08 µM, in green). The 
concentrations of SAMe and SAH were determined based on calibration curve. 
  
 
 
MAT activity was also detected in microsomes prepared from hepatocytes (Figure 40, Table 
5). The comparison of liver extract and microsomes t0, revealed that MAT activity decreased 
notably in the later, however, protein expression levels remain very similar (Figure 38). This 
result suggests that during perfusion of the liver there is some inactivation of MAT activity by 
an unknown mechanism at this time. Furthermore, there was also a decrease in MAT activity in 
microsomes prepared from hepatocytes cultivated for 36 hours in comparison with MAT 
activity detected in microsomes prepared from hepatocytes just obtained after perfusion, 
microsomes t0 (Table 5). This activity decrease correlates with a decrease in protein expression 
level observed by Western (see Figure 38). 
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Figure 40. MAT activity in microsomes prepared from untreated and drug-treated primary hepatocytes. 
Superimposed chromatograms showing the amount of products obtained (SAMe in the top and SAH in the 
bottom) with (in red) or without incubation (in green) in microsomes prepared from: (A) untreated hepatocytes 
(signal corresponding to 0.01 µM for SAMe and 0.02 µM for SAH), (B) APAP-treated hepatocytes (signals under 
limit of quantitation for both products), (C) GalN-treated hepatocytes (signal under limit of quantitation for 
SAMe, and corresponding to 0.164 µM for SAH) and (D) DCF-treated hepatocytes (signal under limit of 
quantitation for SAMe and corresponding to 0.308 µM for SAH).  
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In the case of EVs, MAT activity was clearly detected in EVs preparations obtained from 
DCF and GalN-treated hepatocytes, whereas a minimal activity was quantified in the case of 
untreated and APAP-treated hepatocytes (Figure 41, Table 5). In order to confirm if the 
amount of detected products came from the enzymatic reaction or were already present in the 
EVs preparation (endogenous), chromatograms after samples incubation (Figure 41, in red) 
or without incubating (Figure 41, green) were obtained. As can be observed in the case of 
EVs secreted by DCF and GalN-treated hepatocytes, the product is newly formed by the 
enzymatic reaction (Figure 41C and Figure 41D). In the case of DCF, the products SAMe 
and SAH increases 28 and 30-fold, respectively. In the case of GalN treatment, the products 
SAMe and SAH increases 67 and 17-fold, respectively (Table 5). In the EVs obtained from 
untreated hepatocytes (Figure 41A) it was also possible to determine MAT activity although 
barely quantified (0.45 nmol/mg/h) due mostly to the low yield of EVs production in 
untreated conditions. EVs secreted by APAP-treated hepatocytes also showed low MAT 
activity (0.06 nmol/mg/h) (Figure 41B, Table 5). However, in this case, the amount of EVs 
employed to test the enzymatic assay was not a limitation. Thus, the result suggests that 
APAP treatment reduce MAT activity in hepatocyte-secreted EVs in agreement with previous 
reports showing a decrease in intracellular MAT activity caused by APAP overdose [194]. 
 
Figure 41. SAMe and SAH formed in EVs released by rat hepatocytes treated with different liver-
damaging drugs. Superimposed chromatograms showing SAMe (top) and SAH (bottom) formed (in red) in 
EVs released by: (A) Non-treated hepatocytes (SAMe 0.039µM, SAH ND), (B) Acetaminophen-treated 
hepatocytes (SAMe 0.032µM, SAH 0.030µM), (C) Galactosamine-treated hepatocytes (SAMe 0.203µM, SAH 
0.87µM) and (D) Diclofenac -treated hepatocytes (SAMe 0.770µM, SAH 1.84µM). Not incubated samples were 
used as endogenous controls (in green): (A) Non-treated hepatocytes (SAMe ND, SAH 0.06µM), (B) 
Acetaminophen-treated hepatocytes (SAMe 0.005µM, SAH 0.05µM), (C) Galactosamine-treated hepatocytes 
(SAMe 0.003µM, SAH 0.05µM) and (D) Diclofenac -treated hepatocytes (SAMe 0.027µM, SAH 0.06µM). Not 
incubated samples were used as endogenous control. 
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    Figure 41 (continuation) 
 
 
 
In summary, MAT activity was measured by UPLC-MS in rat liver extract, microsomes t0, 
microsomes t36 and hepatic EVs. As expected by the amount of protein observed in the 
Western-blot analysis (Figure 38), the highest activities were obtained in liver extract and 
microsomes t0 (Table 5). MAT activity was significantly reduced in hepatocytes after 36h 
incubation in all the cases (microsomes t36, Table 5) suggesting that during the culture the 
hepatocytes get out of this enzymatic activity. Remarkably, MAT enzymatic activity was 
detected in hepatic EVs from untreated and drug-treated hepatocytes (Table 5) being 
significantly higher in GalN and DCF treatments. The comparison between enzymatic activity 
in microsomes t36 and EVs in the different treatments aroses different response to the 
treatments. Thus, in untreated conditions the activity was quite similar in microsomes 
(intracellular) and EVs whereas in GalN and DCF conditions MAT activity was much higher 
in EVs. Finally the activity obtained in APAP conditions was not significant neither in EVs 
nor in microsomes t36. These results indicated that intracellular retention or secretion of MAT 
activity is regulated depending on the mechanism of damage. 
 
In conclusion, these results showed that MAT enzyme associated to hepatic EVs is active and 
this could have important implications in methionine metabolism. 
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6.2.9.   COMT ENZYMATIC ACTIVITY ANALYSIS IN HEPATIC EVs 
COMT activity was measured by UPLC-MS in rat liver extract, microsomes obtained from 
hepatocytes previous to seed into collagen-coated dishes (t0) or after 36 hours cultivated in 
the dishes (t36) and finally in hepatic EVs. Obtained results are shown in Table 6. 
 
Table 6. COMT enzymatic activity in rat liver extract, microsomes and EVs. Amount of products obtained 
(3-MT and NMN) per mg of incubated protein in 1 hour incubation. ND; Not detected. 
 
 
 
 
COMT activity was measured by UPLC-MS in rat liver extract, microsomes t0, microsomes 
t36 and hepatic EVs. COMT activity was clearly detected in liver extract (Figure 42, in red). 
As can be observed, the activity was abrogated by the lack of two cofactors in the reaction, 
SAMe and MgCl2 (Figure 42, green line) further supporting that detected activity was 
specific of COMT enzyme.  
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Figure 42.  Chromatograms of the products, NMN or 3-MT of COMT activity in liver extract. Liver 
extract were incubated with (in red) or without (in green) SAMe and MgCl2. (A) NMN product was detected 
with a signal corresponding to 13.03 µM in the mixture reaction containing all components, and to 0.01 µM in 
the mixture reaction lacking SAMe and MgCl2. (B) 3-MT product was detected with a signal corresponding to 
16.02 µM in the mixture reaction containing all components, and to 0.01 µM in the mixture reaction lacking 
SAMe and MgCl2. 
 
Hepatic microsomes also showed detectable levels of COMT activity. Significant differences 
were observed between microsomes prepared from untreated and treated hepatocytes (Figure 
43, Table 6) showing lower activity in microsomes from DCF conditions. These results were 
in concordance with the immunostaining (see Figure 11) that showed a decrease in COMT 
protein expression in DCF-treated hepatocytes with respect to untreated cells indicating that 
hepatic COMT activity is altered in DILI. Furthermore, there was significant difference in 
COMT activity between microsomes t0 and microsomes t36 (Figure 44, Table 6). In this 
regard, a comparison of the activity measured in microsomes t0 and microsomes t36 showed a 
clear COMT activity decrease within time for both products NMN (Figure 44A) and 3-MT 
(Figure 44B). This result also correlates with a decrease in COMT protein expression 
observed by Western blotting (see Figure 38). 
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Figure 43. COMT enzymatic activity in hepatic microsomes from untreated and DCF-treated hepatocytes. 
(A) Superimposed chromatograms showing the amount of 3-MT formed in microsomes. Amount of 3-MT 
obtained in the presence of Microsomes Control t36 (the observed signal correspond to 2.81µM, green) and in 
the presence of Microsomes Diclofenac t36 (1.60µM, red). The amount of 3-MT resulting from dopamine 
degradation was under LLOQ (slightly visible at the bottom of the chromatogram). (B) Superimposed 
chromatograms showing the amount of NMN formed in microsomes: Microsomes Control t36 (3.07µM, 
green) and Microsomes Diclofenac t36 (1.42µM, red). The amount of obtained product coming from 
Norepinephrine (substrate) degradation was under LLOQ (At the bottom of the chromatogram). 
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Figure 44. COMT enzymatic activity in hepatic microsomes and EVs (A) Superimposed chromatograms 
showing the amount of 3-MT formed in: Microsomes t0 (9.41µM, red), Microsomes Control t36 (2.81 µM, 
green), Microsomes Diclofenac t36 (1.60 µM, yellow) and EVs Diclofenac (0.03 µM, blue). (B) Superimposed 
chromatograms showing the amount of NMN formed in: Microsomes t0 (13.30 µM, red), Microsomes 
Control t36 (3.07 µM, green), Microsomes Diclofenac t36 (1.42µM, yellow) and EVs Diclofenac (0.07 µM, 
blue). 
 
 
Remarkably, hepatic EVs also showed COMT enzymatic activity. On this regard, as can be 
observed in the Figure 45, specific activity in EVs secreted from untreated hepatocytes using 
DA (Figure 45A) and NE (Figure 45B) as  substrates was detected although it was quite low 
(0.27 and 0.05 nmol/mg/h respectively) (Table 6). Conversely to microsomes, in the case of 
EVs, the activity was higher in EVs secreted by DCF-treated hepatocytes compared to EVs 
secreted by untreated cells (Table 6).  
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Figure 45. COMT enzymatic activity in hepatic EVs. (A) Superimposed chromatograms showing the 
amount of 3-MT formed in EVs released by non-treated rat hepatocytes cultured for 36h. Incubating: 30µg 
of EVs in the reaction mixture (0.02 µM, green) or 30µg of EVs in buffer (Not detectable, blue). (B) 
Superimposed chromatograms showing the amount of NMN formed in EVs released by non-treated rat 
hepatocytes cultured for 36h. Incubating: 30µg of EVs in the reaction mixture (0.0031, green) or 30 µg of EVs 
in buffer (Not detectable, blue). 
 
 
 
As showed in Figure 46, there was dose-dependence COMT activity for both compounds DA 
(Figure 46A) and NE (Figure 46B). Thus, when the amount of protein employed in the 
reaction was doubled from 50 to 100 µg, 5.6 (3-MT) and 6.6 (NMN) fold more products were 
obtained from DA and NE, respectively. 
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Figure 46. COMT enzymatic activity in hepatic EVs incubating different amounts of protein. (A) 
Superimposed chromatograms showing the amount of 3-MT formed in EVs secreted by primary 
hepatocytes cultured for 36h in the presence of DCF. Each peak represent different incubation reactions as 
follows: 100 µg (in red) or 50 µg (in green) of EVs  in the reaction mixture, 50 µg of  EVs  with DA in absence 
of SAM and MgCl2 (3-MT resulting from dopamine chemical degradation, under LLOQ, yellow) and 50 µg of 
EVs in buffer (endogenous 3-MT, under LLOQ, blue). (B) Superimposed chromatograms showing the 
amount of NMN formed in EVs secreted by rat hepatocytes cultured for 36h in the presence of DCF. Each 
peak represent different incubation reaction as follows, incubating: 100 µg (in red) or 50 µg (in green) of EVs in 
the reaction mixture, 50 µg of EVs with NE in absence of SAM and MgCl2 (NE degradation, in yellow) and 50 
µg of EVs in buffer (Endogenous NMN, under LLOQ, blue) 
 
In summary, in all cases, COMT activity was detected (Table 6). These results support the 
presence of active COMT enzyme in hepatic EVs, increasing its activity in DILI conditions.  
Overall, employing fluorometric assay or UPLC-MS based metabolomics, significant changes 
in the activities of the studied enzymes, CES, MAT and COMT contained in hepatic EVs in 
DILI models were detected. These results also support the development of diagnosis methods 
based on these activities for DILI detection in a low-invasive manner.  
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6.3.   METABOLIC PROFILING OF HEPATIC EVs 
As shown in the previous sections, hepatic EVs are complex in composition containing 
several active metabolic enzymes supporting an important role in metabolism regulation in 
the extracellular space. Following this aim of elucidating the function of these hepatic EVs,  
UPLC-MS metabolomics was applied. It constitutes a powerful unbiased tool to identify 
metabolites associated with a determined biological system. The detection of these 
metabolites would identify additional metabolic pathways and functions where hepatic EVs 
could play a physiological role. 
Metabolomics experiments must be carefully designed to ensure the reproducibility of the 
results. Thus, they must combine the appropriate use of analytical tools to allow the maximum 
coverage of the metabolome. In addition, due to the high heterogeneity of the metabolites 
(chemical structure, physicochemical properties and concentration), the process always has a 
certain degree of bias which is dependent on the metabolite selection and will occur from the 
metabolite extraction until its detection [136][195]. Thus, metabolomic approaches must 
apply adequate sample collection, handling, extraction, preparation and storage procedures to 
reduce these effects [196]. In the same way, the application of adequate tools to acquire, store, 
normalize, analyze and evaluate the data will be necessary in order to draw accurate 
conclusions. Recent advances in both, analytical and computational approaches, as well as the 
optimization of sample preparation protocols, have led to a wide coverage of the metabolome 
[137]. Since there are not studies reported on metabolomics applied to EVs, it was necessary 
to establish the conditions to apply this technology. Thus, for this section, we chose hepatic 
EVs released by MLP-29 murine cell line was choosen since they offer more flexibility and 
homogeneity that primary culture of hepatocytes. The metabolic profile of EVs secreted by 
this cell line is described using UPLC-MS based metabolomics in order to elucidate pathways 
and functions where these vesicles could be involved. Moreover, in this doctoral thesis it was 
also carried out a systematic characterization of metabolic signals detected and in some cases 
enriched in EVs when compared to the cellular content. 
 
6.3.1.   METABOLITES EXTRACTION METHOD SELECTION 
Successful metabolome research requires effective metabolic extraction. Extraction is the 
process by which compounds, in this case metabolites, are selectively separated from other 
compounds, often undesired, such as proteins in this study [197]. 
For metabolic studies, it is important to perform an appropriate extraction method selection to 
choose that one that will extract the maximum number of metabolites in their original state. 
Given the metabolome complexity (metabolites of different chemical nature), there is not one 
unique extraction procedure for metabolome analysis that will cover all metabolites so 
different extraction protocols must be tested. In metabolome studies, metabolites are usually 
extracted with organic solvents, being frequent the use of more than one solvent in the 
extraction procedure [198]. In this study, due to the limiting amount of EVs sample, 
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extraction method evaluation was only performed in cells. The following metabolites 
extraction protocols were tested for UPLC-MS based untargeted metabolic analysis: 
 
- MeOH/Water (50:50, v/v): Methanol and water are miscible within each other and able to 
dissolve polar compounds. Methanol is usually used as aqueous phase co-solvent to 
enhance solubility of less polar metabolites. 
- MeOH/Water/Chloroform (25:25:50, v/v/v): Aqueous phase (methanol/water) is often 
paired with organic phase (chloroform) which are immiscible between them, forming a 
two phase system that allows the separation of polar (in the aqueous phase) and non-polar 
(in the organic phase) metabolites for subsequent chromatographic separation and 
analysis. 
- Isopropanol: Same as Methanol, Isopropanol is also used as aqueous phase co-solvent to 
improve the solubility of less polar metabolites. 
 
After cell lysis by sonication, the three extraction methods listed above were tested in 
triplicate. After metabolic extraction, the solvents were removed by centrifugation under 
vacuum condition and then solubilized in mobile phase and injected into UPLC-MS system to 
obtain the metabolic profile of each method. 
In the Figure 47 is shown the multivariate analysis (PCA) of the metabolic profiles 
corresponding to the different extraction methods analyzed in a C18 chromatographic column. 
A clear group clustering is observed due to the different metabolic profiles obtained for each 
extraction method. There are three clusters clearly separated: one related to metabolites 
extracted with Methanol/Water and Isopropanol methods. Both are very close in the PCA, 
given that they extract metabolites with very similar chemical nature (polar metabolites). 
Regarding MeOH/Water/Chloroform extraction method, two differentiated clusters are 
shown: one group correspond to the metabolites extracted in the organic phase (chloroform) 
and the other to metabolites extracted in the aqueous phase (MeOH/Water). Thus, apolar and 
polar metabolites are separated respectively. 
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Figure 47. Principal Component Analysis (PCA) of the metabolic profiles obtained using different 
extraction methods. Three extraction methods were tested each of them in triplicated.: Methanol/Water (red), 
Isopropanol (IPA, black) and Methanol/Water/Chloroform (organic phase in blue and aqueous phase in green). 
Quality controls are also included (QCs, yellow). t[1] denotes sample type and  t[2]) intraclass variation. 
 
Once metabolites were extracted, they were chromatographically separated using two 
different retention columns in order to cover the maximum number of metabolites: C18 
enables the chromatographic separation of both polar and non-polar compounds and amide 
retains very polar compounds. In the Table 7 is shown the number of metabolic signals 
detected using the different extraction methods combined with C18 or amide chromatographic 
columns. As can be deduced by the sum of the number of metabolites extracted in the aqueous 
phase (2459 signals in the amide column) and in the organic phase (1569 signals in the C18 
column), Methanol/Water/Chloroform was clearly the most efficient extraction method. 
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Table 7. Number of metabolic signals in C18 and amide columns using different metabolites extraction 
methods. Note: methanol/Water/Chloroform extraction method obtains the highest number of extracted 
metabolites. 
 
 
 
 
 
In conclusion, MeOH/Water/Chloroform showed to be the most effective extraction method, 
for both polar and non-polar compounds providing the highest number of metabolic signals.  
 
 
6.3.2.   ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY – MASS 
SPECTROMETRY ANALYSIS 
Because the metabolome is highly complex there is not a single detection/separation 
technique that covers the entire metabolome. The combined application of several different 
techniques is needed in order to enable a broad coverage of the metabolome (polar and non-
polar metabolites). In this regard, in this study two separated chromatographic techniques 
coupled with MS were used to perform optimal metabolic separation. First, reversed-phase 
liquid chromatography-MS (RP-UPLC/MS) was employed using C18 column that results in 
the separation and detection of both polar and non-polar compounds [199]. As the capability 
of RP columns to retain ionic or highly-polar compounds is limited [200][201], an amide 
column was also used in the study which enables the chromatographic separation of very 
polar compounds. 
The conditions of each chromatographic technique are detailed in section 5.17.3 of 
“Experimental procedures”. 
 
6.3.3.   DATA PROCESSING 
In contrast to targeted approaches (such as used in the previous section regarding enzymatic 
assays), untargeted UPLC-MS-based metabolomics provides an enormous volume of data that 
cannot be manually analyzed, and is complicated even more due to experimental drifts in the 
instrumentation [135], [200]. Thus, before data analysis, MS spectra must be corrected for all 
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variation caused by experimental variables adjusting different parameters. This is a critical 
part in data mining as it can drastically interfere with the next step, multivariate data analysis 
[202]. To overcome these issues, specific software that offers the possibility to adjust all these 
parameters are employed. 
After metabolites extraction and injection in the UPLC-MS system, the generated data was 
processed using MassLynx 4.1 software that is a post-acquisition processing package that can 
be applied to MS data files. Both chromatographies (C18 and amide) and their corresponding 
mass spectrometry polarities (ESI+ and ESI- modes) were analyzed separately. The 
UPLC/MS data were peak-detected and noise reduced such that only true analytical peaks 
were further processed by the software. By doing this process, the metabolic background 
introduced during isolation and extraction processes were removed from the data in order to 
identify the metabolome truly associated with the samples of interest. A list of intensities 
(chromatographic peak areas) of the peaks detected was then generated, using the Rt-m/z 
(retention time and m/z) data pairs as identifiers (in a mass window of 0.02 Da and a RT 
window of 0.05 min). 
In the Table 8 is shown the total number of detected signals (cells and EVs) and also those 
ones present in EVs. 
Table 8. Metabolic signals detected by UPLC-MS in MLP29 cells and their secreted EVs. Detected signals 
using two chromatographic columns (Amide and C18) and running the samples in positive and negative 
ion mode. Total number of detected signals (cells and EVs) as well as those ones present in EVs are indicated. 
 
 
 
6.3.4.   MULTIVARIATE DATA ANALYSIS: PRINCIPAL COMPONENT  
ANALYSIS (PCA) 
The UPLC-MS data obtained by peak extraction and background reduction using MassLynx 
is now suitable for mathematical and statistical analyses in order to identify significant 
difference between sample groups. In this regard, multivariate data analysis is a statistical 
approach that facilitates the identification of differences or similarities between groups 
comparing the samples by statistical methods [203]. Its principal objective is to reduce the 
dimensionality of the complex data set to enable easy visualization of any metabolic 
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clustering of the different groups of samples [137], in this case cells and EVs.  This is 
achieved by PCA where the discrimination between samples is done based on their metabolic 
profiling without prior knowledge of sample classes. Basically, the data matrix is reduced to a 
series of principal components (PCs), each a linear combination of the original Rt-m/z pair 
peak areas [204]. 
After data processing, base peak chromatograms extracted in the organic (apolar dataset) and 
aqueous (polar dataset) phase, in ESI+ and ESI- mode, were obtained. In the Figure 48 is 
observed the different chromatographic profiles obtained for cells and EVs, suggesting a 
variable metabolic content. In base peak chromatograms, is clearly observed the enrichment 
of some metabolic signals in EVs (in green) with respect to cells (in red) given the clear 
differences in peaks intensities between two sample groups. 
 
 
 
Figure 48. Representative base peak chromatograms of UPLC-MS analysis of MLP29 cells and 
corresponding secreted EVs. Base peak chromatograms of MLP29 cell line (in red) and secreted EVs (in 
green), extracted in organic (C18 column) (A) and aqueous (amide column) (B) phase and run in ESI+ (top) and 
ESI- (bottom) mode. 
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Figure 48 (continuation) 
 
 
Moreover, apart from the base peak chromatograms, the Rt-mz signals were subjected to PCA 
to determine metabolic profile differences between cells and EVs. Figure 49 shows the PCAs 
corresponding to MLP29 cells and their corresponding EVs samples for polar and apolar 
datasets run in ESI+ or ESI- ion mode. Polar dataset correspond to those metabolites extracted 
in the aqueous phase and apolar dataset to those ones extracted in the organic phase. The final 
dataset was mean centered and log-transformed during multivariate data analysis. As can be 
observed in the Figure 49, this analysis showed clear metabolic clustering that reveals 
metabolic profile differences between cells and EVs, which is in concordance with previously 
shown base peak chromatograms (see Figure 48). Metabolic profile differences are due to 
sample type which is given by the first principal component (t[1]). Second principal 
component (t[2])denotes intraclass variation which is very small in both cases, indicating 
good reproducibility. 
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Figure 49. Principal component analysis of UPLC-MS data obtained from MLP29 cells and their 
corresponding secreted EVs. PCA of polar (A) and apolar (B) datasets run in positive (left) and negative 
(right) ion mode reveals metabolic profile differences between cells and EVs.  The first two principal 
components ( t[1] and t[2]), represent the most important metabolic variation in the samples captured by the 
analysis. t[1]  denotes the contribution of a particular marker to the group differences and t[2] intraclass 
variation. A clear metabolic clustering between cells and EVs is shown which is translated in significant 
metabolic profile differences. Note that Quality Controls (QCs) are not in the center because they were made 
only with cells. 
 
 
6.3.5.   EVs METABOLIC PROFILING, METABOLIC SIGNAL SELECTION AND 
METABOLITE IDENTIFICATION 
After multivariate analysis, next step was to detect on one side metabolic signals that are 
present in hepatic EVs (metabolome of EVs) and on the other side to detect metabolic signals 
that could be enriched in hepatic EVs. For this second aim, scatter plots representation 
obtained from the PCAs, what allows distinguishing the signals that discriminate the two 
sample groups, were used as a statistical tool. Finally, once obtained the list of metabolic 
signals forming EVs metabolome or the signals enriched in them, some metabolic signals 
were pre-selected for further identification. This latter step implicates elemental composition 
calculation together with database search (METLIN/HMDB) [205].  
A robust metabolic profile (metabolome) of hepatic EVs was established among all the 
metabolic signals detected after noise reduction and removing the metabolic signals coming 
from tissue culture media [157] (Figure 50). The applied selection criteria was as follows: all 
the metabolic signals must be present in all analyzed EVs samples (n=5) and their coefficient 
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of variation (CV) must be < 20%. Overall, the number of metabolic signals detected in the 
EVs samples in amide (ESI+), C18 (ESI+) and C18 (ESI-) were 3166, 3006 and 1077, 
respectively. By applying the selection criteria, the number of metabolic signals was reduced 
to 224 (amide ESI+), 81 (C18 ESI+) and 37 (C18 ESI-) (Table 9). The metabolic signals 
extracted in aqueous phase analysed in negative ion mode were not considered given that CV 
was higher than 20% in all the cases. It is important to highlight that a metabolite can 
originate multiple metabolic signals. Thus, the number of metabolites represented in this 
metabolome (formed by 342 metabolic signals) is overestimated, until further identification of 
the signals is achieved. 
 
 
 
Figure 50. Metabolic background introduced by tissue culture media in EVs analysis. Metabolites were 
extracted using Chloroform:methanol from the pellet obtained by applying the conventional ultracentrifugation-
based exosomal purification procedure to 300 ml of EVs-depleted complete media incubated at 37°C during 72h 
in absence of cells. Extracted metabolites were analyzed by UPLC-MS using a C18 chromatographic column. 
Retention time of the metabolites along with their peak intensities are indicated in the plots. Note the elevated 
number of metabolites of different chemical nature that are isolated using the EVs purification procedure and 
that need to be removed in order to determine the metabolome that is truly associated to EVs. 
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Table 9. The metabolome of EVs secreted by MLP-29 hepatic cell line. In this table are listed all the metabolic 
signals present in EVs once subtracted background noise and contaminants coming from culture media. The signals 
are ordered in increasing retention time (RT) and with their respective m/z value. All these metabolic signals are 
present in all EVs samples (n=5) and have a coefficient of variation (CV) < 20%. 
 
 
 
 
 
  Amide_ESI +   Amide_ESI +   Amide_ESI +  C18_ESI + C18_ESI -
0.88_425.1392 1.45_451.2660 3.02_303.1779 0.58_277.1069 0.49_446.9074
0.92_468.3084 1.45_564.2747 3.03_184.0735 1.76_300.2040 0.49_604.8720
0.92_494.3240 1.46_129.0687 3.06_261.1634 2.09_282.1929 2.88_187.0975
0.92_892.4553 1.47_229.1190 3.08_416.2979 4.32_540.3351 5.04_239.1296
0.93_592.3338 1.47_291.0705 3.08_521.3194 4.56_522.3237 5.24_692.3842
0.93_756.3907 1.49_307.0444 3.09_129.1029 5.10_355.1115 5.26_497.2933
0.94_245.1860 1.50_158.8439 3.10_374.2144 5.25_383.3315 5.68_194.0823
0.94_279.1714 1.53_112.0533 3.10_408.2523 5.72_367.2471 5.82_450.2620
0.94_710.8664 1.55_248.0905 3.12_213.0988 5.84_266.6424 5.84_194.0827
0.96_232.1548 1.61_1089.4787 3.12_261.0898 5.94_367.2467 5.98_297.1534
1.00_516.3019 1.62_1173.4403 3.12_275.1724 6.27_267.6490 6.07_194.0821
1.01_297.1547 1.62_294.8445 3.12_290.1465 6.29_107.0724 6.16_194.0822
1.01_472.2759 1.63_248.0904 3.12_333.1873 6.31_308.2814 6.24_452.3133
1.02_275.1113 1.67_448.7408 3.14_257.1245 6.37_504.3079 6.25_443.3486
1.03_184.9807 1.67_532.7013 3.24_289.1622 6.40_246.6258 6.40_452.2785
1.07_202.1086 1.67_700.6267 3.31_168.0771 6.40_454.2933 6.40_520.2650
1.10_215.1396 1.67_702.6244 3.32_303.1777 6.40_476.2757 6.42_421.2803
1.15_335.1061 1.67_786.5878 3.33_584.3580 6.41_494.2903 6.44_1035.6603
1.16_296.1582 1.68_196.8574 3.37_116.0712 6.42_434.3391 6.44_608.3187
1.17_430.2658 1.81_122.0719 3.37_133.0977 6.42_949.6222 6.60_478.2935
1.17_452.2474 1.82_163.0982 3.45_239.1065 6.43_400.3432 6.60_546.2791
1.17_468.2076 1.87_214.0070 3.50_517.2859 6.44_1003.1501 6.63_634.3339
1.18_352.1838 1.88_606.7881 3.59_348.0712 6.44_1011.1448 6.65_526.3508
1.19_261.1452 2.18_275.1356 3.61_215.6495 6.44_1013.6511 6.66_301.1664
1.20_357.2134 2.19_102.0563 3.63_118.0871 6.44_276.6343 6.66_522.2827
1.22_326.1701 2.19_120.0664 3.75_211.0852 6.44_297.1491 6.83_466.2954
1.22_375.2245 2.19_402.2457 3.78_118.0871 6.44_478.3301 6.86_554.3457
1.22_397.2044 2.20_242.6425 3.84_402.2824 6.44_515.3137 7.08_480.3436
1.22_495.2536 2.21_175.1197 3.85_206.1030 6.44_524.2980 7.09_480.3101
1.23_213.1242 2.21_188.1762 3.97_304.0168 6.44_534.2951 7.25_480.3087
1.23_438.2318 2.21_364.2079 4.20_328.2844 6.46_425.3750 7.25_548.2962
1.24_260.1598 2.22_249.1087 4.22_484.1184 6.48_447.3563 7.29_585.3521
1.24_282.1434 2.23_361.2188 4.26_164.9290 6.53_373.2964 7.32_325.1839
1.25_423.2210 2.25_257.1246 4.28_399.1450 6.60_259.6340 7.34_449.3109
1.25_509.2688 2.25_375.2341 4.28_452.2429 6.60_462.2966 8.16_367.2638
1.26_253.1196 2.25_427.1763 4.33_328.2851 6.60_480.3083 8.45_311.2009
1.26_312.1541 2.25_502.8259 4.34_282.2795 6.63_280.6563 8.52_381.1748
Metabolic signals present in hepatic EVs
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Table 9. (continuation) 
 
 
   (Continuation)      Metabolic signals present in hepatic EVs
Amide_ESI +   Amide_ESI +    Amide_ESI +     C18_ESI +
1.26_339.1639 2.26_476.2730 4.36_164.9309 6.63_541.3288
1.26_353.1790 2.26_562.7655 4.63_427.0952 6.64_438.2985
1.26_566.2939 2.28_414.7210 4.64_449.0773 6.65_504.3418
1.27_575.1305 2.29_742.4016 4.65_471.0594 6.66_422.3388
1.27_813.4551 2.30_374.2385 4.66_635.1414 6.67_496.3399
1.29_219.1347 2.30_806.4510 4.67_613.1603 6.78_466.3310
1.29_325.0545 2.45_360.2243 4.67_657.1240 6.80_464.3138
1.29_401.2400 2.48_484.2550 4.81_112.1125 7.08_436.3549
1.30_303.0718 2.49_473.2830 4.81_129.1391 7.08_482.3234
1.30_480.2475 2.50_189.1352 4.81_146.1658 7.09_315.1755
1.30_854.3631 2.50_317.1933 4.90_110.0095 7.11_546.3527
1.30_945.0115 2.55_400.0519 4.90_151.0358 7.23_395.2773
1.31_407.2643 2.55_502.8258 4.90_223.9896 7.25_260.6406
1.31_458.2610 2.55_520.0116 5.15_146.1657 7.25_464.3138
1.32_629.3980 2.56_515.2131 5.20_129.1392 7.25_482.3245
1.34_247.1316 2.63_375.1982 5.39_146.1658 7.25_504.3092
1.35_260.1612 2.64_189.1352 5.75_146.1659 7.25_963.6367
1.35_387.2244 2.66_612.3472 5.90_146.1658 7.27_1027.6648
1.36_612.3358 2.69_124.0866 6.03_146.1658 7.27_517.3721
1.38_137.0463 2.69_868.9383 6.14_146.1661 7.29_1069.7114
1.39_444.3186 2.70_893.4486 6.25_146.1658 7.29_552.3305
1.40_783.4347 2.71_375.1980 6.40_146.1656 7.29_805.0245
1.41_254.1602 2.72_822.4104 6.47_308.2186 7.29_808.0329
1.41_805.4183 2.74_326.0147 6.56_146.1657 7.30_151.0978
1.42_310.1404 2.75_228.0372 6.58_614.3002 7.31_562.3252
1.42_470.2612 2.75_367.1396 6.70_146.1659 7.35_149.0248
1.42_854.4720 2.75_382.8651 6.83_350.2666 7.37_508.3400
1.43_276.1453 2.75_86.0972 6.84_343.1451 7.39_379.2854
1.43_325.1482 2.76_402.6980 6.88_393.5685 7.40_294.6718
1.43_332.1219 2.78_347.2019 6.88_589.8485 7.43_429.2607
1.43_369.1733 2.83_232.1406 6.94_350.2670 7.48_526.3136
1.43_493.2381 2.83_238.0463 7.08_305.1487 7.49_468.3449
1.44_123.0450 2.83_427.1939 7.09_301.1138 7.52_510.3920
1.44_147.0447 2.86_130.1591 7.09_303.1108 7.54_470.3501
1.44_430.3012 2.88_222.6569 7.19_625.2798 7.56_508.3758
1.44_862.4368 2.90_429.2453 7.20_466.2747 7.60_695.4128
1.44_876.4544 2.93_157.1091 7.74_203.2236 8.14_413.3239
1.45_282.2791 2.96_413.2181 7.84_203.2233 8.14_552.4017
1.45_359.2653 2.99_257.1781 8.14_574.3864
8.21_303.2906
8.21_325.2716
8.21_369.2985
8.21_480.4254
8.21_578.4174
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Once selected metabolic signals belonging to hepatic EVs metabolome, some of them that 
belong to the analysis done in aqueous phase (amide) started to be identified by elemental 
composition calculation and database search. Table 10 summarizes some of the origins of the 
metabolic signal together with their corresponding implications. Roughly, the characterization 
of EVs metabolome reveals a very diverse metabolic content that covers a wide range of 
functions and implications in different pathways. Among others, it has been detected 
polypeptides involved in nitric oxide cycle, tissue regeneration or redox reactions. Amino 
acids and related compounds involved in methionine cycle. Lipids involved in lipid 
metabolism, biological membrane integrity, antigen presentation or signal transduction. 
Nucleotides involved in DNA/RNA or glycogen metabolism. Polyamines involved in DNA 
stabilization and proliferation (Table 10).  
In addition to this general characterization of EVs metabolome, in this part of the work a 
targeted metabolomics approach was also employed to look for metabolites that were 
routinely analyzed in the metabolomics platform of CIC-bioGUNE corresponding to the 
methionine cycle [147]. As can be observed in the Table 11, it was possible to detect 
significant levels of SAMe, SAH, MTA, Spermine, Spermidine and GSSG. The detection of 
these metabolites in hepatic EV indicates that these EVs could have a role in the methionine 
metabolism in the extracellular environment. This is also supported by the detection of MAT 
activity in hepatic EVs showed in the previous section of enzymatic activities. Another 
metabolite present in hepatic EVs was the oxidized form of glutathione (GSSG). Interestingly, 
while GSSG was clearly present in all EVs samples, reduced form (GSH) was not detected in 
any of the sample, suggesting that EVs could provide a selective transport of GSSG outside 
the cell.  
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Table 10. Hepatic EVs metabolome characterization. Metabolic signals extracted in the aqueous phase started 
to be characterized. In this table are summarized some of these metabolic signals origins together with their 
corresponding implications. Abbreviations: IDs; Identifications, PUFAs; Poliunsalturated Fatty Acid. 
 
 
 
 
Origin Implications Possibles IDs
Polypeptides (Di-, Tri-, Tetra-peptides) Protein catabolism Aspartyl-Arginine 
Nitric Oxyde cycle L-NMMA (N
G
-monomethyl-L-arginine )
Urea cycle Ornithine
Collagen synthesis (Regeneration) L-Proline 
4-Amino-2-methylenebutanoic acid
Redox reactions (Prevent damage caused by ROS ) GSH (Glutatione)/ GSSG (Gluthathione disulfide)
Cysteineglutathione disulfide 
Amino Acids  and related compounds Methylation (Methionine cycle) Methionine
S-adenosyl methionine (SAMe)
S-adenosyl homocysteine (SAH)
Lipids
            Short chain lipids Steroids degradation 2-Oxo-4E-hexenoic acid
7-beta-D-Glucopyranosyloxybutylidenephthalide 
            Phospholipids Lipids metabolism Glycerylphosphorylethanolamine
Phosphocholine 
sn-glycero-3-phosphoethanolamine
Biological membranes integrity, Antigen presentation Phosphatidylcholine (O-12:0/O-1:0)  (PC)
Phosphatidylethanolamine(O-16:0/0:0) (PE)
Protein targeting PIP2(20:1(11Z)/18:1(9Z)) 
            Glycosphingolipids Signal transduction Gangliosides
Muscle and nerve cell membrane integrity Cerebrosides
            PUFAs Membrane structure and function Docosahexaenoyl Acid (DHA)
Fatty acids oxidation 5,8-tetradecadienoic acid 
Palmitoyl-L-carnitine
 Nucleotides DNA/ RNA metabolism, glycogen metabolism Adenosine monophosphate (AMP)
Deoxyguanosine 5'-monophosphate (dGMP)
7-alpha-D-Ribosyladenine 5'-phosphate
Aromatic compounds Purine metabolism Tetrahydroxypteridine (Pteridine)
Xanthine-8-carboxylate  
Folic acid  metabolism Tetrahydrofolate
Polyamines DNA stabilization, cell division, cell differentiation N8-Acetylspermidine 
N1-Acetylspermidine
Spermine
Dicarboxylic acids Polyamines and poliesters synthesis Undecanedioic acid 
Krebs cycle intermediary Disodium succinate
Steroid Hormones Androgenic activity Testosterone sulfate 
Salts Chemical synthesis Zinc acetate 
Metabolic signals 
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Table 11. Metabolites implied in different pathways are contained in hepatic EVs. The intensity of detected 
compounds is indicated. All of them were detected in cells (data not shown) and EVs except GSH which was 
only detected in cells. Both, cells and EVs, n=5. Abbreviations: SAMe; S-Adenosyl Methionine, SAH; S-
Adenosyl Homocysteine, MTA; 5'-methylthioadenosine, GSH; Glutathione, GSSG; Glutathione disulfide, 
N.D; Not detected. Controls: EVs isolation, Metabolites derived from the culture media; Extraction, Metabolites 
derived from the extraction procedure. 
 
 
 
 
A second aim in the UPLC-MS metabolomics analysis of hepatic EVs, was to detect 
metabolic signals that are enriched in EVs having into account the abundance of this 
metabolic signal in the cells. With this aim, the scatter plots of extracted metabolic signals 
were obtained from the PCAs. In the Figure 51 are represented the scatter plots 
corresponding to polar and apolar datasets run in positive and negative ion mode. Each dot 
represents an individual EMRT (exact mass-retention time pair). Above the straight line that 
crosses the intercept, are plotted those metabolic signals detected preferentially in EVs, 
whereas the metabolic signals enriched in cells are represented behind the line.  The signals 
located in the intercept are supposed to be present in both sample groups at similar levels. 
EVs samples (n=5) and their coefficient of variation (CV) must be < 20% (Table 12). 
 
SAMe SAH MTA Spermine Spermidine GSH GSSG
Controls EVs isolation N.D N.D N.D 677,167 138,066 N.D N.D
Extraction N.D N.D N.D N.D N.D N.D N.D
Samples EVs_1 316,213 13,102 47,784 5286,412 11065,136 N.D 339,27
EVs_2 237,822 7,612 51,379 3916,716 9433,967 N.D 302,309
EVs_3 267,865 9,378 57,418 5083,345 9673,424 N.D 320,599
EVs_4 311,038 13,55 48,913 5787,432 10134,849 N.D 359,135
EVs_5 391,789 5,856 53,814 5369,561 11116,04 N.D 378,672
Metabolites
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Figure  51.  Scatter plots of polar (A) and apolar (B) dataset, run in ESI+ (top) and ESI- (bottom) mode 
for MLP-29 cells and secreted EVs. Each dot represents a single data point. The x axis represents the number 
of metabolic signals and y axis denotes the confidence of a signal contribution to the group differences. Above 
the straight line that crosses the intercept, are plotted those metabolic signals corresponding to EVs, whereas the 
metabolic signals related to cells are those represented behind the line.  The signals situated in the intercept are 
supposed to be present in both sample groups.  The cut-off (red line) delimits the metabolites that are considered 
to be present in one of the two sample groups. The closer the data points come to 0, the higher the similarity 
between the two sample group and vice versa. 
 
 
Thus, in order to obtain metabolic signals enriched in hepatic EVs a cut-off (red line) in the 
scatter plot was arbitrary established in order to delimit the metabolic signals considered to be 
enriched in one of the two sample groups (Figure 51). The metabolic signals enriched in EVs 
(above de cut-off) were selected and listed in the Table 12 indicating their Rt_m/z value. 
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Table 12. Metabolic signals enriched in hepatic EVs secreted by MLP-29 cell line. Metabolic signals are 
ordered in increasing retention time (RT) which their respective m/z value. The ion mode is also specified. Its 
color represent a unique metabolite which different structural conformation 
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Some of the metabolic signals enriched in EVs were pre-selected for further identification. 
Thus, those signals that showed a clear difference in peak intensity (peak area) between cells 
and EVs were selected. With this aim, the extracted ion chromatogram (XIC) and trendplot 
were obtained for the EVs-enriched metabolic signals. XIC represents the selected peak after 
each extraction from the entire chromatogram and the trendplot displays a plot of intensities 
of the selected metabolite throughout the replicates (n=5) and sample types. Two 
representative examples of EV-enriched metabolic signals are showed in Figures 52 and 
Figure 53.  In the chromatogram (A) is clearly observed how, in both cases, the intensity of 
the peak is much higher in EVs (in green) than in cells (in red). Moreover, this intensity 
remains more or less similar across all samples (n=5) as revealed by the trendplot (B), 
supporting the reproducibility of the analysis. 
 
 
Figure 52. Example of the identification of a metabolite enriched in EVs in the aqueous phase. (A) 
Extracted Ion Chromatogram: y axys denotes the intensity of the peak in percentage. X axys indicate the 
retention time of the metabolite. The peak that corresponds to EVs is represented in green and cells in red. (B) 
Trendplot: y axys denotes the intensity of the peak in percentage and X axys analyzed sample in the trendplot. 
Samples 7-11 correspond to EVs and 17-21 to cells. (C) Possible identifications of the metabolite after a 
database search.  
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For organic phase some polipeptides and abundant lipids were detected. In Figure 54 are 
shown some examples of metabolites enriched in EVs extracted in organic phase. 
 
 
 
 
Figure 53. Example of the identification of a metabolite enriched in EVs in the organic phase. (A) 
Extracted Ion Chromatogram: y axys denotes the intensity of the peak in percentage. X axys indicate the 
retention time of the metabolite. The peak that corresponds to EVs is represented in green and cells in red. (B) 
Trendplot: y axys denotes the intensity of the peak in percentage and X axys analyzed sample in the trendplot. 
Samples 10-14 correspond to EVs and 20-24 to cells. (C) Possible identifications of the metabolite after a 
database search. 
 
In summary, metabolomics applied to the functional study of hepatic EVs offer a powerful 
tool to identify the different pathways in which hepatic EVs are implied. Moreover, several 
potential metabolic signatures discovered through untargeted metabolomics have been 
reported over the past year in several diseases. Therefore, the recognition of the potential of 
EVs as a source of biomarkers discovery could open novel perspectives in the prediction, 
diagnosis, prognosis, and therapy of hepatic diseases and liver injury. 
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7.   GENERAL DISCUSSION 
This work is focused on the study of the functional role that hepatic EVs could play in the 
endogenous and xenobiotics metabolism in the organism. The results obtained by using 
different cellular models of DILI in combination with cellular and biochemical techniques as 
well as UPLC-MS-based metabolomics technology have provided strong indications that 
hepatic EVs carry active enzymes and metabolites that can influence significantly the 
extracellular environment. In addition, the study has also provided several molecules and 
enzymatic activities that could be useful to develop low-invasive diagnosis methods for DILI.  
A key interest in clinical diagnosis and pharmaceutical industry is to have a repertoire of non-
invasive biomarkers to be able to predict the degree of liver injury caused by a pathological 
condition or a drug. The first part of this thesis shows that compounds and drugs-causing 
acute liver injury, such as GalN, APAP and DCF, modified the intracellular distribution and 
in some cases the abundance of RNAs, proteins and metabolic enzymes that can be detected 
in hepatic EVs. In addition, modified-molecules play important role in different cellular 
pathways, supporting that modified-EVs would impact biological processes by several 
mechanisms. Thus, a chaperone protein induced under stress conditions [206] as Hsp70 is 
increased in hepatic-EVs secreted in GalN and DCF treatments, which is, at the same time, 
accompanied with a decrease in cells. This suggests a selective transport of this protein 
outside the cell under acute liver injury, maybe to avoid the damage of extracellular proteins. 
On the other side, the expression of Rab8 protein was significantly reduced by the APAP 
treatment in both, cells and EVs, whereas in GalN and DCF treatments the protein is 
increased in the secreted EVs. This result points that the cellular response to GalN and DCF 
could implicate vesicular trafficking that depends on Rab 8 protein. This differential impact of 
the drugs on the intracellular trafficking is also supported by the alteration in the levels of 
LIMP II, that plays a role in the regulation of endosome and lysosome biogenesis [207]. 
Another protein affected by the drugs is the tetraspanin Cd63, an endosomal and exosomal 
marker implicated in immune response [80]. These results, apart from supporting the effect of 
the drugs on intracellular trafficking also implicates the secreted EVs in the regulation of the 
immune response under DILI conditions. 
The protein levels and also the activity in hepatic EVs of metabolic enzymes such as CES, 
COMT and MAT are differentially altered in DILI cellular models. This supports the 
existence of different mechanisms of action ejected by the cells to overcome a toxic challenge 
and importantly, supports hepatic EVs as the vehicles to perform a response to overcome the 
damage. In this context, COMT enzyme expression levels decreased significantly in EVs in 
APAP and DCF treatments, subsequently affecting the catechols methylation carried out by 
COMT activity. In this regard, it is reported that the inactivation of catecholamines by COMT 
in the brain have an effect on blood pressure regulation [208]. The data provided in this 
doctoral thesis indicates that modifications in the EVs-associated COMT-activity could 
regulate blood pressure in the liver under DILI conditions. In agreement with this hypothesis, 
it has been shown that the methylation ability of catecholamines by COMT is attenuated in 
liver and kidney of spontaneously hypertensive rats [128]. Yet, not only the protein cargo is 
affected by DILI conditions, also the RNA cargo of EVs was differentially altered under DILI 
GENERAL DISCUSSION 
 
144 
 
conditions tested in this study. This effect on the RNA suggests that EVs carry the 
information to respond to a determined stress in a time depending manner. Thus, a first quick 
wave of response mediated by direct protein interaction and enzymatic activities, and then a 
time-delay response ejected by the regulation of the translation of determined RNAs in the 
recipient cells. Thus, the mixture composition of the vesicles highlights the complex 
mechanisms implicated in the DILI. It is also important to highlight that all DILI models used 
in this study increased significantly the amount of EVs secreted by the hepatocytes. Together, 
all these data strongly support that hepatocytes under liver-damaging conditions employ the 
secretion of EVs to respond to liver insults loading them with specific cargos depending on 
the mechanism of action required to overcome the challenge. 
Furthermore, the data also supports the study of EVs under controlled conditions as an 
approach to identify low-invasive candidate markers for early detection of disease conditions. 
The use of EVs as a source to identify DILI biomarkers has several advantages [209]. First, it 
may be possible to identify highly specific DILI biomarkers in circulating EVs. This is 
important as currently used DILI biomarkers lack organ specificity [210]. Second, EVs 
components are protected from degradation [49] and thus have a longer survival time, 
providing a wider time window for injury detection. Third, efforts to directly use serum and 
plasma to discover new DILI biomarkers are often hindered by highly abundant blood 
constituents. The true signal may escape detection among those very strong and irrelevant 
background signals. Using isolated EVs may avoid this problem. Finally, one additional 
benefit of using EVs in DILI is that not only changes in their sizes, but also patterns of their 
association with specific molecules maybe is indicative of the etiology of liver injury [211]. 
Over the past years, several potential metabolic signatures discovered through untargeted 
metabolomics have been reported in several diseases such as hepatocarcinoma in patients with 
cirrhosis [212], Parkinson’s disease diagnosis and progression [213], depression 
,schizophrenia, diabetes and also cardiovascular and coronary artery disease [137]. The 
recognition of the potential of EVs will open novel perspectives in the prediction, diagnosis, 
prognosis, and therapy of hepatic diseases and liver injury in general. 
In addition to the molecular characterization of EVs, a second aim of the work was the study 
of the role that these vesicles could play in the development and progression of DILI. The 
proteomics analysis of hepatocyte-derived EVs revealed the presence of metabolic enzymes 
involved in the central regulation of hepatocyte metabolism (MAT enzyme) as well as 
specifically in the xenobiotics and endogenous compounds metabolism (CES, COMT 
enzymes). In this work, alterations on the protein level of these enzymes were found under 
tested DILI models. Furthermore, these three enzymes activities were detected in hepatic EVs 
extending the intracellular effects described for them in relation with DILI to the extracellular 
space.  
CES activity efficiently catalyzes the hydrolysis of a variety of ester- and amide-bonds 
contained in chemicals and drugs to their respective free acids. In this way, CES activity is 
involved in detoxification of various drugs, environmental toxicants and carcinogens. Apart 
from metabolizing drugs to their corresponding inactive form, it also is responsible of other 
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drugs metabolic activation that may cause a toxicological effect through direct hepatotoxicity 
allowing, in this way, the development of DILI. A clear example is 7-ethyl-10-[4-(1-
piperidino)-1-piperidino] carbonyloxy-camptothecin (CPT-11) which is a drug currently used 
for the treatment of different types of cancers such as colon or rectum [214]. CPT-11 requires 
the CES activity mediated biotransformation to convert to its active metabolite 7-ethyl-10 
hydroxycamptothecin (SN-38), which is approximately 100-1000 fold more cytotoxic than 
the parent drug [215].  
MAT enzyme is responsible for the biosynthesis of SAMe, the principal biological donor of 
methyl groups [100] and a master regulator of hepatocyte metabolism [216]. Abnormal 
activity of this enzyme is linked to many diseases outside (e.g. depression and osteoarthritis 
[216])  and inside (e.g. steatohepatitis, cirrhosis, HCC [100]) the liver. With regards its 
possible implication in DILI, it has been observed an increase in MAT1A protein expression 
levels, one of the subunits forming the enzyme, in EVs released by primary cultures of rat 
hepatocytes exposed to GalN and in serum-isolated EVs from GalN treated rats [95]. In this 
sense, ethionine is an amino acid structurally related to methionine with an ethyl group 
instead of a methyl group [217] and it is also a substrate for MAT. In vivo, ethionine causes 
hepatic SAMe and ATP depletion leading to DILI [218]. Indeed, this toxin induces steatosis, 
impaired methylation reactions and hepatic glucose and glycogen depletion among others 
[219]. Another example that connects MAT with DILI is cycloleucine, an inhibitor of MAT 
activity [217]. This non metabolizable analog of methionine, induces SAMe and GSH 
depletion and potentiates drug-induced cytochrome P-450 2E1 (CYP2E1)-mediated 
cytotoxicity in hepatocytes [220].  
In the case of COMT activity, its general function is the elimination of biologically active or 
toxic catechols and some other hydroxylated metabolites. COMT protein has been recently 
reported as a biomarker of liver injury in APAP induced toxicity model. Indeed, in the early 
stages, even before the current standard liver biomarker ALT  and histopathology indicated 
liver injury, COMT protein levels changed significantly in both liver tissue and plasma [126]. 
Moreover, COMT has several substrates related to DILI. 17-beta estradiol is a cathecol drug 
converted to its toxically active form by the activity of the COMT enzyme [112][113]. Is an 
essential estrogen hormone for females that has important effects in the liver. For example, it 
can lead to cholestasis by inducing a reversible inhibition of bile flow. Another cathecholic 
drug is Salvianoic acid A (SAA). COMT is responsible of methylated transformation of this 
phenolic acid metabolically unstable. Metabolites derived from O-methylation of SAA, 
display high antioxidant potency against liver lipid peroxidation [114]. Moreover, 
considerable evidence has also demonstrated the potent protective effects of SAA against 
ischemia-induced injury [115][116].  
As conclusion of this part of the work, the presence of these activities in hepatic EVs suggest 
a possible contribution of these secreted vesicles to the metabolism of drugs what should be 
taken into consideration in further studies to avoid undesired secondary effects. 
In the case of MAT and COMT activities, it was necessary to develop in-house methods using 
UPLC-MS technology. As a result,  sensitive and specific methods for determination of MAT 
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and COMT activities were developed, being now available for the scientific community for 
future laboratory and clinical research. 
Finally, it is important to remark that these EVs-associated activities are differentially 
expressed depending on the treatment, offering a way to discriminate among different type of 
liver injuries. In this regard, the introduction of novel detection methods that enable the 
identification of EV signatures in patients with liver injury and also in-depth characterization 
of EVs derived from liver would help to identify DILI low-invasive markers and novel 
therapeutics targets. 
The characterization of EVs metabolome was further achieved to unravel metabolic pathways 
and functions that hepatic EVs could be performing in the organism. Our study reveals a very 
diverse metabolic content that covers a wide range of putative functions and suggest the 
implication of hepatic EVs in different cellular pathways. In this regard, an elevated number 
of metabolic signals were clearly associated to these vesicles and comparing with chemical 
standards, some of them were identified. The presence of several intermediaries of methionine 
cycle including SAMe, SAH and MTA was confirmed in hepatic EVs. The presence of these 
metabolites joined to the fact that hepatic EVs also carry MAT enzymatic activity strongly 
suggest that hepatic EVs could have an important role in the methionine cycle regulation in 
the extracellular environment or in adjacent or far-away-localized recipient cells. The 
polyamines, spermine and spermidine, were also detected in hepatic EVs, supporting the 
hypothesis of these vesicles as vehicles sending metabolic signals influencing DNA synthesis 
and stabilization, gene expression regulation or cell proliferation among others functions that 
are controlled by these metabolites [221]. In this sense, it has been reported that EVs released 
by adult stem cells residing in the liver have the capacity to repair damage tissue by inducing 
liver regeneration [222]. Moreover, it is known that polyamines are also involved in 
carcinogenesis, prompting intensive research into polyamine metabolism as a target in cancer 
therapy. Furthermore, the implication of hepatic EVs in polyamine metabolism it is also 
supported by the fact that SAMe takes part also in the polyamine biosynthesis [100]. Another 
metabolite detected in hepatic EVs is the oxidized form of glutathione (GSSG). Interestingly, 
while GSSG was clearly detected, the reduced form GSH was not, suggesting that hepatic 
EVs could constitute a selective transport of GSSG outside the cell. GSH is an important 
antioxidant that prevents damage caused by reactive oxygen species such as free radicals or 
peroxides. In redox reactions, GSH is converted to GSSG. An increased GSSG-to-GSH ratio 
is considered indicative of oxidative stress [223]. Hence, the elevated presence of GSSG in 
EVs could be considered an indication of oxidative stress in the cell from where it came from. 
Moreover, SAMe is an important precursor of GSH since SAMe is the precursor of SAH, 
which is then hydrolysed to homocysteine which finally forms GSH in the transsulfuration 
pathway. Here again, it is observed certain correlation between the metabolites contained in 
hepatic EVs, suggesting an organized functionality inside the EVs.  
In conclusion, several metabolites detected in these vesicles, indicate the implication of 
hepatic EVs in methylation, polyamine and DNA synthesis (amynopropylation) and oxidative 
stress (transsulfuration) response. 
GENERAL DISCUSSION 
 
147 
 
Other metabolic signals from the hepatic EV metabolome were tentatively identified using 
mass accuracy and database search. Among this group of metabolites, tetrahydroxypteridine 
and tetrahydrofolate were detected, both implicated in the synthesis of purines and DNA. The 
presence of these two metabolites along with the polyamines above mentioned, indicate that 
one of the mechanism of action of hepatic EVs could implicate the regulation of these 
processes. In agreement with this, it has been also reported that EVs derived from endometrial 
epithelial cells have a potential role in purine metabolism [224]. Another metabolic signals 
tentatively identified was adenosine monophosphate (AMP), that has an important role in 
glycogen metabolism in the liver, suggesting that hepatic EVs could be implicated in 
regulation of the energetic metabolism. N
G
-monomethyl-L-arginine (L-NMMA), an inhibitor 
of nitric oxide synthase, was also among the possible metabolites contained in hepatic EVs, 
suggesting a possible role of these vesicles in controlling the vasodilatation and 
vasoconstriction of blood vessels. This effect could be connected with the COMT enzymatic 
activity found in hepatic EVs.  
Another group of metabolic signals of hepatic EVs with tentative IDs belong to the lipids. In 
agreement with the membrane-base of these vesicles, two structural membrane lipids such as 
phosphatidylcholine and phosphatidylethanolamine were in this group. Lipids involved in the 
sorting of molecules into vesicles including docosahexaenoic acid (DHA) and 
phosphatidylinositol-(4,5)-bisphosphate (PIP2) phospholipids were also in the lipid group 
[225] [226], indicating that they could be involved in sorting to hepatic EVs. An intermediary 
of the unsaturated fatty acid oxidation, 5,8-tetradecadienoic acid [140], was also identified as 
a possible metabolite contained in hepatic EVs, as well as  the glyceryl 
phosphorylethanolamine, which is a membrane breakdown product that acts as a growth 
stimulating factor for hepatocytes [227].  
In conclusion, all these data clearly support the complexity of the cellular processes in which 
hepatic vesicles could be involved, being required additional experimentation to elucidate in 
more detail. In the Figure 54 is represented a schematic view of the main results obtained in 
this doctoral thesis. 
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Figure 54. Overview of the main results obtained in this doctoral thesis. In normal (green) conditions 
hepatocytes release EVs (black dots) containing RNAs, proteins, enzymes and metabolites into the extracellular 
environment. These vesicles can be captured by neighbor or distant cells modifying their metabolism. 
Hepatocytes-secreted EVs could also modify the metabolism in the intercellular space as well as in body fluids. 
Under DILI (red) conditions hepatocytes secrete more EVs to the extracellular environment and bloodstream 
increasing the risk of damage. The composition of these vesicles varies depending on the induced liver damage 
being possible to discriminate between different injuries (Hsp70 and Rab 8 proteins expression increases in DILI 
conditions whereas Cd63 and Limp II decrease). Moreover, the activity of some of the enzymes contained in 
hepatic EVs such as CES, COMT and MAT, increases in liver damaging conditions. Indeed, the activity varies 
depending on the induced damage. The implication of these enzymes in DILI suggests that hepatic EVs could be 
involved in the development of DILI. Furthermore, hepatic EVs metabolome contains metabolites that take part 
in important cellular pathways such as methionine metabolism (SAMe and SAH), redox reactions (GSSG) or 
purine and DNA biosynthesis (spermine and spermidine).  
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8.     CONCLUSIONS 
 
1.  GalN, DCF and APAP have different effects on hepatocytes indicating that different 
responses are carried out in hepatocytes depending on the induced liver damage. 
 
2. APAP affects more severely to the hepatocytes than GalN and DFC under tested 
conditions. 
 
3. Hepatocytes secreted more EVs under DILI conditions.  
 
4. Composition of EVs is altered by DILI conditions and different drugs affect 
differentially to the composition of the EVs. 
 
5. Hepatic EVs display CES, MAT and COMT activities and the activities vary depending 
on treatments with DCF, GalN or APAP. 
 
6. Hepatic EVs are a suitable biological source to identify markers for detecting and 
classifying DILI. 
 
7. The implication of CES, MAT and COMT activities in DILI suggests that hepatic EVs 
could be involved in the development of DILI. 
 
8. UPLC-MS based metabolomics is a good technology to characterize MAT and COMT 
activities in EVs, and to identify the metabolites that are associated with hepatic EVs. 
 
9. The metabolome of hepatic EVs is constituted by more than 340 metabolic signals. 
 
10. Hepatic EVs carry a complex mix of metabolites belonging to different cellular 
pathways including methionine metabolism, redox metabolism, purine and DNA 
biosynthesis. 
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